Synthesis of novel sialidase inhibitors to target influenza A virus and Chagas’ disease by Resende, Ricardo
Synthesis of novel sialidase inhibitors to target

influenza A virus and Chagas’ disease

Ricardo Resende

A thesis submitted for the degree of Doctor of Philosophy

University of Bath

Department of Pharmacy and Pharmacology

September 2010

COPYRIGHT

Attention is drawn to the fact that copyright of this thesis rests with its author. A

copy of this thesis has been supplied on condition that anyone who consults it is

understood to recognise that its copyright rests with the author and they must not

copy it or use material from it except as permitted by law or with the consent of the

author.

This thesis may be available for consultation within the University Library and may 
be photocopied or lent to other libraries for the purposes of consultation 
Signed 
Date 



Abstract 
This thesis is divided into two parts. Part One describes inhibitors towards influenza 
neuraminidase and Part Two describes inhibitors towards Trypanosoma cruzi 
trans-sialidase. 
In Part One, a description of the influenza virus is given followed by details of the 
current approved therapies and our approach. 
Influenza is a virus that has the ability to cause a pandemic with a possible high 
mortality rate. The life cycle of the influenza virus exhibits several key stages that, if 
inhibited, would hinder its replication and have potential as therapeutic targets. The 
two currently approved drugs on the market (zanamivir (25) and oseltamivir (6)) 
target influenza neuraminidase. Influenza neuraminidase has the function of cleaving 
terminal sialic acid groups from glycoconjugates present at the surface of cells, 
enabling the release of the newly formed viral particles. 
Our strategy towards the syntheses of novel inhibitors against influenza 
neuraminidase is based on 2,3-difluorosialic acid (19). Modifications were made at 
position C-5 of sialic acid to replace the 5-N-acetamido with a 5-N­
trifluoroacetamido group. The formation of 5-N-trifluoroacetamido-2,3-difluorosialic 
acid (41) was achieved by deprotecting 5-N-acetamido-2,3-difluorosialic acid (52) 
using methanesulfonic acid. Modifications were also performed at position C-7, 
introducing a series of 7-N-alkylamines on 2,3-difluorosialic acid (47) by oxidative 
cleavage of the glycerol side chain and reductive amination. 
A series of 4-epi-N-alkylamines were introduced onto the Neu5Ac2ene moiety, with 
the intention of probing the size of the enzyme pocket available in the surroundings 
of position C-4. 
The C-4, C-5 and C-7 modified compounds were tested against a panel of influenza 
viruses (CSIRO). Furthermore, 7-N,N-diethylamino-2,3-difluorosialic acid (39) was 
tested against influenza neuraminidase N9. The compounds showed poor levels of 
inhibition, with the IC50’s referring to the influenza neuraminidase N9 wild type, 
being 326 and 68 mM for the 7-N-ethyl-N-methylamino (37) and 7-N,N­
diethylamino-2,3-difluorosialic acid (39), respectively. 
i 
In Part Two, a description of Chagas’ disease is given followed by the currently 
approved therapies and our approach. 
Chagas’ disease is endemic in Central and South America and is caused by a 
parasite, Trypanosoma cruzi. There are currently two approved drugs to treat 
Chagas’s disease, and both have a similar mode of action, inducing oxidative stress 
in the parasite. 
Our approach is to target Trypanosoma cruzi trans-sialidase (TcTS), which has two 
important roles in the life cycle of the parasite. TcTS cleaves sialic acid from 
glycoconjugates present at the host cell surface and transfers them to mucin like 
receptors present on the parasite. This action allows the parasite to evade the host 
defence mechanisms. In addition, TcTS enables the parasite to enter the host cell 
during the infection process. 
Our strategy towards the synthesis of novel inhibitors against Trypanosoma cruzi 
trans-sialidase is based on 2,3-difluorosialic acid (19), akin to the inhibitors 
developed in Part One. Several modifications were made at position C-7 via cleavage 
of the glycerol side chain and introducing a series of cyclic 7-N-alkylamines by 
reductive amination. 
ii 
The synthesised compounds were then tested against trypomastigotes, the infectious 
form of the parasite. The inhibitory results showed an IC50 of 3.1 mM for 7-N­
pyrrolidino-2,3-difluorosialic acid (145); 35.5 mM for 7-N-morpholino-2,3­
difluorosialic acid (146); and 4.2 mM for 7-N-anilino-2,3-difluorosialic acid (147). 
iii 
iv
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Chapter 1 - General Introduction 
1.1 Sialic acids in Nature: structures and roles 
Sialic acid is the generic name given to a family of carboxylic acid containing 
monosaccharides. This family comprises over 40 different compounds with common 
characteristics that include a 9-carbon backbone and a carboxylic acid at C-1 
(pKa ~2.2) conferring a negative charge to the molecule under physiological 
conditions (Figure 1).1 
Figure 1 General structures of the major sialic acid classes, with the numbering of the carbon 
backbone indicated. Substituents at C-5 generally include a -hydroxyl, -amino, N-glycol or an 
N-acetamido group (1 – 4). 
There are several possible substituents commonly found at C-5, such as a hydroxyl, 
amino, N-glycol or N-acetamido group, which define the four major classes in the 
sialic acid family: deaminoneuraminic acid (KDN) (1), neuraminic acid (2), 
N-glycolylneuraminic acid (Neu5Gc) (3) and N-acetylneuraminic acid (Neu5Ac) 
(4).1-3 Guntar Blix, Ernst Klenk and Alfred Gottschalk were the pioneers of sialic 
acid research, with Gottschalk publishing the first book on sialic acids, Klenk the 
first to introduce the term neuraminic acid, and Blix the first to crystallise a number 
of sialic acid derivatives.4,5 As a group, the three collectively agreed on a common 
term to define the family generally as sialic acids, and the individual members of the 
family, defined as derivatives of neuraminic acid (2).4,5 
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The vast numbers of sialic acids found in nature result from the numerous 
modifications that are observed on the hydroxyl groups present at C-7, 8 and 9 of the 
glycerol side chain, where they are often found to be acetylated.1 
Sialic acids are commonly present as the terminal carbohydrate moieties on 
glycoproteins and gangliosides, which are frequently expressed at the outer cell 
membrane. Sialic acids are therefore exposed to the blood plasma and due to their 
inherent negative charge (carboxylate) they are associated with influencing the 
mobility of cells and cations (for instance Ca2+).1 Sialic acids are associated with 
several important roles in human biology, such as having a possible interaction with 
neuronal plasticity, and maintaining a normal filtering function of the glomerular 
epithelium.6-11 In addition to the previous features, sialic acids are also involved in 
the masking of cells, such as erythrocytes, from target receptors (Figure 2). 
Erythrocytes are covered with a layer of sialic acid containing glycoconjugates, and 
throughout their life span, sialic acids are slowly cleaved from the surface by the 
action of serum sialidases and spontaneous hydrolysis.1 This cleavage unmasks the 
penultimate sugar residue of the glycoconjugate, a galactose, which signals the cell 
for degradation.1 Ultimately, the unmasked galactose will bind to macrophages and 
the erythrocyte phagocytise. Therefore, the presence of sialic acids on the surface of 
erythrocytes prevents degradation by masking the underlying galactose residues.5 
Figure 2 The role of sialic acid of masking an erythrocyte and the mechanism of binding to a 
macrophage. Ө sialic acid; ■ galactose; ○ and ∇ other residues; galactose specific receptor on the 
macrophage surface.1 
Sialic acids have also been found to be involved in the proliferation of cancer cells, 
where they are usually over-expressed on the surface glycoproteins of some cancer 
cell lines.12-17 Gangliosides, present on the plasma membrane of cancer cells, play an 
important role in the regulation of these cells. It has been shown by Miyagi’s group 
that the action of a specific human sialidase (NEU3) on gangliosides induces 
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inhibition of apoptosis and promotes cancer cell mobility (metastasis) in some colon 
and rectal cancer cells.17,18 
In parallel to the important roles that sialic acids play in numerous biological 
processes in the human body, many pathogens (viruses, bacteria and parasites) have 
also evolved to rely on sialic acids for a number of processes, such as evading the 
host immune response, cell targeting and infection. By sialylating their external 
glycoconjugates, pathogens can increase their chance of passing undetected through 
the host immune system, as well as enhancing their ability to target specific host 
cells. Two such examples, which make up the focus of this thesis, include the 
parasite Trypanosoma cruzi and the influenza A virus. Both of these pathogens 
interact with sialic acid containing glycoconjugates in order to evade the host 
immune response, and to target specific cells thus aiding the infection process. This 
thesis will focus on sialic acid modifying enzymes, discussing their roles in the 
infection processes and life cycles, as well as the current therapeutic targets 
associated with Trypanosoma cruzi and influenza A virus. 
1.2 Carbohydrate degrading enzymes 
As monosaccharides, carbohydrates do not generally exhibit a strong cellular 
function in living organisms; however, when linked to other carbohydrates to form 
complex oligosaccharides, polysaccharides or glycoconjugates, they then become 
relevant in a diverse range of biological functions.19 These include cell-cell 
communication; maintenance of the physical tissue structure, integrity and porosity; 
and being present during the folding of polypeptides in rough endoplasmic reticulum, 
and in the subsequent maintenance of protein solubility and conformation.20 As a 
consequence of the important roles played by carbohydrates, the enzymes 
responsible for the selective formation (glycosyltransferases) or cleavage (glycoside 
hydrolases) of glycosidic bonds hold the key to a vast number of processes occurring 
in the human body.19 For the purpose of this work, we shall focus on glycoside 
hydrolases, their mechanism of action and inhibitors. 
Glycoside hydrolases are a group of enzymes that are characterized by their ability to 
catalyse the hydrolysis of glycosidic linkages. Some important representative 
3 
Chapter 1

examples of glycosidases include those necessary for the correct assembly of 
mammalian glycoproteins, such as α-glucosidases I and II; the metabolism of lactose 
by β-galactosidase; and the catabolism of starch and various carbohydrates present in 
aliments by α- and β-amylases.21-23 
Glycosidases can be classified into different classes, depending on the 
stereochemistry of the initial glycosidic linkage being processed (α- or β-); 
comparison of the anomeric stereochemistry of the product to that of the substrate 
(retaining or inverting); whether the glycosidic cleavage occurs internally in the 
oligosaccharide (endo-), or at the terminus (exo-); and the identity of the substrate 
carbohydrate towards which each glycosidase is selective (e.g. mannosidase, 
glucosidase).24 Furthermore, glycosidases can be divided into different families 
based upon sequence homology, and further divided into clans, based upon 
similarities of their three-dimensional (tertiary) structures.24-28 This method is the 
basis of the CAZy classification system.25 Within each CAZy family there is also 
found the conservation of the catalytic mechanism and the class of catalytic process 
involved.24-28 
The chemical mechanisms employed by glycosidases to catalyse the cleavage of 
glycosidic linkages have been well studied over the years, and the subject of several 
reviews.26,29,30 In 1953, Koshland first postulated a mechanistic model to rationalise 
the anomeric configuration of the hemiacetal produced upon hydrolysis of a 
glycoside by a hydrolase.31 Since then, several techniques have been employed 
(individually or in combination) in order to study, and ultimately prove, the 
mechanisms originally proposed by Koshland.32-34 
Glycosidases can cleave the glycosidic bond via two pathways, either with inversion 
or overall retention of configuration at the anomeric centre. 
1.2.1 Inverting glycosidases 
Inverting glycosidases are thought to operate through a concerted mechanism, where 
cleavage of the glycosidic bond is accompanied by general base assisted nucleophilic 
attack of water at the anomeric carbon, passing through an oxocarbenium ion-like 
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transition state (Scheme 1).35 This process is aided by the general acid assisted 
protonation of the glycosidic oxygen by a second catalytic amino acid. The two 
catalytic amino acid residues are generally separated by a distance of ~11 Å, to 
enable access of the participating water molecule.35 
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Scheme 1 Proposed mechanism of action for inverting exo-α-glycosidases.35 R – Glycoconjugate. 
1.2.2 Retaining glycosidases 
Retaining glycosidases, usually proceed through a double displacement mechanism 
involving the formation, and subsequent hydrolyses, of a covalent glycosyl-enzyme 
intermediate (Scheme 2).35 Within the active site, there are two catalytic amino acid 
residues generally separated by ~5.5 Å that act as acid/base catalysts, namely 
aspartate and glutamate.36 Unlike inverting glycosidases, one of the catalytic amino 
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acid residues will have both functions, acting as acid catalyst for the first step 
(glycosylation) and as base catalyst on the second step (deglycosylation).35 
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Scheme 2 Proposed mechanism of action for retaining exo-β-glycosidases.37 R – Glycoconjugate. 
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Firstly there is the protonation of the glycosidic oxygen by the general acid/base 
residue, followed by nucleophilic attack to the anomeric position from the 
nucleophilic residue which will generate the covalent glycosyl-enzyme 
intermediate.35 An incoming water molecule is deprotonated by the general acid/base 
residue, and performs a nucleophilic attack at the anomeric position, resulting in the 
cleavage of the covalent glycosyl-enzyme intermediate. One key aspect of this 
mechanism is the importance of the nucleophilic amino acid residue, where studies 
have shown that a point mutation in this residue originates a reduction in the activity 
of the glycosidase.38 
Another explanation for the mechanism of retaining glycosidases could be through a 
substrate assisted mechanism, where the group present at the adjacent position to the 
anomeric centre acts as the nucleophilic species. 
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R - Glycoconjugate. 
8 
Chapter 1

The glycosidic oxygen is protonated by the general acid/base residue, and the 
adjacent group to the anomeric position performs a nucleophilic attack at the 
anomeric centre (Scheme 3). An incoming water molecule is deprotonated by the 
general acid/base amino acid residue, which then performs a nucleophilic attack at 
the anomeric centre. The role of the catalytic amino acid residues is to act as general 
acid/base and orientate the nucleophilic attack of the neighbouring group as well as 
stabilizing the transition states.39 
1.3 Inhibitors of retaining glycoside hydrolases 
Owing to the importance of glycoside hydrolases in many biological processes, the 
ability to regulate their enzymatic function is associated with numerous medical 
applications, ranging from treatment of type II diabetes to antiviral and cancer 
therapeutics.40-43 
Broadly, glycosidase inhibitors can be divided into two different categories, 
non-covalent (competitive) and covalent inhibitors, depending on their mode of 
action. 
1.3.1 Competitive glycosidase inhibitors 
A strategy to develop potent competitor inhibitors towards a specific glycosidase is 
to target the transition state that is formed during the catalytic cycle of the enzyme. 
The rationale for this approach is due to the fact that the transition state is the species 
with the highest energy formed during the catalytic cycle and enzymes have evolved 
to form strong binding interactions with such species.44 During the development of a 
competitive inhibitor the charge distribution in the transition state is taken into 
account as well as the geometry adopted in the catalytic site.44 Transition state theory 
has proven successful, and has been applied in different areas ranging from 
agrochemical (insecticides), anti-diabetic, antiviral and molecular therapy for human 
genetic disorders.45,46 Two examples of different competitive inhibitors, in this case 
compounds that were developed to inhibit type II diabetes and influenza A virus are 
shown. Miglitol (5) is a second-generation α-glucosidase inhibitor prescribed 
towards type II diabetes, whilst Tamiflu® (6) was developed as a competitive 
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inhibitor of influenza neuraminidase, a key enzyme in the life cycle of influenza A 
virus.45 
Both compounds attempt to mimic the charge distribution that occurs during the 
catalytic cycle, as well as the geometry of the sugar ring at the transition state. 
1.3.2 Covalent inhibitors 
Covalent inhibitors are a class of molecules that inactivate the enzyme through the 
formation of a covalent bond between the inhibitor and the enzyme.47 The enzyme 
activity is reduced as the inhibitor may either physically block the access of the 
substrate to the active site, or may modify an important active site residue, which is 
essential in the catalytic cycle.47 The covalent bond formed between enzyme and 
inhibitor is usually a result of a nucleophilic residue present in the enzyme attacking 
an electrophilic centre of the inhibitor. Covalent inhibitors have been used for a 
myriad of applications, such as to identify the residues within the active site and their 
function; and to determine the role of an enzyme in a complex biological system by 
inhibiting it and measuring the effects of this inhibition in the system.47 
Covalent inhibitors can be separated into two broad classes, affinity probes and 
mechanism-based inhibitors.47 Affinity probes are molecules that are divided in two 
regions, one that is designed to afford specificity towards a given enzyme and a 
reactive functionality that irreversibly binds to a neighbouring region of the 
enzyme.47 This irreversible bond will not necessarily be formed in the active site, 
since the reactive functionality does not possess any specificity to any amino acid 
residue in the active site. Affinity probes can be divided in two classes, ones that are 
inherently reactive as a consequence of their chemical structure (7); and 
photo-affinity labels (8), which require external energy (such as light) to be activated 
towards reacting with the enzyme.47,48 
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A mechanism-based inhibitor, as opposed to affinity labels, is a molecule that is 
chemically inert and requires specific activation by processing through the catalytic 
process of the enzyme to become activated.47 Regarding glycoside hydrolases, this 
activation can occur either by the hydrolytic cleavage of a glycosidic bond to release 
a reactive aglycone that can bind with a protein residue. Looking firstly at the class 
of inhibitors with a reactive aglycone, two compounds (9 – 10) are shown that were 
tested against yeast-α-glucosidase and almond-β-glucosidase (Figure 3).47 The 
α-glucoside (9) was tested against yeast α-glucosidase inhibiting it (Ki = 0.7 mM) 
through its reactive aglycone (13), whilst the β-glucoside (10) was tested against 
almond β-glucosidase inhibiting it (Ki = 1.7 mM) also via its reactive aglycone 
(14).49,50 After the enzymatic cleavage of the glycosidic bonds, the aglycones (11 and 
12) rapidly decompose, releasing an HF molecule and generating a reactive species 
(13 and 14). 
Alternatively a nucleophilic residue attacks a position in the inhibitor that has been 
activated by the general acid residue.47 We will focus our attention on 
mechanism-based inhibitors of glycoside hydrolases, their mode of action and 
applications. 
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Figure 3 Two examples of mechanism-based inhibitors (9 and 10) towards yeast-α-glucosidase and 
almond-β-glucosidase, and the mechanism of formation of the reactive aglycones (13 and 14).47 
1.3.3 Fluorinated carbohydrates as mechanism-based inhibitors of 
retaining glycosidases 
Fluorinated glycosides have found much use as a class of mechanism-based 
inhibitor, specific to retaining glycosidases owing to their mode of action. These 
inhibitors rely on the differentiation of rates between the two key steps involved in 
the catalytic mechanism, the glycosylation and deglycosylation rates (Scheme 2). 
The presence of a fluorine at the carbon adjacent to the anomeric centre leads to the 
destabilization of the formation of positive charges at the anomeric centre during the 
transition states due to the electronegativity of fluorine. This destabilization leads to 
a reduction in the rate of formation of the glycosyl-enzyme intermediate 
(glycosylation) and its subsequent hydrolysis (deglycosylation) (Scheme 4).47 The 
incorporation of a good leaving group at the anomeric carbon enables the 
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glycosylation step to still occur at an appreciable rate. Owing to the difference in 
relative rates between both steps, the covalent intermediate will accumulate, leading 
to enzyme inhibition.51,52 
O 
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OH 
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HLG 
k1 
k2 
H2O 
Nuc 
Nuc 
H 
Nuc 
H 
Scheme 4 General proposed mechanism of inactivation of retaining exo-β-glycosidase by a 
fluorinated-β-glucoside.47 HLG – Protonated leaving group. 
The enzymatic activity can be regained by hydrolysis of the glycosyl-enzyme 
intermediate.47 
A range of fluorinated glycosides have been synthesised (15 - 18) and tested against 
a myriad of α- and β-retaining glycosidases (Figure 4).37,47,52-55 Although these 
compounds do not render the enzyme inactive per se, the intermediate that is formed 
between the inhibitor and the catalytic nucleophile is stable enough to inhibit the 
enzyme through accumulation of the glycosyl-enzyme intermediate. 
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Figure 4 Structures of some fluorinated glycosides. DNP – 2,4-dinitrophenyl, 
TNP - 2,4,6-trinitrophenyl.47 
One of the uses of mechanism-based inhibitors is to label and identify the 
nucleophilic amino acid residues, since a covalent glycosyl-enzyme bond is 
formed.51 There are several examples in the literature that use this class of 
compounds to determine which of the catalytic amino acid residues is responsible for 
the nucleophilic attack, such as E. coli lacZ β-galactosidase, CGTase, almond 
β-glucosidase; identification of threonine as the nucleophilic residue in Ferroplasma 
acidiphilum and tyrosine in trans-sialidases.35,56-60 
Moreover, the rationale behind the mode of action of the fluorinated inhibitors has 
been applied to study different enzymes in order to identify the amino acid residue 
that is involved in the nucleophilic attack.61 For example, the nucleophilic amino 
acid residues present in xylanases and galactosidases were identified as a glutamate 
and aspartate residues respectively.62,63 
The mode of action of the mechanism-based inhibitors to halt the enzyme is 
intertwined with the catalytic mechanism and catalytic residues used naturally by the 
enzyme. This class targets the nucleophilic amino acid residue, and as it was shown 
this amino acid is of paramount importance to the activity of the enzyme. Such an 
approach is of use when developing new inhibitors against pathogenic enzymes. 
Pathogenic enzymes are able to mutate their catalytic amino acid residues; however, 
if such a mutation occurs with a nucleophilic residue, the activity of the enzyme 
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would be compromised, losing efficacy and ultimately, the mutated enzyme would 
not be functional. 
1.4 Thesis overview 
This thesis is presented in two parts. Part One is concerned with the development of 
2,3-difluorosialic acid derivatives as mechanism-based inhibitors of influenza 
neuraminidases, a crucial enzyme in the life cycle of the influenza virus. A brief 
introduction to the influenza virus is presented, followed by a description of the 
synthesis of the target compounds and the inhibition results of these compounds 
against a panel of strains of influenza virus. 
Part Two is dedicated to the development of 2,3-difluorosialic acid derivatives as 
mechanism-based inhibitors towards Trypanosoma cruzi trans-sialidase, an enzyme 
that has an important role in the life cycle of Trypanosoma cruzi parasite, which is 
the causative agent of Chagas’ disease. An overview of Chagas’ disease will be 
presented followed by a description of the synthetic methods employed to synthesise 
the target compounds, as well as results of biological testing against the parasite. 
The general strategy for both projects is based on a series of modifications to the 
parent compound, 2,3-difluorosialic acid (19), in order to generate potent and 
specific inhibitors to influenza neuraminidase and Trypanosoma cruzi trans-sialidase 
(TcTS). 
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Chapter 2 - Introduction to influenza A virus 
2.1 Prelude 
Historically, there are a number of reliable recordings of influenza pandemics dating 
back to the 18th century, although it was not until 1918-20 that the first well 
documented account of an influenza pandemic was recorded.64 This pandemic 
became known as the “Spanish flu” and it is considered that half of the world’s 
human population at the time was infected, with the death toll estimated to be 
between 50 and 100 million people.65,66 
Following the “Spanish flu” of 1918, caused by a strain of H1N1 influenza A virus, 
there were two more influenza pandemics in the last century, arising in 1957-58 and 
1968, with the appearance of two new strains of influenza A virus, those being H2N2 
and H3N2 respectively. Both of these strains were originally of avian origin, but 
underwent a genomic reassortment with a circulating strain of human H1N1.67 The 
next major outbreak of influenza A virus occurred in 1997, where a new strain, 
H5N1, (commonly referred to as “bird flu”) emerged in the human population. This 
subtype is still active, with a new outbreak occurring in 2005; however, it has not 
reached pandemic status.65 The World Health Organization (WHO) continues to 
monitor this H5N1 strain of influenza A virus and, in the beginning of 2010, there 
were further cases recorded of infection by this strain.68 
In 2009, when the world was vigilant towards H5N1 and expecting the next 
pandemic to arise from this strain, the WHO announced the first pandemic of the 21st 
century caused by an H1N1 strain which originated from pigs (commonly referred to 
as “swine flu”). This H1N1 strain had been endemic in pigs since 1918, when the 
virus crossed the species barrier to infect them and had remained virtually 
unmodified until recently.69 
The drugs currently available for the treatment of the influenza virus proved effective 
towards the outbreak of H5N1 and H1N1, although some serious setbacks emerged. 
One of the most worrying factors was the rapid development of resistance towards 
the approved drugs. These high levels of resistance are derived from a number of 
point-mutations in key enzymes, with one mutation in particular found to be present 
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in virtually all of the isolates of seasonal influenza H1N1 of 2009, making the front 
line drug against influenza virus virtually ineffective.70 As a consequence, there is an 
urgent need to develop new inhibitors towards the influenza virus that are less 
susceptible to drug induced resistance. 
2.2 The influenza A virus family 
The influenza virus belongs to the Orthomyxoviridae family, which is characterised 
by having six or eight single-stranded negative-sense RNA segments and includes six 
genera, Influenzavirus A, Influenzavirus B, Influenzavirus C, Isavirus, Thogotovirus 
and Quarjavirus.71 The genus Isavirus consists only of the salmon anaemia virus, 
whilst the Thogotovirus has three different viruses: Thogoto; Dhori; and Araguari 
virus. Quarjavirus was the last genera to be classified into the Orthomyxoviridae 
family and it is comprised of three different viruses: Quaranfil; Johnston Atoll; and 
Lake Chad virus. Due to the genetic capacity of the Orthomyxoviruses to undergo 
reassortment within a specific genus, new virus strains can emerge that continue to 
elude the immune response and infect humans, poultry and livestock.71-73 By far the 
most important virus from this family in terms of infection and mortality to humans 
is influenza A virus. 
2.3 Structure and life cycle of influenza A virus 
As mentioned previously, influenza A viruses are single-stranded negative-sense 
RNA viruses. Their genome is divided into eight segments which encode for 10 viral 
proteins: the polymerases PA, PB1 and PB2; hemagglutinin (HA); nucleoprotein 
(NP); neuraminidase (NA); ion-channel proteins M1 and M2; and finally 
non-structural proteins NS1 and NS2 (Figure 5).65,74-76 
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Figure 5 Cartoon illustration of an influenza virus particle. Details of hemagglutinin, neuraminidase, 
the M2 ion channels and the RNA material (RNP) are shown.74 
The first step in the infection process involves the binding and fusion of the viral 
particle onto the host cell (Figure 6).77 This process is facilitated by hemagglutinin 
proteins present on the virion surface, binding to terminal sialic acid residues present 
on glycoproteins, or glycolipid, receptors located on the host cell surface.78 
Following binding to the host cell surface, the viral particle is internalised via 
endocytosis to produce an endosome within the cell cytoplasm. The M2 ion-channel, 
present in the viral lipid bilayer, facilitates fusion of the viral membrane with the 
endosome, by allowing the passage of H+ from the endosome to the interior of the 
viral particle. This leads to a structural modification of hemagglutinin, which extends 
a fusion peptide towards the endosome membrane in order to fuse both membranes, 
liberating the viral RNA into the host cell cytoplasm.79-81 Additionally, the M2 
protein controls the pH in the Golgi apparatus during hemagglutinin biosynthesis.76,78 
Viral RNA is then transported to the nucleus, where transcription occurs. The M1 
matrix protein forms a protective layer within the viral particle for the RNA material, 
and once the viral and cellular membranes have been fused it will interact with the 
host cell genome, nuclear export factor and initiating progeny viral assembly.76,78 
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Figure 6 Schematic representation of the replication cycle of influenza A virus.77 
The role of the nucleoprotein, NP, is to encapsulate the viral RNA once in the 
nucleus of the host cell, whilst the non-structural proteins NS1 and NS2, the PB1, 
PB2 and PA polymerases are involved in the process of viral RNA 
transcription.65,76,78 The newly transcribed viral RNA is then released from the 
nucleus into the cytoplasm where it can migrate to the inner cell membrane. 
Furthermore, mRNA transcribed from the viral RNA is translated into the various 
viral proteins which also begin to aggregate near the host cell membrane. The 
aggregation of the viral material near the host cell membrane gives rise to the 
formation of a capsule, or envelope, utilizing the host cell membrane and is aided by 
the M1 protein. Once the budding process is complete, the newly formed viral 
membrane detaches from the host membrane, forming a new viral particle. Once the 
new viral particle is formed, it first remains attached to the host cell membrane 
through binding of its hemagglutinin protein to the terminal sialic acid present on cell 
surface glycoconjugates. The neuraminidase enzyme now plays a crucial role at this 
late stage of viral replication, as it is required to hydrolyse the terminal sialic acid 
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residues on the host cell surface receptors in order to liberate the new viral particle 
from the infected cell.76,82 More recently, it has been reported that neuraminidase 
also has an active role in the initiation of influenza virus infection in the human 
airway epithelium, where it is thought that the existence of mucins and cilia, amongst 
other glycoconjugates with terminal sialic acids, could hinder access of the virus to 
the target cells.83 Therefore, neuraminidase aids the virus in proceeding through the 
human airway epithelium by cleaving the terminal sialic acids present on 
glycoconjugates, enabling the virus to reach the lower respiratory tract (Figure 7).84 
Figure 7 Cartoon representation of the different stages involved with an influenza virion proceeding 
across the human airway epithelium to reach a suitable endocytic site.84 
2.4 Nomenclature of influenza A viruses and their sub-types 
The nomenclature (HxNy) of the different subtypes of influenza A virus relates to the 
immunological characteristics of the hemagglutinin and neuraminidase surface 
proteins. Presently, there are 16 different hemagglutinin subtypes (H1-H16) 
identified, and nine different subtypes of neuraminidase (N1-N9).85,86 
The large diversity of subtypes of hemagglutinin and neuraminidase is a result of two 
different processes known as antigenic drift and antigenic shift (Figure 8).87 
Antigenic drift occurs as a result of random errors during polymerisation of the viral 
RNA (where the rate of mutation is about 1 in 104 bases per replication) 
(Figure 8, a)).88 If a host cell is infected with two strains of influenza virus, a process 
called antigenic shift can occur. The viral RNA is divided into segments, with each 
carrying genetic information; therefore, when two different strains infect the same 
host cell the probability of the genetic information from strain X being exchanged 
with strain Y is elevated (Figure 8, b)).65,85 In combination, these two processes are 
capable of continually generating new subtypes of influenza viruses with the 
potential to initiate a new pandemic. 
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a) Antigenic drift b) Antigenic shift 
Figure 8 Illustration of the process of antigenic drift and shift in influenza virus.87 a) Small mutations 
occurring during replication; b) Genetic information exchange between different strains of influenza 
virus. 
2.5 Therapeutic targets for the clinical treatment of influenza A 
infection 
Looking closely at the life cycle of influenza virus there are several key stages that, if 
inhibited, would hinder its replication and have the potential to act as therapeutic 
targets. These stages include the viral uncoating process, where the role of the M2 
ion-channel is of prime importance for effective release of the viral RNA into the 
host cytoplasm; the RNA transcription process, where inhibition of the RNA 
polymerase would halt the replication of the viral RNA; and finally, the viral release 
process, where the action of neuraminidase is of paramount importance for the 
efficient release of new viral particles from the host cell surface (Figure 6). 
For the past several decades, numerous small molecules have been developed to 
inhibit these processes with reasonable success; however, the rapid development of 
resistance by the virus or the toxicity associated with the inhibitors has been a serious 
handicap, significantly impairing their long-term effectiveness and use. 
2.5.1 M2 ion-channels 
A class of compounds called adamantamines were developed in order to inhibit the 
M2 ion-channel, which is closely linked to the viral uncoating process. Two 
compounds have been approved onto the market, amantadine (Symmetrel®) (20) and 
22 
Chapter 2

rimantadine (Flumadin®) (21) and are specific towards influenza A virus, since 
influenza B virus does not possess the M2 protein. 
Resistance arose rapidly towards both of these two compounds, which was a major 
setback to their use as stand-alone therapeutics. As such, they are now only used as a 
component of combination therapy in the presence of other inhibitors.89-91 
2.5.2 RNA transcription 
The inhibition of viral RNA transcription and genome replication can be achieved by 
using ribavirin (Virazole®) (22), which lowers the intracellular GTP levels via the 
inhibition of inosine 5’-monophosphate dehydrogenase as well as through 
interference with transcription and genome replication.92 Although rbavirin (22) has 
so far only been approved for the treatment of hepatitis C, it has been tested against 
wild type H5N1 in vivo.93 The treatment of H5N1 infected mice with either ribavirin 
(22), oseltamivir (6) or amantadine (20) at a dose of 20 or 40mg/kg/day showed an 
average survival rate of 30% for each. However, when ribavirin (22) was used in a 
combination therapy with either oseltamivir (6) or amantadine (20), the survival rate 
increased to 90%, showing a significant synergetic effect for these combinations.93 
So far however, the use of ribavirin (22) is limited due to the severity of side effects 
that it causes, which in extreme cases can include haemolytic anaemia and the 
possibility of teratogenic effects in pregnant women.92 Another inhibitor of RNA 
transcription that has shown promising results is the pyrazine derivative, T-705 
(Favipiravir) (23) which is now in phase II clinical trials.94 Once T-705 (23) enters 
the cell it is converted into its active form, ribofuranosyl triphosphate, T-705RTP 
(24) by the host’s cellular glycosylation, phosphorylation and kinase pathways.94,95 
23 
Chapter 2

O 
NHO 
N 
N 
H2NOC 
HO OH 
22 
F 
N 
CONH2 
F N CONH2 O O O 
NP P PHO O O O O O 
N OH OH OH OH 
HO OH 
23 24 
T-705RTP (24) is a general inhibitor of RNA type viruses, acting by selectively 
inhibiting the viral RNA polymerase.92,95 Smee et al have studied the therapeutic 
effects of using T-705 (24) as a single drug and in combination with oseltamivir (6) 
and zanamivir (25) to treat mice infected with the H1N1, H3N2 and H5N1 strains of 
influenza A.94 The results observed illustrate that used as a stand-alone therapy; 
T-705 (24) does not have a significant effect on the survival rate of the animals. 
However, when used in a combined therapy with either oseltamivir (6) or zanamivir 
(25), survival rates increase dramatically, from an average of 20% survival in 
monotherapy to an average of 90% in the combination therapy, irrespective of the 
strain under analysis.94 T-705 (24) has also shown minor interactions with human 
DNA polymerase, resulting in a small number of side effects in humans during 
clinical trials.96 
2.5.3 Influenza neuraminidase 
Influenza neuraminidase (EC 3.2.1.18) is an exo-glycohydrolase which catalyses the 
hydrolysis of α-ketosidically-linked terminal sialic acids from glycoconjugates.97 As 
mentioned previously (Chapter 2.3) the hydrolysis of sialic acid from the 
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glycoconjugates can facilitate the progression of the virus in the upper respiratory 
tract, as well as the release of the progeny viral particles that would otherwise remain 
bound to the host cell surface via sialic acid-hemagglutinin interactions and be 
phagocytised by the host immune system.77,98 
Over the past few decades, the determination of the X-ray crystal structure of 
influenza neuraminidase, allied with the study of its biochemical properties, has 
provided new opportunities for the development of several novel therapeutics.99,100 
The study of the catalytic mechanism of influenza neuraminidase greatly assisted the 
development of the two neuraminidase inhibitors currently approved for the 
treatment of influenza, Relenza® (25) and Tamiflu® (6). A detailed explanation of 
both inhibitors is given in subsection 2.6. 
The current accepted catalytic mechanism of influenza neuraminidase is composed 
of four major steps. These involve the binding of the sialic acid substrate, protonation 
of the anomeric oxygen and subsequent formation of the oxocarbenium-ion transition 
state, followed by hydrolysis of the glycosidic linkage and liberation of sialic acid 
(Scheme 5).101 Sialic acid needs to shift from the stable chair conformation to a 
pseudo boat conformation in order to interact with the arginine triad present in the 
active site of neuraminidase.77 The glycosidic hydroxyl is then protonated by the 
Asp151, with the subsequent hydrolysis of the glycosidic bond, forming the 
oxocarbenium ion transition state.77 The negative charges from Asp151 and Glu277 
are considered to stabilize the oxocarbenium ion.102 An incoming water molecule is 
then deprotonated by the same Asp151 residue, and is then able to perform a 
nucleophilic attack onto the anomeric carbon of sialic acid affording the free sialic 
acid. 
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Scheme 5 Proposed mechanism of hydrolysis of the sialic acid from the glycoconjugate (R) by 
influenza neuraminidase.77 
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2.6 Overview of competitive inhibitors of influenza neuraminidase 
The first competitive inhibitors of influenza neuraminidase were designed to mimic 
the flattened conformation adopted by the sugar ring at the transition state (26). This 
led to the development of a series of 2,3-ene derivatives based on the structure of 
2-deoxy-2,3-dehydro-N-acetylneuraminic acid (Neu5Ac2ene) (27), found to have a 
Ki of 4 µM against influenza A N2.103 
It is thought that the loss of binding energy derived by removing the hydroxyl 
present at C-2 (loss of a hydrogen bond interaction) is compensated for by the fact 
that no energy is required to distort the conformation of the ring, since it already 
exists in the geometry required to mimic the transition state.103 Although 
Neu5Ac2ene (27) showed good inhibition towards influenza neuraminidase, it was 
also found to be a potent inhibitor against bacterial and mammalian neuraminidases 
both in vitro and in vivo.103 
2.6.1 Zanamivir 
Molecular modelling, in addition to the information obtained from the crystal 
structure of influenza neuraminidase, was used in order to develop a new inhibitor. 
Several atomic probes (such as amino, carboxy and hydroxyl) were used in the 
molecular model studies, until an important interaction was discovered around the 
hydroxyl at C-4, where it was noticed that the introduction of a basic nitrogen group 
would benefit from interactions with neighbouring amino acid residues.97,101 
Therefore, 4-N-amino Neu5Ac2ene (28) and subsequently 4-guanidino Neu5Ac2ene 
(25) were synthesised and tested in vitro and in vivo against influenza A and B virus 
strains.104,105 
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Both compounds were tested against influenza A N2, with 4-N-amino Neu5Ac2ene 
(28) showing a 100 fold improvement in the Ki compared with the parent compound, 
Neu5Ac2ene (27), whilst 4-guanidino Neu5Ac2ene (25) showed an improvement of 
10000 fold. The Ki value obtained for 4-N-amino Neu5Ac2ene (28) was 40 nM 
whilst for 4-guanidino Neu5Ac2ene (25) was 0.2 nM.77 X-ray crystallographic 
structure determination of 4-guanidino Neu5Ac2ene (25) in the active site of 
influenza neuraminidase N2, showed that the guanidino group at C-4 made several 
binding interactions with glutamate, aspartate and tryptophan amino acid residues 
(Figure 9).104 In addition to the good inhibition shown by 4-guanidino Neu5Ac2ene 
(25), this compound was also highly selective for influenza neuraminidases, showing 
only low levels of inhibition towards bacterial and mammalian neuraminidases.77 
4-Guanidino Neu5Ac2ene (25) was selected as the lead drug candidate by Biota, now 
on the market as zanamivir (25). Zanamivir was the first approved drug to target 
influenza neuraminidase, under the name of Relenza® (25), in 1993.77 Due to the 
highly polar nature of Zanamivir (25), it has a low bioavailability (< 5%); therefore, 
it was developed as an inhaled formulation, delivering the drug directly to the main 
site of infection.77 Unfortunately this method of administration cannot be employed 
to people with impaired lung capacity. To address this problem new methods of 
administration are being investigated, such as an intravenous formulation; however, 
this formulation method is yet to be approved.106-108 Notwithstanding the difficulties 
associated with the administration of zanamivir (25), it is a very effective treatment 
against both influenza A and B viruses. 
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Figure 9 Interactions of 4-guanidino Neu5Ac2ene (25) with the different residues present at the active 
site of influenza A N1. Generated with LigPlot+ (PDB 2HTQ).109 
Zanamivir (25) has shown a low incidence of drug induced resistance, most likely as 
a consequence of its close similarity to the natural substrate sialic acid (4), with only 
one clinical case of resistance reported in the literature. This was detected in an 18 
month old immunocompromised child after a long period of infection with influenza 
B virus.110,111 One other mutant with a lower sensitivity towards zanamivir (25) was 
identified in a study conducted between 2006 and 2008 and a detailed account on 
these mutations is given in Chapter 6.2.112 The side effects associated with zanamivir 
(25) are very mild, and largely confined to the airways (e.g. cough, nasal symptoms), 
although episodes of bronchospasm have also been reported in patients with an 
underlying asthma conditions.113,114 
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2.6.2 Oseltamivir 
It was observed that the presence of the ring oxygen in Neu5Ac2ene (27) and 
zanamivir (25) does not contribute significantly to their binding in the active site, so 
it was considered that substituting this oxygen with a methylene isostere could help 
to increase hydrophobicity and potentially increase bioavailability, without 
introducing any loss of inhibitory activity.103 The removal of the ring oxygen would 
also allow the development of cyclohexene analogues that more closely mimic the 
geometry of the transition state by changing the position of the alkene bond.103 Two 
compounds were initially synthesised, 29 and 30, and the inhibition against influenza 
A N2 results proved encouraging.115 
Both compounds adopt half chair conformations, although they differ from each 
other by the position of the double bond. The position of the double bond proved to 
be of paramount importance when the compounds were tested, with compound 30 
(IC50 of 20 µM) observed to be 40 times more active than 29 (IC50 of 850 µM).115 In 
order to increase the binding of the compound it was planned to replace the hydroxyl 
at C-4 for an amino group and to increase the hydrophobicity it was planned to the 
replace the glycerol moiety by an hydroxyl group.103 The rationale for the 
introduction of an hydroxyl group at C-6 was that it could pose an inductive electron 
withdrawing effect, reducing the electron density of the double bond akin to the 
oxocarbenium ion which is a highly polarized species.103 Furthermore, the C-6 
hydroxyl could become the basis for the synthesis of ether analogues to further 
increase the hydrophobicity of the compound improving its potential to be orally 
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bioavailable.103 Two further derivatives were then synthesised and the results 
supported the idea that the position of the double bond is of paramount importance, 
with compound 31 having an IC50 of 6.3 µM whilst compound 32 was found to be 
inactive, when tested against influenza A N1.103,116 
Taking compound 31 as a scaffold, several alkoxy analogues were then synthesised 
in an effort to optimize the hydrophobic interactions in the binding pocket, 
previously occupied by the glycerol side chain.103 Ultimately, the pentyloxy side 
chain derivative in compound GS4071 (33) was found to be the most potent, with a 
IC50 of 1 nM against H1N1.116,117 
Although GS4071 (33) is more hydrophobic when compared to zanamivir (25), its 
oral bioavailability was still found to be poor.77 Therefore, it was decided to produce 
the ethyl ester as a prodrug, oseltamivir (6), which is readily converted into the active 
form in vivo by the action of endogenous esterases present in the liver.118 This 
compound, marketed as Tamiflu®, was approved in 1999 as the second drug 
targeting influenza neuraminidase.77 
Co-crystallization of GS4071 (33) with influenza neuraminidase, revealed that the 
alkoxy side chain is involved in several hydrophobic contacts in the space previously 
occupied by the glycerol side chain (Figure 10). Within this pocket, in order to create 
the additional space required by the alkoxy side chain, there is the movement of 
Glu276, being reoriented outwards, interacting with Arg224 creating a reasonable 
hydrophobic pocket that can accommodate the alkoxy side chain.77 
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a) 
b) 
Figure 10 a) Interactions of oseltamivir (33) with the catalytic amino acid residues of neuraminidase 
subtype N8. b) Superimposed view of the active site of influenza neuraminidase, subtype N9 (blue) 
with Neu5Ac2ene (27) and subtype N8 (green) with oseltamivir (33) where it is possible to observe 
the movement of Glu276 and Arg224. Generated with PyMOL and LigPlot+ (PDB’s 1F8B, blue, and 
2HT8, green).119 
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Oseltamivir (6) can be administered orally and displays high systemic bioavailability. 
It is very likely that these two factors played a significant role in it being selected as 
the drug of choice towards the fight against the influenza virus, and being stockpiled 
by countries around the world in preparedness for a sudden influenza outbreak.91 
In terms of side effects, oseltamivir (6), like zanamivir (25), produces very mild 
adverse effects (e.g. diarrhoea, cough); however, it has additionally been linked with 
some more serious conditions, such as an indication of mental instability and suicidal 
tendencies.120-122 Although some cases of psychiatric incidents have been recorded in 
patients using oseltamivir (6), consensus as to whether these were caused by its use 
has not been reached.122,123 Owing to the potential for psychiatric interactions it is 
now mandatory for a warning to be present in the label of oseltamivir (6).122 
In drug design, one of the major risks that researchers undertake is to design an 
inhibitor that is structurally different from the natural substrate, targeting 
non-essential amino acids for catalysis. Non-essential amino acids for catalysis are 
more likely to suffer point-mutations than nucleophilic ones, since their mutation 
does not greatly influence the overall catalytic mechanism. Comparing oseltamivir 
(6) with the natural substrate, sialic acid (4), the differences are easily apparent, and 
once in the active site both compounds are capable of interacting with different 
amino acids. Oseltamivir (6) interacts with some non-nucleophilic amino acids; 
therefore, the probability of a mutant virus arising that is resistant towards 
oseltamivir is high. The number of mutated influenza viruses resistant to oseltamivir 
(6) that circulate in the human population is already alarming, with five specific 
point mutations identified so far; however, these mutants are still sensitive towards 
zanamivir (25).91,124,125 One particular mutation that has caused concern occurred in 
H1N1 where the percentage of resistance towards oseltamivir (6) passed from 0.4% 
in the 2007-2008 flu season to a virtually 100% in the following year.70,126 A 
description of each of the specific neuraminidase point mutations conferring 
resistance to the neuraminidase inhibitors will be given in Chapter 6.2. 
2.6.3 Novel clinical candidates 
In light of the alarming rate at which resistance is being observed towards the 
currently approved neuraminidase inhibitors, there is a critical need to design and 
develop new inhibitors for the treatment of the influenza A virus before the 
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emergence of a new, global influenza pandemic with more dramatic effects than the

recent one.

In an effort to aid the development of new inhibitors towards influenza, the United

States Federal Drug Administration created a fast track programme for the

development of such drugs. Peramivir (34); a dimeric derivative of zanamivir (35);

and CS-8958 (36) are currently in clinical trials as part of this programme.
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Peramivir (34) was designed to take advantage of the hydrophobic pockets present in 
the active site. In vitro and in vivo testing showed that it is as active as zanamivir 
(25) and oseltamivir (6) in vitro, with the advantage of being highly specific towards 
viral neuraminidase over bacterial and mammalian neuraminidases.127 In human 
clinical trials Peramivir (34) has been shown to have a low oral bioavailability; 
therefore, it has been tested by intramuscular injection in vivo in mice infected with 
H1N1 (and H3N2), affording the same survival rate as oseltamivir (6) (100% with a 
10 or 20 mg/kg/day).127 Dimeric zanamivir (35) and CS-8958 (36) are long lasting 
neuraminidase inhibitors, which offer the potential for a weekly administration 
instead of a daily dosing.128,129 Furthermore, the dimeric zanamivir (35) has been 
shown to be a 100-fold more potent inhibitor than the parent compound, zanamivir 
(25), against influenza virus H1N1 and H3N2.129,130 It is thought that the increased 
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inhibitory activity of the dimeric inhibitors is due to the ability to cross-link and 
possibly cause aggregation of several viral particles.129 
Also noteworthy is the development of a new influenza virus inhibitor, that does not 
target any of the viral replication pathways or even the two viral surface proteins, 
hemagglutinin and neuraminidase. DAS181 (Fludase®) is a broad-spectrum drug 
candidate for the prophylactic treatment of the influenza virus, and is presently 
undergoing Phase II clinical trials.131 DAS181 is a recombinant fusion protein with a 
molecular mass of 45kDa, composed of the catalytic domain of Actinomyces viscosus 
sialidase and an epithelial anchoring domain of human amphiregulin.132 This new 
approach is based on the concept of cleaving cell-surface terminal sialic acid residues 
present on the respiratory epithelium; removing these receptors leads to the influenza 
virus being unable to attach itself to the host cells.133,134 By targeting the epithelium 
cells instead of the influenza virus, DAS181 avoids the potential development of 
resistance.132,135 
2.7 Aims of the present project 
The currently approved drugs, zanamivir (25) and oseltamivir (6), have already been 
observed to induce the generation of several drug resistant mutations within the 
influenza virus. This may be due to the fact that both inhibitors target the 
oxocarbenium ion-like transition state in the catalytic mechanism of neuraminidases, 
targeting non-essential amino acid residues for catalysis (Scheme 5, Chapter 2.5.3). 
As an alternative mechanism for sialidases, it has been shown that bacterial and 
parasitic sialidases use a tyrosine/glutamate couple as the catalytic nucleophile, 
rather than the more common glutamate/tyrosine couple found in the majority of 
retaining glycosidases.57 This is most likely to be due to the chemical nature of the 
substrate, sialic acid.57 Watts et. al. postulated that since sialic acid possesses a 
carboxylate group adjacent to the anomeric position, a possible nucleophilic attack 
from a glutamate residue would be unfavourable due to electrostatic interactions 
between the incoming nucleophile and the carboxylate group.57 Therefore, by 
employing a tyrosine/glutamate nucleophilic pair, the tyrosine residue is able to 
perform the nucleophilic attack without facing such repulsive electrostatic 
interactions, only achieving a considerable ionic character at the transition-state.57 
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In the first step of this alternative mechanism, a glutamate residue acts as a general 
base catalyst, deprotonating the hydroxyl group of the catalytic tyrosine residue 
(Scheme 6).136 The hydroxyl group of the tyrosine residue then acts as a nucleophile, 
attacking the anomeric position (C-2) of the sialic acid residue, forming a covalent 
sialyl-enzyme intermediate. Parallel to this action, the aglycone is protonated by an 
aspartate residue activating it towards leaving. During the glycosylation step, there is 
then the cleavage of the sialic acid from the host cell membrane glycoconjugate. 
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Scheme 6 Proposed catalytic mechanism for Trypanosoma cruzi trans-sialidase.137 
R - Glycoconjugate. 
However, the sialidase enzyme needs to complete the catalytic cycle to regain 
enzymatic activity, as its tyrosine residue remains covalently bound to the sialic acid 
residue after the first (glycosylation) step. 
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In the second stage of the mechanism, an aspartate residue deprotonates a molecule 
of water, activating it towards nucleophilic attack on the sialosyl-enzyme 
intermediate. This step passes through a second oxocarbenium ion-like transition 
state with concomitant cleavage of the bond between the sialic acid (4) and the 
tyrosine residue. This second (deglycosylation) step is important for the recovery of 
enzymatic activity. The key aspect of this alternative mechanism for sialidases is that 
a covalent bond is formed between sialic acid and the catalytic tyrosine residue, 
ultimately yielding an overall retention of configuration at the anomeric centre of the 
sialic acid. 
Recent unpublished work by the research groups of Dr. Andrew Watts and Prof 
Stephen Withers has observed that influenza neuraminidase also operates through a 
similar mechanism, with the presence of both oxocarbenium ion-like transition states 
and formation of the covalent sialyl-enzyme intermediate. This project aims to 
develop a novel class of inhibitors of influenza neuraminidase based on 
2,3-difluorosialic acid (19), and evaluate these compounds as potential therapeutics 
for the treatment of the influenza virus. However, rather than targeting the transition 
state of the neuraminidase catalysed reaction like the current therapeutics, zanamivir 
(25) and oseltamivir (6), our strategy will target the covalent sialyl-enzyme 
intermediate formed during the catalytic cycle (Scheme 6). It is anticipated that these 
compounds, known as mechanism-based inhibitors, have the potential to be less 
susceptible to drug induced resistance. By targeting key residues essential for 
catalysis, evolutionary pressure for the enzyme to mutate these specific amino acid 
residues will be greatly reduced, as mutations to catalytically essential residues will 
result in the generation of non-viable influenza neuraminidase. 
In order to achieve this, an approach based on 2,3-difluorosialic acid (19) was 
developed. It has been shown by Watts et al that 2,3-difluorosialic acid differentiates 
the rate constants of glycosylation (k1) and deglycosylation (k2) of Trypanosoma 
rangeli sialidase which has a similar catalytic cycle.138 The electronegative 
substituent at C-3 destabilises the formation of the oxocarbenium ion formed in the 
transition states (slowing down k1 and k2), whilst the fluorine at C-2 allows the 
glycosylation step to occur, by acting as a leaving group (Scheme 7).137,138 
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Scheme 7 Neuraminidase catalytic reaction with 2,3-difluorosialic acid (19). 
It was envisaged that the introduction of a series of N-alkyl amines at C-7 (namely 
7-N-ethyl-N-methylamino (37), 7-N-ethylacetamido (38) and 7-N,N-diethylamino 
(39)) could result in an increase of hydrophobic and hydrophilic contacts with 
neighbouring amino acid residues around the pocket of the glycerol moiety akin to 
those observed in oseltamivir (6).139 
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In addition, it was shown by Meindl that the 5-N-trifluoracetamido-Neu5Ac2ene (40) 
had an IC50 of 8.6 µM; therefore, it was decided to probe the change of the 
N-acetamido group to a N-trifluoroacetamido group in the 2,3-difluorosialic acid 
moiety (41).140 
In addition to the modifications at C-7 and C-5, a study to probe the interactions 
found around an N-alkylamine substituent at C-4 was undertaken.97 For this reason a 
series of 4-epi-N-alkylamines Neu5Ac2ene derivatives were synthesised, namely 
4-epi-N-methylamine (42), 4-epi-N-ethylamine (43) and 4-epi-N,N-diethylamine 
(44). 
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The reasons why it was decided to use the Neu5Ac2ene scaffold were due to the

straightforward synthesis of the common precursor for the synthesis of the C-4

and C-3 could be attempted.

N-alkylamines, and once they were inserted, the introduction of the fluorines at C-2
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Chapter 3 - Synthesis of C-7 modified 
2,3-difluorosialic acids 
3.1 Prelude 
This chapter describes the synthesis of several 7-N-alkylamine 2,3-difluorosialic 
acids; 7-N-ethyl-N-methylamino (37), 7-N-acetamido-N-ethyl (38) and 
7-N,N-diethylamino (39) -2,3-difluorosialic acids, as mechanism-based inhibitors of 
influenza neuraminidase. We aimed to probe the effect of these substitutions on the 
binding to Arg224 and Glu276, which are associated with hydrogen bond forming 
interactions with the glycerol side chain of sialic acid. 
It was predicted that compound 7-N-ethyl-N-methylamino-2,3-difluorosialic acid 
(37) may represent an isosteric analogue of the glycerol side chain of sialic acid. It 
was hoped that this compound might provide information regarding the importance 
of the hydrogen bonds formed between the hydroxyl groups of the glycerol side 
chain and the amino acid residues (principally Arg224 and Glu276). Furthermore, by 
replacing the hydrophilic side chain with a hydrophobic one, the overall 
hydrophobicity of the compound could be also increased. 
The 7-N,N-diethylamino derivative (39) was designed as an isostere of the pentyloxy 
ester side chain of oseltamivir (6). In addition to the presence of the diethyl side 
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chain, the presence of a nitrogen, instead of oxygen, may show further hydrogen 
bonding interactions to residues and this could improve the binding. 
Compound 7-N-ethylacetamido-2,3-difluorosialic acid (38) was synthesised after the 
study of the crystal structure of influenza neuraminidase N2, where the presence of 
amino acid residues (Arg224 and Glu276) above the nitrogen atom that could 
interact with an acetate moiety was observed (A. Watts, unpublished results). 
Therefore, it was envisaged that the synthesis of the 7-N-ethyl-N-acetamido 
derivative could help to maximize this possible interaction. 
3.2 Retrosynthetic analysis 
Our general strategy for the construction of the series of 7-N-alkylamino 
2,3-difluorosialic acids was based on the retrosynthetic analysis shown in Scheme 8. 
Retrosynthetic cleavage of the bond indicated on the 7-N,N-dialkylamino (45) 
furnishes the C-7 aldehyde (46) as a viable precursor. This key intermediate contains 
the aldehyde, which could support the introduction of the N,N-dialkylamines via a 
reductive amination. It was anticipated that the aldehyde intermediate (46) could be 
derived from the 2,3-difluorosialic acid (47) through an oxidative cleavage of the 
glycerol side chain. The synthesis of 2,3-difluorosialic acid (47) has been reported 
previously by Watts et al.137 
Scheme 8 Retrosynthetic scheme outlining the strategy for the synthesis of a series of 
7-N,N-dialkylamino 2,3-difluorosialic acids. 
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3.3 The synthesis of 2,3-difluorosialic acid (47) 
The synthesis of 3-fluorosialic acid (50) was accomplished enzymatically using 
N-acetylneuraminic acid aldolase (Neu5Ac aldolase, EC 4.1.3.3) following the 
literature procedure of Watts et al.137 A solution of N-acetylmannosamine (48) and β­
fluoropyruvic acid (49) was treated with Neu5Ac aldolase for 5 days (Scheme 9).137 
The reaction mixture was purified by passing it through an ion-exchange column 
(formate form), followed by freeze-drying the eluent, to afford 3-fluorosialic acid 
(50). 
Scheme 9 Aldolase reaction. Neu5Ac aldolase, H2O, r.t., 5 days. 
The reaction was followed using 19F NMR by monitoring the disappearance of the 
signal from β-fluoropyruvic acid (49) at δ -233.3 ppm, and the formation of a signal 
corresponding to the axial 3-fluorosialic acid (50) at δ -208.3 ppm (Figure 11). 
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t = 0 days 
t = 3 days 
t = 5 days 
A 
B 
C 
Figure 11 Overview of the aldolase reaction over 5 days, showing the consumption of 
β-fluoropyruvic acid (δ -233.3 ppm) and the formation of the product, axial 3-fluorosialic acid (50) (δ 
-208.3 ppm). t - time; A – β-fluoropyruvic acid; B – C-3 equatorial fluorine; C – C-3 axial fluorine 
(desired product). 
The aldolase used in this reaction is a type I aldolase, which forms a Schiff base 
intermediate in the active site with β-fluoropyruvic acid (49), adding the 
β-fluoropyruvic acid stereospecifically to the acyclic form of N-acetylmannosamine 
(48). The β-fluoropyruvic acid (49) forms an enamine with an active site residue, 
Lys, subsequently reacting with the aldehyde of N-acetylmannosamine, which is 
activated by protonation from an active site residue, His, generating the new carbon-
carbon bond (Scheme 10).141,142 
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Scheme 10 Aldol reaction between N-acetylmannosamine (48) and β-fluoropyruvic acid (49) 
catalysed by Neu5Ac aldolase.142 The numbering of the carbon backbone is indicated corresponding 
to the final compound, 3-fluorosialic acid (51). 
Under the experimental conditions used here, the axial isomer of the fluorine at C-3 
was produced as the major product. The ratio between the fluorine having an axial or 
equatorial orientation depends on the relation between β-fluoropyruvic acid (49) and 
N-acetylmannosamine (48), with a ratio of 1:2 affording as the predominant isomer, 
the axial one. In the work developed by Beliczey et al, no specific reasons were 
given for this occurrence.143 
The optimal conditions for the aldolase reaction are at a pH 6-9 and at 37 ºC.141 It has 
been shown that Neu5Ac aldolase, although being specific to the pyruvate donor 
group, can accept slight modifications to the molecule such as the presence of a 
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fluorine at the β carbon. On the other hand, the enzyme is able to accommodate a 
variety of modifications at C-4, 5 and 6 of the acceptor hexose moiety.137,141 
However, modifications at the C-3 hydroxyl of the hexose moiety (labelled as C-6 in 
Scheme 10) are not tolerated by the aldolase, as this hydroxyl is crucial for the 
formation of the new nonulose ring, since this hydroxyl oxygen will ultimately 
become the endocyclic oxygen of the sialic acid formed.142 As a result of the subtle 
change of using β-fluoropyruvic acid as a substrate a large reduction in the rate of 
reaction was observed. 
The 3-fluorosialic acid (50) was then esterified by treatment with trifluoroacetic acid 
in methanol to give the 3-fluorosialic acid methyl ester (52), which was used in the 
next step without further purification (Scheme 11). Global acetylation of the 
3-fluorosialic acid methyl ester (52) was achieved using acetic anhydride in pyridine 
which proceeded slowly over 4 days (owing to the low reactivity of the anomeric 
hydroxyl) to give the per-O-acetylated-3-fluorosialic acid methyl ester (53) in good 
overall yield (72% from the aldolase reaction) (Scheme 11).137 
Scheme 11 Formation of per-O-acetylated 3-fluorosialic acid (53). a) TFA, MeOH, r.t., O/N; b) Ac2O, 
Pyr, r.t., 5 days. 72% from the aldolase reaction. 
The low reactivity observed for the anomeric hydroxyl is likely to be a consequence 
of the fluorine present at C-3, which will reduce the nucleophilicity of the hydroxyl. 
Furthermore, the anomeric hydroxyl is a tertiary hydroxyl and so sterically quite 
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hindered. The per-O-acetylated-3-fluorosialic acid methyl ester (53) was then 
selectively deprotected at C-2 using hydrazine acetate in a 1:1 mixture of DCM and 
MeOH, affording the hemiketal (54) in good yield (65%) (Scheme 12).137 
Scheme 12 Anomeric deprotection of per-O-acetylated sialic acid (53). Hydrazine acetate, 
DCM/MeOH 1:1, 4 °C, 3h, 65%. 
Owing to a higher reactivity of the anomeric acetal (relative to the other hydroxyl 
groups) combined with a weak nucleophile, hydrazine acetate, the deacetylation 
reaction is selective for the anomeric acetal.144 
It was found that the ratio of DCM/MeOH had an effect on the yield of the reaction, 
where a ratio of 1:1 gave a yield of 65%. The ratio of 4:1 DCM/MeOH was found to 
improve the yield of reaction, increasing from 65 to 81%. 
The next step in the synthesis was to introduce a fluorine atom into the anomeric 
position. Following the methodology employed by Watts et al, the hemiketal (54) 
was treated with DAST (55), in dichloromethane, at -30 ºC, resulting in the 
fluorination at C-2 to give the desired 2,3-difluorosialic acid derivative (58) in 
modest yield (45%) (Scheme 13).137 The mechanism for this reaction involves the 
nucleophilic attack on the sulfonium ion (56) by the anomeric hydroxyl of the 
hemiketal (54) to form the intermediate species (57) (Scheme 13). This intermediate 
activates the anomeric hydroxyl to become a good leaving group, which then 
undergoes SN2 displacement by a fluorine ion.145 This class of fluorination reaction 
usually occurs with stereochemical inversion of configuration at C-2. 
The existence of such intermediate species has been supported by 19F NMR data 
obtained during a similar fluorination reaction, between DAST and a glucose 
derivative.146 
The equatorial orientation of the fluorine atom at C-2 of 2,3-difluorosialic acid (58) 
was confirmed using 19F NMR. The chemical shift and coupling constant for the 
fluorine at C-2 were compared with the literature. A coupling constant between F2-F3 
of 12 Hz was observed, which is in agreement with literature.137,147 For the diaxial 
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2,3-difluorosialic acid methyl ester (59), the F2-F3 coupling constant observed was 
17 Hz, confirming a trans-diaxial relationship by comparing with values reported in 
the literature (Scheme 15).147 
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Scheme 13 Mechanism of fluorination of the hemiketal (54) using DAST (55) as the fluorinating 
agent. DAST, DCM, -30 ºC, 30 min, 45%. 
Global deacetylation of the per-O-acetylated 2,3-difluorosialic acid methyl ester (58) 
was performed following classic Zemplén conditions using a solution of sodium 
methoxide in methanol at 4 ºC, to afford the desired 2,3-difluorosialic acid methyl 
ester (47) in quantitative yield (Scheme 14).148 
Scheme 14 Deacetylation of per-O-acetylated 2,3-difluorosialic acid (58). NaOMe, MeOH, 4 ºC → 
r.t., 1h, 100%. 
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3.4 Investigation the conditions for the synthesis of the anomeric 
fluoride 
The total yield obtained for the fluorination reaction (95%) was considered ideal; 
however, a mixture of axial (35%) and equatorial (45%) fluorines at C-2 was 
produced that proved difficult to separate. The mixture of fluorine anomers at C-2 
can be rationalized if one postulates the existence of a oxocarbenium-ion (60) 
(Scheme 15). Once the oxocarbenium-ion is formed, the fluoride ion may attack the 
anomeric position at either the si-face, to form the axial isomer (59) (pathway I), or 
at the re-face, to form the equatorial isomer (58) (pathway II) (Scheme 15). 
Scheme 15 Proposed mechanism for the formation of the 2,3-difluorosialic acid methyl ester (59). 
A series of alternative fluorinating reagents were investigated, in addition to DAST 
(55) in an effort to improve the fluorination step in the synthetic pathway. These 
reagents included bis(2-methoxyethyl)aminosulfur trifluoride, Deoxo-fluor® (61) and 
morpholinosulfur trifluoride (62). The advantage of using such aminosulfur 
fluorinating reagents is that they are less reactive, potentially enabling a higher 
selectivity towards the fluorination at C-2 and reducing the possibility of undesired 
side reactions such as rearrangements and eliminations.149 
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Moreover, these aminosulfur reagents do not require elaborate experimental 
conditions or apparatus for their use.149 
In addition to investigating different fluorinating reagents, a range of temperatures 
was also tried varying from -30 ºC to reflux. The solvents employed included DCM 
(from the original conditions) and THF due to its ability to stabilize charged 
intermediates. 
The original condition, DAST in DCM at -30 ºC, was the starting point for the 
improvement of the yield (entry 1, Table 1). This condition afforded both anomers in 
a 1:1 ratio, and after purification gave the desired equatorial fluorine (58) in 
reasonable yield (45%), and the axial fluorine (59) obtained equally with a 
reasonable yield (30%). 
The solvent was then changed from DCM to THF, using DAST as the fluorinating 
agent and the reaction was performed at -30 ºC (entry 2, Table 1). This afforded the 
undesired axial fluorine exclusively in low yield (30%). An explanation for the 
predominant formation of the axial fluorination product (59), instead of a 1:1 ratio 
(entry 2, Table 1) when using THF as solvent of the reaction, could be if THF (63) is 
participating in the fluorination reaction by displacing the activated hydroxyl 
intermediate (57), which can then be attacked by the fluorine ion (Scheme 16). 
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Table 1 Overview of the different conditions used for the fluorination step. Ratio of isomers 
determined by 19F NMR. a Supplied in THF; b Supplied in toluene; a Not isolated. 
Yield (%) 
Entry Reagent Solvent Temp (ºC) Fax Feq 
of Feq 
1 (55) DCM -30 1 1 45 
2 (55) THF -30 1 0 30 
3 (61)a DCM -30 1 0 30 
4 (61)a DCM r.t. 1 1 a 
5 (61)b DCM r.t. → reflux 5 1 40 
6 (62) DCM 0 → r.t. 2 1 a 
7 (62) DCM reflux 1 0 20 
The fluorine ion can attack the intermediate (65) either at the anomeric position, 
displacing the THF to form the diaxial fluorination product (59), or at the carbon 
adjacent to the THF ring oxygen, leading to the opening of the THF ring, generating 
the 4’-fluorobutoxy-3-fluorosialic acid (64) in low yield (26%). The observed 
formation of this product serves as confirmation of participation of THF in the 
reaction. The anomeric stereochemistry of the ether derivative (64) has not been 
confirmed; however, equatorial stereochemistry presented is inferred on the basis of 
the proposed mechanism (Scheme 16). 
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Scheme 16 Possible mechanism towards the formation of compound 59 and 64 with DAST (55) in the 
presence of THF (63). 
When the hemiketal (54) was treated with either Deoxo-fluor® (61) or

morpholinosulfur trifluoride (62), a mixture of anomers was observed (entries 3-7).

When the reaction was performed in DCM with morpholinosulfur trifluoride (62) at

reflux, only the axial isomer (59) could be observed (entry 7).

Initially these findings seemed contradictory; however, further rationalization

revealed that the ether oxygens present in the structures of both Deoxo-fluor® (61)

and morpholinosulfur trifluoride (62) might be participating as a Lewis base,

stabilizing the formation of an oxocarbenium-ion (60).

The conditions investigated did not provide a method that would afford the desired

compound (fluorine in a equatorial orientation) as a pure isomer and in good yield.

The conditions that proved to be the best in terms of yield and anomeric ratio were

the ones initially used (entry 1); therefore, no improvement was attained.
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3.5 Preliminary investigations into the oxidative cleavage and 
reductive amination synthesis of a series of 7-N,N-dialkylamino 
2,3-difluorosialic acids 
In order to synthesise the desired final compounds (37 – 39) an oxidative cleavage 
was performed on the glycerol side chain of the 2,3-difluorosialic acid methyl ester 
(47), affording the aldehyde (46) which was then treated with a series of N-alkyl or 
N,N-dialkylamines to afford the desired final compounds. 
It was envisaged that the formation of the 7-aldehyde (46) could be achieved in a 
single transformation from the 2,3-difluorosialic acid methyl ester (47) by 
performing an oxidative cleavage of the glycerol side chain. An aqueous solution of 
the 2,3-difluorosialic acid methyl ester (47) was treated with a 0.4 M solution of 
sodium periodate at room temperature for 90 min followed by passage of the reaction 
mixture through a plug of silica gel in order to remove periodate salts, with no 
product being isolated (Scheme 17). 
Scheme 17 Oxidative cleavage of 2,3-difluorosialic acid (47). NaIO4, H2O, r.t., 1h30 min. 
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Considering the structure of the 2,3-difluorosialic acid methyl ester (47), the 
oxidative cleavage with sodium periodate has the potential to occur at two positions 
in the glycerol side chain, between either the C-9 and C-8, or the C-8 and C-7 diols. 
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Scheme 18 Proposed mechanism for the oxidative cleavage of the glycerol side chain of 
2,3-difluorosialic acid methyl ester (47) using sodium periodate. 
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Oxidative cleavage at either of these positions would produce the aldehydes (46 or 
66), respectively (Scheme 18). The aldehyde formed from the oxidative cleavage of 
the C-8 - C-9 diol (66) has the potential to undergo a further oxidative cleavage 
reaction between C-8 and C-7 to afford the desired aldehyde (46). 
In an attempt to determine why the formation of the aldehyde could not be detected 
upon periodate treatment of the 2,3-difluorosialic acid (47) it was decided to repeat 
the reaction and monitor the progress of the reaction by 1H NMR using periodic acid 
as the reagent (due to its higher solubility in D2O) and the 2,3-difluorosialic acid 
methyl ester (47). After only 15 min of reaction, a signal at δ 8.06 ppm could be 
observed, which was attributed to the presence of an aldehyde proton (Figure 12). 
t = 0 min 
t = 15 min 
Figure 12 1H NMR spectrum of the oxidative cleavage reaction, showing the formation of a signal at 
δ 8.06 ppm after 15 min. 
A second experiment was undertaken, using sodium periodate in water at room 
temperature (30 min) after which the solvent was removed in vacuo, and 1H NMR 
again confirmed the presence of a singlet signal at δ 8.06 ppm. These results lead us 
to propose that the aldehyde may be unstable, decomposing when passing through a 
silica gel column. Therefore, it was decided to use the product of the periodate 
reaction crude, only removing the solvent from the reaction (in vacuo). Confirmation 
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of the desired cleavage of the glycerol side chain (between C-7 and C-8) was 
provided by mass spectrometry (MS). The compound identified was not the aldehyde 
but the geminal diol (67) (322.07 m/z) (Figure 13). 
Figure 13 Mass spectrum of the C-7 aldehyde 2,3-difluorosialic acid (46). 
The next step in the synthesis involved the reductive amination at the aldehyde (46) 
with a series of amines to afford the desired C-7 modified targets. The first derivative 
synthesised was the 7-N,N-diethylamino (68). A solution of the aldehyde (46) in 
methanol was treated with diethylamine and sodium cyanoborohydride at room 
temperature (Scheme 19). 
Scheme 19 Reductive amination of the aldehyde (46). Diethylamine, NaCNBH3, AcOH, MeOH, r.t., 
O/N. 
The reaction was monitored using t.l.c. and MS, following the consumption of 
starting material. Once all starting material was consumed, the mixture was 
evaporated in vacuo and purified by passage through silica gel. Unfortunately, it was 
not possible to isolate any of the desired 7-N,N-diethylamino derivative (68). 
Several attempts where made to repeat the reaction, varying the temperature and the 
time of reaction with no positive outcome. 
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The synthesis of the 2,3-difluorosialic acid (47) compound is arduous to obtain, 
primarily due to the problems associated with the fluorination step. Therefore, it was 
decided to investigate the oxidative cleavage and reductive amination conditions 
with a more readily available substrate. 
3.5.1 Formation of the methyl sialoside (70) 
The readily available methyl sialoside (69) was selected in order to test the 
conditions for the oxidative cleavage and reductive amination at C-7. Once the 
amines are introduced at C-7, the removal of the methyl sialoside could be 
investigated and the introduction of fluorine attempted. With this intent, the 
hemiketal (54) was methylated by treatment with methyl iodide in DMF, generating 
the methyl sialoside (69) in good yield (68%) (Scheme 20).150 Deacetylation under 
Zemplén conditions afford the 3-fluorosialic acid methyl sialoside (70) in 
quantitative yield. 
Scheme 20 Formation of 3-fluorosialic acid methyl sialoside (70). a) NaH, MeI, DMF, r.t., 2h, 68%; 
b) NaOMe, MeOH, r.t. O/N, 100%. 
The 3-fluorosialic acid methyl sialoside (70) was treated with a 0.4 M solution of 
sodium periodate in water for 30 min, after which the solvent was removed in vacuo 
affording the aldehyde (71), which was used without further purification (Scheme 
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21). The aldehyde was subsequently dissolved in methanol and ethylamine added 
and the reaction was stirred at room temperature for 2h. The solution was treated 
with sodium cyanoborohydride at room temperature and left stirring over night. The 
solvent was then evaporated in vacuo and the reaction mixture passed through a plug 
of silica affording the 7-N-ethylamine-3-fluorosialic acid methyl sialoside (72). 
Scheme 21 Formation of 7-N-ethylamine 3 fluorosialic acid. a) 0.4 M NaIO4, H2O, r.t., 30 min; b) 
Ethylamine, NaCNBH3, AcOH, MeOH, r.t., O/N; c) 1 M HCl, H2O, r.t. 
In order to introduce the fluorine at the anomeric position, removal of the methyl 
substituent of the 7-N-ethylamine-3-fluorosialic acid methyl sialoside (72) was 
attempted. The conditions tried, 1 M HCl at room temperature, were ineffective and 
no reaction was observed. When the concentration of hydrochloric acid was 
increased to 6 M, and used at room temperature no reaction was observed. At reflux, 
decomposition of the starting material was observed by t.l.c. and MS. A possible 
reason as to why the removal of the methyl sialoside was not possible is the fluorine 
at C-3. The fluorine could be inductively reducing the electron density away from the 
glycosidic hydroxyl, hampering the deprotection reaction. 
With this result, it was clear that this route was not realistic in terms of achieving the 
desired 7-N-alkylamine 2,3-difluorosialic acids, as the removal of the methyl 
sialoside required conditions that proved to be too extreme for the compound, 
resulting in decomposition. 
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3.5.2 Formation of the benzyl sialoside (75) 
As the previous route involving the methyl sialoside proved unsuccessful, an 
alternative protecting group was investigated, this time forming a benzyl sialoside 
that should be possible to remove via a simple hydrogenation, after the oxidative 
cleavage and reductive amination reactions were performed. The benzylation of the 
hemiketal (54) was carried out using benzyl bromide in DMF, affording the 3­
fluorosialic acid benzyl sialoside (74) in excellent yield (95%). Zemplén conditions 
were used to deacetylate the benzyl sialoside (74), affording the 3-fluorosialic acid 
benzyl sialoside (75) in excellent yield (95%). Oxidative cleavage of the 
3-fluorosialic acid benzyl sialoside (75) was performed under similar conditions to 
those used successfully to synthesise aldehyde (71), i.e. a 0.4 M solution of sodium 
periodate in water, at room temperature for 30 min. The reductive amination was 
performed in methanol using different amines, ethylamine; diethylamine; and 
dimethylamine; with sodium cyanoborohydride and acetic acid, at room temperature. 
In an attempt to simplify the purification procedure and the characterisation process, 
the synthesised 7-N-alkyllamines were acetylated (Scheme 22). 
During the reductive amination, the presence of salts could be observed, from 
unreacted sodium periodate and excess sodium cyanoborohydride. It was considered 
that the presence of such salts could hamper the reductive amination since the 
reducing agent could be reacting with the excess periodate, impeding the reductive 
amination step. In order to address the problems derived from the presence of sodium 
periodate salts in the reductive amination, the oxidative cleavage reaction products 
were passed through a reverse phase column, in an attempt to separate the salts from 
the product, the C-7 aldehyde (76). Using this method, the majority of salts could be 
removed successfully. The next approach attempted was to precipitate the unreacted 
periodate by the addition of cold THF to the reaction mixture once this was 
complete. During the reductive amination, a large excess of the reducing agent was 
used. Once the reaction was complete, this excess of NaCNBH3 had to be removed; 
however, this procedure proved to be complicated due to a similarity of polarities 
between the sodium cyanoborohydride salts and the products, when separating them 
using silica gel. 
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Scheme 22 Formation of 7-N-ethylacetamido (70) and diethylamino (78) 3-fluorosialic acid benzyl 
sialosides. a) NaH, BnBr, DMF, r.t., 1 day, 95%; b) NaOMe, MeOH, r.t., 1h, 95%; c) NaIO4, H2O, r.t., 
30 min; d) i) Amine, AcOH, NaCNBH3, MeOH, r.t., O/N; ii) Ac2O, Pyr, r.t., O/N. 36% for 
N-ethyl-N-acetamido (77) (over 3 steps); 2% for N,N-diethylamine (78) (over 3 steps). 
A solution was to acetylate the reaction mixture, generating the acetylated final 
compounds, which at this stage were easier to separate from the reducing agent by 
work up and chromatography. Therefore, the 7-N-ethylamino-3-fluorosialic acid 
benzyl sialoside was treated with acetic anhydride in pyridine at room temperature 
(overnight). The solvent was then removed in vacuo and the reaction mixture passed 
through a silica gel column to afford the 4-O-acetyl-7-N-ethyl-N-acetamido-3­
fluorosialic acid benzyl sialoside (77) in reasonable yield (36%). 
Once the 7-N-ethyl-N-acetamido was purified, the removal of the benzyl group was 
attempted successfully by using hydrogen with palladium adsorbed on charcoal 
(10%) in THF acidified to pH 5 with AcOH to give the hemiketal (79) in moderate 
yield (48%) (Scheme 23). 
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Scheme 23 Formation of 7-N-ethylacetamido-2,3-difluorosialic acid (80). a) H2, Pd/C (10%), THF, 
AcOH, r.t., 10 days, 48%; b) DAST, DCM, -30 ºC, 30 min, 50%. 
The hydrogenolysis reaction proved to be very slow, taking 10 days to reach 
completion, and required the addition of fresh catalyst each day. Notwithstanding, 
the hydrogenation was accomplished after 10 days affording the hemiacetal (79) in 
moderate yield (48%). A variety of conditions were investigated in an attempt to 
improve the rate of reaction. Tetrahydrofuran and methanol were investigated as 
alternative solvents, using Pd/C 10%; however, no improvement in rate was 
observed. An alternative Pd catalyst, Pd(OH)2, was investigated using either 
tetrahydrofuran or methanol, again with no improvement in the rate. Finally, the 
reaction was also attempted at high pressure (4 atmospheres), with again no 
significant improvement to the rate of reaction. 
Despite our lack of success at improving the rate of reaction, the removal of the 
benzyl sialoside could be effected over 10 days, with a reasonable yield (48%). 
With the anomeric hydroxyl deprotected (79), we then attempted the fluorination of 
the anomeric position using DAST (55). This reaction proceeded smoothly, giving 
the desired 7-N-ethylacetamido-2,3-difluorosialic acid methyl ester (80) in moderate 
yield (50%). Although this synthetic route produced the desired 7-N-ethylamido-2,3­
difluorosialic acid (80), the deprotection step of the benzyl sialoside proved to be less 
than ideal. It was hypothesised that due to the presence of the fluorine at C-3, the 
stability of the sialoside present at C-2 is increased. Although the bond that is being 
cleaved is not the glycosidic one (as with the methyl sialoside), but that between the 
63 
Chapter 3

glycosidic oxygen and the CH2, the effect of the electronegativity of the fluorine at 
C-3 makes the deprotection of the anomeric hydroxyl more complex than it would 
have been if the fluorine at C-3 were to be absent. 
3.5.3 Formation of the para-methoxybenzyl sialoside (82) 
In an attempt to improve the removal of the protecting group of the anomeric 
hydroxyl, para-methoxybenzyl (pMB) was used, since the pMB is a more labile 
group than either the methoxy or the benzyl sialosides. The procedure to introduce 
the pMB was similar to the one employed for the introduction of the methoxide and 
benzyl groups. Therefore, starting from the hemiketal (54) the protecting reaction 
was undertaken generating the 3-fluorosialic acid pMB sialoside (81) in good yield 
(86%). The next step was the removal of the acetyl groups, using for that purpose the 
Zemplén conditions, generating the 3-fluorosialic acid pMB sialoside (82) in good 
yield (81%). The conditions employed for the oxidative cleavage of the glycerol side 
chain and the reductive amination with diethylamine, were similar to the ones used 
with the benzyl sialoside. The acetylation, once again with conditions similar to 
those previously used with the benzyl sialoside, afforded, surprisingly, the reduced 
aldehyde, 4,7-di-O-acetyl-3-fluorosialic acid pMB sialoside (83) rather than the 
expected 7-N,N-diethylamine-3-fluorosialic acid pMB sialoside (Scheme 24). With 
this result in hand, a decision had to be made on whether the strategy of protecting 
the anomeric hydroxyl should be pursued or if the fluorine at the anomeric position 
should be introduced prior to the modifications at the glycerol side chain. The main 
reason for trying more readily available substrates was to develop a robust method 
for performing the oxidative cleavage and reductive amination steps. This goal was 
accomplished, since the removal of the salts derived from unreacted sodium 
periodate and excess sodium cyanoborohydride had been optimized, as well as 
methods developed for the purification of the 7-N-alkylamino products. 
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Scheme 24 Formation of 4,7-di-O-acetyl-3-fluorosialic acid pMB sialoside. a) NaH, pMBCl, DMF, 
r.t., 1 day, 86%; b) NaOMe, MeOH, r.t., O/N, 81%; c) NaIO4, H2O, r.t., 30 min; d) i) Diethylamine, 
AcOH, NaCNBH3, MeOH, r.t., O/N; ii) Ac2O, Pyr, r.t., O/N, 10% from the C-7 aldehyde. 
Therefore, it was decided at this stage to return to the 2,3-difluorosialic acid methyl 
ester (47) scaffold as a substrate for the oxidative cleavage and reductive amination 
and employ the knowledge developed on the synthesis of the methyl, benzyl and 
para-methoxybenzyl sialosides. 
3.6 Synthesis of a series of 7-N-alkylamino 2,3-difluorosialic acids 
The aldehyde (46) was obtained by treating the 2,3-difluorosialic acid methyl ester 
(47) with a 0.4 M aqueous solution of sodium periodate in water, removal of the 
sodium periodate salts by precipitation (using cold tetrahydrofuran), evaporation of 
the solvent in vacuo and then used without further purification. During the reductive 
amination reaction, and due to the use of excess of reducing agent, salts were present, 
which proved difficult to remove from solution; therefore, a solid supported sodium 
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cyanoborohydride was used in an attempt to remove the excess of sodium 
cyanoborohydride salts from solution by a simple filtration. By this “desalting” 
procedure, the purification of the desired amines by silica gel column became 
simpler, since the salts that have the same polarity has the 7-N-alkylamines were no 
longer present. To avoid any possible reduction of the aldehyde to the alcohol, as 
seen previously for pMB-3-fluorosialic acid sialoside (82), longer reaction times 
were allowed for the formation of the iminium ion. With all of these measures in 
place, the reactions were performed in a two-step fashion, with the reductive 
amination being performed immediately after the oxidative cleavage, successfully 
affording the desired N-alkylamines in rather moderate/low yields after two steps 
(Table 2). 
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Table 2 Yields of the 7-N-amines synthesised. 
i) 0.4 M NaIO4, H2O, r.t., 20 min; ii) R1R2NH, NaCNBH3, MeOH, AcOH, r.t., O/N. 
Amine 
Entry	 R1 Product Yield (%) 
NH 
R2 
1 
R1 = Methyl 
R2 = Ethyl 
11 
2 
R1 = Ac 
R2 = Ethyl 
22 
3 R1 = R2 = Ethyl 18 
Following the successful oxidative cleavage and reductive amination of 
2,3-difluorosialic acid (47) to produce the series of 7 modified amines (68, 80, and 
85), the final step in order to achieve the desired 7-N-amines-2,3-difluorosialic acids 
was the saponification of the methyl ester. This proceeded smoothly using a 1 M 
sodium hydroxide solution in water to afford the final targets (37 - 39) in good yield 
(Table 3). 
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Table 3 Yields for the saponified final compounds, 7-N-alkylamine 2,3-difluorosialic acids. 
1 M NaOH, H2O, 4 ºC, 1h 
Entry Product Yield (%)

1 50 
2 75 
3 67 
These final compounds (37 - 39) were subsequently tested against a series of 
influenza viruses and the results are shown in Chapter 6.3. 
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Chapter 4 - Synthesis of 5-N-trifluoroacetamido-2,3­
difluorosialic acid (94) 
4.1 Rationale 
Until the end of the 1980’s, 5-N-trifluoroacetamido-Neu5Ac2ene (86) was the most 
potent inhibitor known towards the influenza A virus, having an IC50 of 5 µM against 
influenza neuraminidase N1, whilst Neu5Ac2ene (27) showed inhibition of 30 µM 
against the same strain of influenza virus.77,140,151 
Smith et al synthesised derivatives of zanamivir (25), and amongst other C-5 
modifications, the 5-N-trifluoroactemido analogue (87). The compounds were tested 
against influenza neuraminidase N2 and 5-N-trifluoroacetamido (87) had an IC50 of 
21 nM whilst zanamivir (25) had an IC50 of 5 nM.152 
The N-acetamido group present at C-5 interacts with three amino acid residues, with 
the methyl group appearing to have hydrophobic interactions with Trp178 and 
Ile222, while the oxygen appears to form hydrogen bond interactions with Arg152 
(Figure 14). 
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Figure 14 Interactions of the N-acetyl group with Arg152, Ile222 and Trp178. Generated with 
LigPlot+ (PDB 2C4A). 
It was our aim to exchange the 5-N-acetamido group present in the inhibitor 
2,3-difluorosialic acid (19) with a 5-N-trifluoroacetamido in order to assess the 
impact of this modification on mechanism-based inhibition towards a series of 
influenza neuraminidases. By combining the presence of the 2,3-difluoro 
substituents, targeting the covalent intermediate formed during the catalytic 
mechanism of influenza neuraminidase, with the 5-N-trifluoroacetamido group, 
which interacts with active site arginine and glutamate residues, a synergistic effect 
could occur to improve the binding of this class of compound towards influenza 
neuraminidases. 
4.2 Synthesis of the 5-N-trifluoroacetamido-2,3-difluorosialic acid 
(94) 
For the synthesis of the 5-N-trifluoroacetamido-2,3-difluorosialic acid (94), it was 
envisaged that we could utilise an intermediate compound produced previously 
during the synthesis of 2,3-difluorosialic acid (19) and simply exchange the 
N-acetamido for a N-trifluoroacetamido at a late stage in the synthetic sequence. It 
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has been shown by Schroven et al that the NHAc group can be converted to the 
primary amine, which should then be readily convertible to the desired NHTFA 
derivative.153 
As such, the 3-fluorosialic acid methyl ester (52) was treated with methanesulfonic 
acid in methanol at room temperature, to produce the primary amine at C-5 (88) 
(Scheme 25).153 Acetylation using trifluoroacetic anhydride in methanol at room 
temperature, generated the 5-N-trifluoroacetamido-3-fluorosialic acid (89).153 Global 
acetylation of the hydroxyl groups of 5-N-trifluoroacetamido-3-fluorosialic acid 
methyl ester (52) was achieved using acetic anhydride in pyridine; this proceeded 
slowly over 5 days to afford the per-O-acetylated-5-N-trifluoroacetamido-3­
fluorosialic acid (90) in low yield (20% over three steps). 
Scheme 25 Formation of 5-N-trifluoroacetamido-3-fluorosialic acid (90). a) MsOH, MeOH, reflux, 1 
day; b) TFA2O, Et3N, MeOH, 4 ºC, 1h; c) Ac2O, Pyr, r.t., 5 days, 20 % (over 3 steps). 
One possible reason for the low yield in the reaction sequence could be due to the 
deprotection and subsequent acylation of the amine not being optimized. One other 
plausible reason was the choice of solvent in which the acylation of the primary 
amine was performed, methanol. Methanol could have reacted with the 
trifluoroacetic anhydride to reduce the effectiveness of the acylation of the primary 
amine. Unfortunately, owing to the high polarity of the free amine (88), it was 
71 
Chapter 4

difficult to follow the progress of the reaction and determine when the acylation was 
complete. 
The next step in the synthetic pathway was to deprotect selectively the anomeric 
position. A solution of the per-O-acetylated-5-N-trifluoroacetamido-3-fluorosialic 
acid (90) was treated with hydrazine acetate to afford the 5-N-trifluoroacetamido-3­
fluorosialic acid (91) in good yield (67%) (Scheme 26). The hemiketal (91) was 
treated with DAST, in DCM, at -30 ºC, resulting in fluorination at C-2 to produce the 
desired 2,3-difluorosialic acid derivative (92) which was isolated in moderate yield 
(44%) (Scheme 26).137 Subsequent deacetylation of the per-O-acetylated-5-N­
acetamido-2,3-difluorosialic acid (92) was performed following Zemplén conditions 
by treatment with a solution of sodium methoxide in methanol at 4 ºC, to yield the 
5-N-trifluoroacetamido-2,3-difluorosialic acid (93) in quantitative yield (Scheme 26). 
OAc OAc OH AcO OAc AcO OAc OAc 
O CO2Me 
AcO AcO 
TFAHN CO2Me a) TFAHN 
O 
F F 
90 91 
O F 
CO2Me 
AcO 
TFAHN 
AcO 
OAc 
OAc 
F 
b) 
O F 
CO2Me 
HO 
TFAHN 
HO 
OH 
OH 
F 
c) 
93 92

d) 
O F 
CO2H 
HO 
TFAHN 
HO 
OH 
OH 
F 
94 
Scheme 26 Formation of 5-N-trifluoroacetamido-2,3-difluorosialic acid (94). a) Hydrazine acetate, 
DCM/MeOH 4:1, 4 °C, 3h, 67%; b) DAST, DCM, -30 °C, 30 min, 44%; c) NaOMe, MeOH, 4 ºC → 
r.t., 1h, 100%; d) NaOH, H2O, 4 ºC, 1h, 100%. 
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Finally, saponification of the methyl ester (93) was performed with a 1M sodium 
hydroxide solution in water, generating the desired target 5-N-trifluoroacetamido­
2,3-difluorosialic acid (94) in quantitative yield. The 5-N-trifluoroacetamido-2,3­
difluorosialic acid (94) will be tested in vitro against a series of influenza viruses 
(CSIRO, Australia). 
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Chapter 5 - Synthesis of C-4 N-alkylamino 
Neu5Ac2ene derivatives 
5.1 Prelude 
Work performed by the group of von Itzstein originally showed that the introduction 
of an equatorial amino group at the C-4 position of Neu5Ac2ene (95) resulted in 
improved inhibitory activity against influenza neuraminidase N2, when compared 
with the “parent” compound Neu5Ac2ene (27), improving the Ki from 4 µM to 
0.04 µM.97,104,154 This seminal finding was one of the early results that ultimately led 
to the development of both zanamivir (25) and oseltamivir (6), as potential inhibitors 
of influenza neuraminidase. Alongside this modification, von Itzstein’s group also 
synthesised the 4-epi-amino Neu5Ac2ene derivative (96), where the C-4 amino 
group is now in a axial orientation. Interestingly, the 4-epi-amino Neu5Ac2ene (96) 
also showed superior inhibitory activity (Ki = 0.3 µM) when compared to the parent 
compound Neu5Ac2ene (27), but was never developed further as the equatorial 
amino derivative (95) showed the most potent inhibitory activity.97 
Within the active site of influenza neuraminidase there are several acidic amino acids 
capable of interacting with basic substituents in either an equatorial, or axial, 
conformation at C-4 of sialic acid (Figure 15). Examining the X-Ray crystal structure 
of sialic acid bound to the active site of influenza neuraminidase N2, it is clear that 
there is potential for an axial amino substituent at C-4 to interact with the residues 
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Glu119 and Glu227. Alternatively, an amino group in the equatorial orientation can 
interact with Asp151, which is the case observed with zanamivir (25) and oseltamivir 
(6). 
Figure 15 Possible interactions with glutamate or aspartate residues around C-4 position of sialic acid 
bound in the active site of influenza neuraminidase N2 with an axial or equatorial amino substituent at 
this position, respectively. Generated with PyMOL (PDB 2BAT). 
5.2 Rationale 
We were interested in investigating the effect of an axial C-4 amino group on the 
inhibitor activity of 2,3-difluorosialic acids towards influenza neuraminidase. As a 
first course of action, we set out to investigate the size of modifications that could be 
accepted axially at C-4. Owing to the difficult synthesis of the 2,3-difluorosialic 
acids, we first investigate the C-4 amine substituents on Neu5Ac2ene and the 
information gained would be implemented into the synthesis of the 2,3-difluorosialic 
acid derivatives. Furthermore, the presence of an axial group at C-4 could allow 
some steric control over the introduction of a fluorine at C-3 to afford an improved 
yield of the desired stereochemistry (axial fluorine). In order to study the binding 
between the glutamate residue and the C-4 amines, in addition to the study of the 
available physical space around this position, it was decided to undertake the 
synthesis of a series of 4-epi-N-alkylamines, namely 4-epi-N-methylamino­
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Neu5Ac2ene (42); 4-epi-N-ethylamino-Neu5Ac2ene (43); and 4-epi-N,N­
diethylamino-Neu5Ac2ene (44). 
5.3 Retrosynthetic analysis of the formation of the series of 4-epi-
N-alkylamines (97) 
The general strategy for the construction of a series of 4-epi-N-alkylamino 
Neu5Ac2ene (97) is based on the retrosynthetic analysis shown (Scheme 27). 
Through a straightforward sequence of deprotections, the desired 4-epi-N,N­
alkylamino Neu5Ac2ene (97) could be derived from the per-O-acetylated compound 
(98). Retrosynthetic cleavage of the bond indicated in the 4-epi-N,N-alkylamino 
Neu5Ac2ene (97) furnishes the oxazoline (99) as a viable precursor. The oxazoline 
(99) is readily available form sialic acid (102) via literature procedures.155,156 
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Scheme 27 Retrosynthetic pathway for the formation of a series of 4-epi-N,N-alkylamino 
Neu5Ac2ene (97). 
5.4 Synthesis of the common precursor, oxazoline (99) 
In order to synthesise oxazoline (99), esterification of sialic acid (102), using TFA in 
MeOH at room temperature and subsequent acetylation with acetic anhydride in 
pyridine, was conducted affording the per-O-acetylated sialic acid (101) in good 
overall yield (81% over two steps) (Scheme 28). 
Scheme 28 Acetylation of sialic acid (102). i) TFA, MeOH, r.t., O/N; ii) Ac2O, Pyr, r.t., 4 days, 81% 
(over 2 steps). 
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Elimination of the anomeric acetyl group was then achieved by following a literature 
procedure.155 The per-O-acetylated sialic acid (101) was dissolved in acetonitrile and 
trimethylsilyl trifluoromethanesulfonate (TMSOTf) was added. The reaction was 
stirred at room temperature overnight, affording the per-O-acetylated Neu5Ac2ene 
(100) in good yield (75%) (Scheme 29). The elimination of the anomeric acetyl 
group occurs due to the activation of the anomeric acetyl of the per-O-acetyl sialic 
acid (101), which triggers a trans-diaxial elimination, forming the per-O-acetylated 
Neu5Ac2ene (100) (Scheme 29). 
Scheme 29 Mechanism of formation of the per-O-acetylated Neu5Ac2ene (100). TMSOTf, MeCN, 
r.t., O/N, 75%. 
The formation of the oxazoline (99) was also achieved following a literature 
procedure, where the per-O-acetylated Neu5Ac2ene (100) was dissolved in 
acetonitrile, TMSOTf was added and the reaction heated to 50 ºC overnight 
generating the oxazoline (99) in good yield (76%) (Scheme 30).156 In this 
transformation TMSOTf (103) activates the C-4 acetyl group, which can be 
displaced by a nucleophilic attack from the oxygen of the N-acetamido present at 
C-5. Oxazoline (99) is then the product of such a nucleophilic attack (Scheme 30). 
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Scheme 30 Mechanism for the formation of oxazoline (99). TMSOTf, MeCN, 50 ºC, O/N, 76%. 
5.5 Overview of the use of palladium for the formation of C-C 
bonds 
The oxazoline (99) is an excellent starting point towards the introduction of alkyl 
amines at C-4, since this position is susceptible to nucleophilic attack and, 
furthermore, the orientation of the 5 member ring dictates the pattern of substitution. 
If a direct nucleophilic attack from an amine at C-4 of oxazoline (99) were to occur, 
the product would yield an equatorial amine at C-4, as opposed to our desired C-4 
axial derivatives. Therefore, methodology was developed that would enable the 
introduction of the desired amines with an axial stereochemistry at C-4. 
Palladium is widely used in organic chemistry to form carbon-carbon bonds, due to 
its versatility, stability and low toxicity. Two forms of palladium (Pd) are commonly 
used in synthesis, Pd (0) complexes and Pd (II) salts.157 The Pd (II) salts can be used 
as stoichiometric reagents or catalysts, and as a general example we have Pd(OAc)2; 
whilst Pd (0) complexes are solely used as catalysts, for instance Pd(PPh3)4.157 
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The Pd complexes can promote the formation of the carbon-carbon bond in different 
ways such as oxidative addition; insertion; transmetallation; reductive elimination; 
β-H elimination; and elimination of β-heteroatom groups and β-carbon.157 We shall 
focus our attention on oxidative addition. The reaction between a molecule of general 
structure X-Y and Pd (0) leads to the cleavage of the chemical bond between X and 
Y and the formation of two new bonds, between X, Pd and Y, to form X-Pd-Y.157 
Two non-bonding electrons of Pd are now involved in the coordination with X and 
Y; therefore, the formal oxidation state of Pd is raised by two, passing from Pd (0) to 
Pd (II).157 Taking Pd(PPh3)4 as an example of a Pd (0) complex, this undergoes a 
reversible dissociation in situ losing two molecules of PPh3, reducing the four 
coordination sites to two and from 18 electrons to 14, and it is this species that 
undertakes the oxidative addition (Figure 16).157 
Figure 16 Example of an oxidative addition between Pd(PPh3)4 and a general molecule X-Y. 
The oxidative addition is aided if the Pd has a high electron density, meaning the 
more electron donating the ligands are, the faster the oxidative addition will occur.157 
However, the presence of π-acceptor ligands tends to diminish the rate of oxidative 
addition.157 Notwithstanding these factors, when one is about to undertake a 
oxidative addition reaction with a palladium complex, it is necessary to investigate a 
myriad of ligands as their effects are not fully understood, therefore surprises can be 
encountered.157 
In general, the formation of a π-allylpalladium complex involves the cleavage of a 
bond (leaving group) and the delocalization of the double bond (Scheme 31).157 
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Scheme 31 General method for the formation of π-allylpalladium complexes. 
Applying this general example to the structure of the oxazoline (99), there is the 
presence of the double bond between C-2 and C-3 and it is possible to envisage that 
the “leaving group” is the oxygen of the oxazoline. The addition of palladium to the 
oxazoline (99) enables the formation of an η3-allylpalladium complex (106) (Scheme 
32). 
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Scheme 32 Opening of the oxazoline with the aid of a palladium (0) complex. 
Once the palladium is coordinated to the π system (106), the nucleophile, in our case 
an N-alkyl amine, will attack the palladium complex from the opposite face, either at 
the α position (path I) or at the γ position (path II), forming the axial C-4 
N-alkylamino (107) or the axial C-2 N-alkyl amine (108) (Scheme 33). 
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Scheme 33 The two different pathways that the nucleophilic N-alkylamine can use to attack the 
palladium complex, in both cases from the re-face. 
As can be seen, the palladium orientates the attack of the N-alkylamine from the 
desired face of the ring, the re-face, inverting the stereochemistry at C-4. The 
incoming nucleophile can attack either of two positions, at C-4 to give the α product, 
or at C-2 to afford the γ product. These two distinct attacks may be controlled by the 
choice of catalyst employed in the reaction; however, a clear explanation on the 
reasons why this orientation can be directed with a change in the catalyst used has 
84 
Chapter 5

not been found. Due to a possible decomposition of the compound, the 
stereochemistry of 2-epi-N-alkylamino (108) could not be confirmed; however, it is 
inferred by observation of the mechanism of the reaction.158,159 
5.6 Palladium-catalysed allylic amination for the direct synthesis 
of epi-4-N-alkylamino Neu5Ac2ene derivatives 
In order to probe the optimal conditions for the introduction of N-alkyl amines into 
C-4 of the oxazoline (99), methylamine (114) was used as a model 
amine whilst the solvent and catalyst were varied. The catalysts investigated were 
tetrakis(triphenylphosphine)palladium (0) (Pd(Ph3P)4) (109); 
tri(dibenzylideneacetone)dipalladium (0) (Pd2(dba)3) (110); and allylpalladium (II) 
chloride dimer (Pd2(π-allyl)2Cl2), exchanged with triethylphosphine (111), 
trimethylphosphine (112) or triphenylphosphine (113) (Figure 17). Once the optimal 
conditions were achieved two further N-alkylamines were used, ethylamine (115) 
and diethylamine (116) (Figure 17). 
Figure 17 Structures of the different catalyst (109 - 113) used for the opening of the oxazoline (99) 
with a series of N-alkylamines (114 - 116). 
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The reactions were performed in dichloromethane at room temperature. The first 
catalyst to be employed was Pd(Ph3P)4 (109) which was found to give a mixture of 
amination products at the α and γ positions in a ratio of 1:5, with a low combined 
yield (37%) (Table 4). Pd2(dba)3 (110) was found to produce a α:γ ratio of 1:0; 
however, the yield of the reaction was found to be poor (16%). 
Table 4 Resume of the conditions used to synthesise the series of 4-N-alkylamines with an axial 
orientation. 
Catalyst, ligand, R2R1NH, DCM, r.t., 2h. 
Entry 
Amine 
R1 R2 
Catalyst 
Ratio 
α : γ 
Yield (%) 
α + γ 
1 Me H Pd(Ph3P)4 1:5 37 
2 Me H Pd2(dba)3 1:0 16 
3 Me H Pd(π-allyl)2(Me3P)2 1:0 20 
4 Me H Pd(π-allyl)2(Et3P)2 1:0 46 
5 Me H Pd(π-allyl)2(Ph3P)2 1:10 61 
6 Et H Pd(π-allyl)2(Et3P)2 1:0 75 
7 Et Et Pd(π-allyl)2(Et3P)2 1:0 71 
Allylpalladium (II) chloride was then used, with trimethylphosphine as ligand (112),

producing a slight improvement in the yield (20%); therefore, it was then decided to

try a slightly longer alkyl chain in the ligand, triethylphosphine (111), with
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satisfactory results (46%) (Table 4). With these results in hand, only generating the α 
product and the yields increasing, the replacement of the ligand for 
triphenylphosphine (113) was tried; however, the ratio of substitution changed to a 
1:10 of α to γ amination products, albeit with a good overall yield (61%) (Table 4). 
Analysing the results, it can be concluded that the electronic donating effect of the 
ligand in the Pd complex is important for increasing the yield of the reaction, since a 
significant increase in yield was observed when passing from trimethyl to 
triethylphosphine (20 to 46%) (entries 3 and 4) (Table 4). The replacement of the 
linear chain of the phosphine with a phenyl group changed the ratio between both α 
and γ amination reactions, shifting from a 1:0 to 1:10 ratio, respectively (entry 5) 
(Table 4). It is postulated that this may be due to steric effects arising from the 
phenyl substituent, since a similar trend was observed when Pd(Ph3P)4 was used, 
where there was a ratio of 1:5 between α and γ amination products (entry 1) (Table 
4). Regarding the alkyl amines employed, the yield of the reaction improved with 
longer alkyl chain amines, from 46% for the methylamine (114) (entry 4) to 75 and 
71% when using ethylamine (115) and diethylamine (116), respectively (entries 6 
and 7). It is worth mentioning that when the amination reaction was performed either 
with no catalyst or with no ligand; or with only the allylpalladium chloride catalyst 
present, no reaction was observed, proving that the presence of the activated catalyst 
is essential for the reaction to proceed.159 
It was decided to use the Pd(π-allyl)2(Et3P)2 for the formation of the desired amine 
products. Therefore, the oxazoline (99) was dissolved in dichloromethane and a 
solution of the catalyst was added at room temperature. The amine was then added 
and the reaction stirred at room temperature for 2h, affording the desired epi-4-N­
alkylamines in reasonable to good yields (Table 5). 
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Table 5 The series of 4-N-epi-alkylamines (117 - 119) synthesised. 
NHR1R2, Pd(π-allyl)2(Et3P)2, DCM, r.t., 2h. 
Amine 
Entry 
R1 R2 
Product Yield (%) 
1 Me H 46 
2 Et H 75 
3 Et Et 71 
In order to confirm the stereochemistry of the amino substituent at C-4, the 4-N­
methyl and 4-N-ethyl-amines (117 and 118) were protected using TsCl (Scheme 34). 
The N-alkylamines (117 and 118) were dissolved dichloromethane at room 
temperature and TsCl was added, and the reaction left overnight to afford the desired 
sulfonamide compounds (120 and 121) in low yields (38 and 29%). 
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Scheme 34 Formation of sulfonamides (120 and 121). TsCl, DCM, r.t., O/N, 38% for 120 and 29% 
for 121. 
NOESY was then used to assign the stereochemistry of the N-alkylamines at C-4, 
where an interaction between the methyl group of the N-alkylamine and H-6 could be 
clearly be seen. This interaction can only occur when the amino group is in an axial 
orientation, since the stereochemistry of position 6 is well established (Figure 18). 
H-6 
Methyl group of amine 
Figure 18 NOESY spectrum of 4-epi-N-sulfonamide (120) where the interaction between H-6 and the 
methylamine can be observed (highlighted with a circle). 
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Following the successful introduction of the axial amino groups at C-4, the next step 
was the global deacetylation of 4-epi-N-alkylamines Neu5Ac2ene (98) which was 
performed using classical Zemplén conditions. A solution of sodium methoxide in 
methanol at 4 ºC was added to the 4-epi-N-alkylamines Neu5Ac2ene (98), affording 
the deprotected 4-epi-N-alkylamines (122) in good overall yields (60 – 78%) (Table 
6).148 
Table 6 Yields of the different 4-epi-N-alkylamines (123 - 125) synthesised. 
NaOMe, MeOH, r.t., 1h. 
Amine 
Entry 
R1 R2 
Product Yield (%) 
1 Me H 80 
2 Et H 70 
3 Et Et 78 
The final step of the synthesis was the saponification of the ester functionality 
present at C-1, which was accomplished with a solution of 1M NaOH to give the 
desired products (42 - 44) in quantitative yields (Table 7). 
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Table 7 Yields for the saponified final compounds, 4-epi-N-alkylamino Neu5Ac2ene (42 - 44). 
1M NaOH, H2O, 4 ºC, 1h. 
Amine 
Entry 
R1 R2 
Product Yield (%) 
1 Me H Quantitative 
2 Et H Quantitative 
3 Et Et Quantitative 
5.7 Synthesis of 4-epi-azido (131) and 4-epi-N-amino Neu5Ac2ene 
(126) 
In addition to the synthesis of the secondary (42 and 43) and tertiary amines (44), the 
synthesis of 4-epi-azido Neu5Ac2ene (131) was carried out in order to investigate 
the effects of the azide in the active site of influenza neuraminidase. Moreover, the 4­
epi-azide was a desired scaffold in order to introduce the fluorines at C-2 and C-3 
since the group at C-4 could direct the attack of the incoming fluorine. Additionally, 
reduction of the azide would provide a route to the primary amine (126). 
The general strategy for the construction of the 4-epi-N-amino Neu5Ac2ene (126) 
was based on the retrosynthetic analysis shown (Scheme 35). As a result of a simple 
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sequence of deprotections, the 4-epi-amino Neu5Ac2ene (126) could be obtained 
from the per-O-acetylated-4-epi-N-amino Neu5Ac2ene (127). Through a 
straightforward hydrogenation, the per-O-acetylated-4-epi-N-amino Neu5Ac2ene 
(127) could be obtained from per-O-acetylated-4-epi-azido Neu5Ac2ene (128). 
Retrosynthetic cleavage of the bond indicated in the per-O-acetylated-4-epi-azido 
Neu5Ac2ene (128) furnishes the oxazoline (99) as a viable precursor, to which the 
retrosynthetic analysis has been explained previously. 
Scheme 35 Retrosynthetic analysis towards 4-epi-N-amino Neu5Ac2ene (126). 
5.7.1 Studies towards the introduction of an azide at C-4 of oxazoline 
(99) 
The first set of conditions employed for the introduction of an azide group axially at 
C-4, were the ones that proved successful for the introduction of the N-alkylamines. 
Therefore, to a solution of oxazoline (99) in dichloromethane at room temperature, 
was added a solution of Pd(π-allyl)2(Et3P)2 (111) in dichloromethane, using as a 
source of azide, TMSN3 (entry 1) (Table 8). Unfortunately, these conditions proved 
to be unsuccessful, with no desired product being observed. As a result, a variety of 
solvents were investigated, as well as the source of azide. 
Using Pd2(dba)3 (110) with triphenylphosphine in THF at 50 ºC overnight, the per-O­
acetyl-4-epi-azido Neu5Ac2ene (128) was prepared in moderate yield, (30%) (entry 
5) (Table 8). 
92 
Chapter 5 
Table 8 Different conditions used in order to introduce the azide in an equatorial orientation. 
a Stereochemistry of the OH group is undetermined; b Microwave reaction set at 100 ºC. 
Entry Azide Catalyst Solvent Temp (ºC) Yield (%) 
1 TMSN3 Pd(π-allyl)2(Et3P)2 (111) DCM r.t. No rx. 
2 TMSN3 Pd(π-allyl)2(Et3P)2 (111) MeCN reflux No rx. 
3 TMSN3 Pd(π-allyl)2(Et3P)2 (111) MeCN + tBuOH reflux No rx. 
4 TMSN3 Pd(π-allyl)2(Et3P)2 (111) DCM + tBuOH r.t. No rx. 
5 TMSN3 Pd2(dba)(PPh3)2 (110) THF 50 30 
6 NaN3 Pd(Ph3P)4 (109) THF + H2O 50 No rx. 
7 NaN3 Pd(Ph3P)4 (109) THF + H2O 60 Hydrolysis a 
8 NaN3 Pd(Ph3P)4 (109) DMF 100 b No rx. 
The assignment of the stereochemistry of the azide at C-4 was achieved by 
comparing the 13C NMR chemical shifts of the per-O-acetyl-4-epi-azido 
Neu5Ac2ene (128) with the per-O-acetyl-4-azido Neu5Ac2ene (129), reported in the 
literature (Table 9).160 
Table 9 Comparison of the 13C NMR chemical shifts for the 4-epi-azido and 4-azido Neu5Ac2ene 
derivatives (128 and 129) 
C-1 C-2 C-3 C-4 C-5 C-6 C-7 C-8 C-9

(128) 161.5 146.3 104.5 54.8 44.8 73.6 67.6 71.3 62.1 
(129) 161.5 145.1 107.6 57.8 48.3 75.9 67.7 70.9 62.1 
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In addition, a mass spectrum of the per-O-acetylated-4-epi-azido Neu5Ac2ene (128) 
was conducted, showing a peak referring to the sodium salt of the compound 
(479.1379), confirming the presence of the azide (Figure 19). 
Figure 19 Mass spectrum showing the sodium peak (479.1379 m/z) of the per-O-acetylated-4-epi­
azido Neu5Ac2ene (128). 
5.7.2 Synthesis of the 4-epi-azido Neu5Ac2ene (131) 
After the insertion of the azide at C-4, the next steps comprised the deacetylation and 
saponification in order to achieve the desired compound, 4-epi-azido Neu5Ac2ene 
(131) (Scheme 36). 
Scheme 36 Formation of 4-azido Neu5Ac2ene (131). a) NaOMe, MeOH, 4 ºC, 2h, 92%; b) 1M 
NaOH, H2O, 4 ºC, 1h, 100%. 
Zemplén conditions, aqueous sodium methoxide in water at 4 ºC, were used to 
remove the acetyl groups, affording the 4-epi-azido methyl ester (130) in excellent 
yield (92%). The saponification reaction was performed in water using a 1M sodium 
hydroxide solution to remove the methyl ester and afford 4-epi-azido Neu5Ac2ene 
(131) in quantitative yield. 
94 
Chapter 5

5.7.3 Synthesis of the 4-epi-N-amino Neu5Ac2ene (126)

Once the azide was inserted with the correct stereochemistry at C-4, it could then be 
reduced; after which the removal of the acetyl groups would take place, with the last 
reaction being the saponification, to afford the free acid (126) (Scheme 37). 
Scheme 37 Formation of 4-aminoNeu5Ac2ene (126). a) Pd2(dba)(PPh3)2, TMSN3, THF, 50 ºC, O/N, 
30%; b) 1,3-propanedithiol, Et3N, MeOH, 4 ºC � r.t., 2h, 63%; c) NaOMe, MeOH, 4 ºC, 2h, 54%; d) 
1M NaOH, H2O, 4 ºC, 1h, 100%. 
The reduction of the azide to the amino group was first attempted using H2 with Pd/C 
10%; however, the reduction of the double bond was observed. Reduction of the 
azide was subsequently attempted in the presence of 1,3-propanedithiol and 
triethylamine in methanol, following a literature procedure.161 The reaction 
proceeded smoothly, affording the per-O-acetylated-4-epi-N-amino Neu5Ac2ene 
(127) in good yield (63%). The next step was the deacetylation of the compound, and 
once again, this was accomplished by using Zemplén conditions, with a solution of 
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sodium methoxide in methanol at 4 ºC for 2h, giving the 4-epi-N-amino (132) in 
average yield (54%). The reaction produced more than one compound, thus 
necessitating a flash chromatography step where due to the polar nature of the 
compound, material was lost, affecting the yield. 
The final step in the synthetic pathway was the saponification of the methyl ester, 
accomplished in water using a 1M sodium hydroxide solution. The reaction 
proceeded smoothly, affording the 4-epi-N-amino (126) in quantitative yield. 
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Chapter 6 - Inhibitory activity of a series of 7-N­
alkylamino 2,3-difluorosialic acids against a panel of 
influenza viruses 
As discussed previously (Chapter 2), the influenza virus has a high propensity to 
generate point mutations (antigenic drift and shift). In addition, during the treatment 
of the influenza virus with specific inhibitors, the virus will suffer pressure to mutate 
certain amino acid residues in order to reduce (or eliminate) the inhibitory activity of 
such compounds. As a result, when developing any new inhibitors it is necessary to 
investigate the performance of such inhibitors against both the wild type virus and 
prevalent mutants of the virus. 
This chapter will begin by discussing a crystal structure obtained with the 7-N,N­
diethylamino-2,3-difluorosialic acid (39) and influenza neuraminidase N9 followed 
by a brief explanation of the different neuraminidase mutations observed clinically as 
a result of the treatment of influenza with the currently approved drugs, zanamivir 
(25) and GS4071 (33). A brief explanation will be given as to how each point 
mutation influences the inhibitory activity of each inhibitor. Finally, the inhibitory 
profile of each of the inhibitors developed in this thesis will be described against a 
panel of wild type and drug resistant influenza viruses. 
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6.1 Crystal structure obtained with 7-N,N-diethylamino-2,3­
difluorosialic acid (39) and influenza neuraminidase N9 
The inhibitor 7-N,N-diethylamino-2,3-difluorosialic acid (39) was co-crystallised 
with influenza neuraminidase N9 and the crystal structure obtained is shown in 
Figure 20. 
Figure 20 Superimposition of the view of 7-N,N-diethylamino-2,3-difluorosialic acid (39) covalently 
bound in the active site of influenza neuraminidase N9 (green) with the uncomplexed influenza 
neuraminidase N9 (blue). Only the residues interacting with the diethylamino side chain are shown. 
Generated with PyMOL (PDB unpublished, green, and 2C4A, blue). 
This crystal structure (Figure 20) is the first one to prove the formation of the 
covalent intermediate with influenza neuraminidase (A. Watts, unpublished results), 
which confirms our inhibitor design strategy based on an alternative catalytic 
mechanism for influenza neuraminidase. There are two important aspects observed in 
the crystal structure, firstly the presence of the covalent intermediate between Tyr406 
and the 7-N,N-diethylamino derivative (39), which proves that during the catalytic 
cycle of influenza neuraminidase there is the formation of a covalent enzyme­
sialoside intermediate. The other important aspect is that there is a rotation of the 
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Glu276 to accommodate the diethyl side chain, akin to the rotation observed with 
GS4071 (33). 
6.2 Point mutations conferring resistance towards influenza 
neuraminidase inhibitors 
The mutations so far observed clinically, and in vivo, have been Glu119, Arg292, 
His274, Arg152 and Gln136. Their relative position in the active site, and the 
position of the sialic acid moiety with which they interact is summarised in Figure 
21. 
Figure 21 Mutants of influenza neuraminidase known to confer resistance to the currently approved 
drugs and their interactions with C-4, 5 and glycerol side chain of Neu5Ac2ene. 
One of the major problems affecting oseltamivir (6), and to a lesser extent zanamivir 
(25), is the development of resistant strains where the efficacy of the inhibitor is 
diminished or abolished. A brief overview at the important mutations identified so 
far from clinical isolates, and their effect on the efficacy of the inhibitors towards 
them is given here. 
Glu119 
Glu119 interacts strongly with the basic nitrogen groups present at C-4 of both 
zanamivir (25) and GS4071 (33).125 Therefore, mutation of this residue will alter the 
binding affinity between the inhibitors and the active site, making them less 
effective. The Glu119Val mutation was identified in a patient infected with H3N2 
and being treated with oseltamivir (6).125 Replacement of Glu119 with a smaller 
amino acid residue, allows space for a water molecule. Val119 has the effect of 
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pushing the water molecule into the space required by the basic moiety present at 
C-4 in the inhibitors (zanamivir (25) and GS4071 (33)).125 As no crystal structure of 
the Glu119Val mutation exists, the Glu119Gly mutation is shown instead, in order to 
illustrate the difference in size (Figure 22).162 
Figure 22 Superimposition of the active site of wild type N9 (blue) with Neu5Ac2ene (27) present in 
the active site and Glu119Gly N9 (green). Generated with PyMOL (PDB 1F8B, blue, and 1L7G, 
green). 
Arg292 
Arg292 is part of the three highly conserved arginine amino acid residues that form 
the catalytic triad of the active site binding to the carboxylic acid present in the 
natural substrate and inhibitors. The Arg292Lys mutation occurred in patients being 
treated with oseltamivir (6). This new strain of influenza virus is highly resistant to 
oseltamivir (6) whilst with zanamivir (25) it shows low levels of resistance.125 This 
difference in resistance can be explained by a secondary cause of this mutation. For 
GS4071 (33) to bind in the active site of influenza neuraminidase a reorientation of 
Glu276 towards Arg224 is needed, so that a salt bridge can be formed between 
them.124 With this reorientation, a hydrophobic pocket is created to accommodate the 
hydrophilic side chain of GS4071 (33) (Figure 23). However, due to the Arg292Lys 
mutation, the lysine will stabilize the Glu276, preventing this from moving and 
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forming a salt bridge with Arg224. As a result, the space necessary to accommodate 
the hydrophobic side chain is not created and the binding action of GS4071 (33) in 
the active site is heavily diminished.125 
Figure 23 Superimposition of the active site of wild type N9 (blue) with Neu5Ac2ene (27) bound in 
the active site, and the active site of N9, with the Arg292Lys mutation (green). Generated with 
PyMOL (PDB 1F8B, blue, and 2QWB, green). 
His274 
One other mutation that stabilizes the Glu276 residue, halting its reorientation is the 
His274Tyr (Figure 24).124 This mutation was identified in seasonal H1N1 in the 
2008-2009 flu season in the United States and Japan. 99% of the circulating virus 
had this mutation, with cases also reported concerning the pandemic strain of 
H1N1.70,163,164 
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Figure 24 Superimposition of the active sites of the wild type N9 (blue) and the His274Tyr N1 
(green) with Neu5Ac2ene bound in the active site. Generated with PyMOL (PDB 1F8B, blue, and 
3CKZ, green). 
Arg152 
An immunocompromised child infected with influenza B that was being treated with 
zanamivir (25) developed a mutation on the Arg152 residue.110 This residue is 
conserved in all influenza A and B viruses, forming a hydrogen bond with the 
N-acetamido group present at C-5.124 The enzyme shows a lower activity when 
compared with the wild type and is less sensitive to zanamivir (25) and oseltamivir 
(6).124 
Gln136 
This mutation, Gln136Lys, was identified during a study on almost 400 cases of 
influenza virus H1N1 between 2006 and 2008.112 The mutated virus showed a 
reduced susceptibility towards zanamivir (25), and no effect with oseltamivir (6). 112 
A possible explanation to this selected susceptibility is due to a complex hydrogen 
bond network.112 Gln136 interacts with Arg156 side chain, which in turn interacts 
with Asp151. All of these interactions imply that the residues are in a stable 
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conformation so any mutation will disrupt these interactions. This mutation is highly 
prejudicial to zanamivir (25) since it possesses a guanidine moiety at C-4, which 
forms two hydrogen bonds with Asp151. Furthermore, Arg156 forms van der Waals 
interactions with the same moiety. Therefore, a mutation in Gln136 disrupts the 
intricate network of hydrogen bonds, leaving the residues with increased mobility, 
greatly disturbing the interactions between the residues and the inhibitor.112 GS4071 
(33) only interacts with the backbone of Asp151, which should be unaltered in the 
mutant.165 
6.3 Inhibition of a panel of influenza viruses with 7-N-alkylamine 
2,3-difluorosialic acids 
6.3.1 IC50 results obtained against a panel of influenza viruses (CSIRO) 
In order to evaluate the inhibitory activity of the synthesised C-7 modified 
compounds, 7-N-ethyl-N-methylamino (37); 7-N-ethyl-N-acetamido (38); and 7-N,N­
diethylamino (39) -2,3-difluorosialic acids were tested against a series of influenza 
viruses (CSIRO). The influenza viruses used were the H1N1 wild type and 
His274Tyr mutant; H3N2 wild type and Glu119Val mutant; H1N9 wild type and 
Glu119Gly mutant. Inhibitory results are given in comparison to the currently 
approved drugs for the treatment of influenza virus, zanamivir (25), the active moiety 
of oseltamivir (33), as well as to the parent 2,3-diflurosialic acid (19). 
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The compounds tested by our collaborators were the 7-N-ethyl-N-methylamino (37), 
7-N-ethyl-N-acetamido (38) and the 7-N,N-diethylamino (39) -2,3-difluorosialic acid. 
Two different experimental conditions were used, one with no pre-incubation, with 
the inhibitor and substrate being added simultaneous to the influenza virus; and with 
pre-incubation, where the inhibitor and the influenza virus are incubated for 30 min 
prior to addition of the substrate.166 
The first experiment (no pre-incubation) allowed the examination of the rate of 
association of the inhibitor with the influenza neuraminidase over a 60 min period. 
The rate of reaction is measured by the cleavage of a fluorescent tag present at the 
anomeric position of the substrate (sialic acid). If there is a reduction in the 
fluorescence it implies that there is a slow association of the inhibitor to the enzyme, 
slowing down the rate at which the enzyme can process the substrate, releasing the 
fluorescent tag. All of the inhibitors tested showed a slow association with influenza 
neuraminidase (results not shown). 
Subsequently, the IC50’s were measured at 60 min with the data shown in Table 10. 
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Table 10 IC50 values obtained for the inhibitors given in µM. wt – wild type. 
No pre-incubation

H1N1 H3N2 H1N9 
Compound wt His274Tyr wt Glu119Val wt Glu119Val 
Zanamivir 
0.008 0.006 0.03 0.05 0.006 0.816 
(25)

GS4071

0.007 2.4 0.005 0.208 0.004 0.005 
(33) 
(19) 0.1 0.1 1.7 0.5 1.1 1.2 
(39) 30.1 57.1 333.6 84.1 152.5 219.4 
The 7-N,N-diethylamino (39) derivative showed poor IC50 results, either when tested 
against the wild type or the mutants of the several strains of influenza virus. When 
tested against H3N2, there was an improvement of the IC50 with the mutant 
Glu119Val when compared with the wild type. The same occurrence happened with 
the parent inhibitor, the 2,3-difluorosialic acid (19). This could be due to the fact that 
neither inhibitor possesses a bulky group at C-4 (the position targeted by this 
mutation), therefore they are not affected by it. The reason why there is an 
improvement of the inhibition with the mutation, at the present time eludes us. 
Analysing the inhibition results obtained for the 7-N,N-diethylamino derivative (39) 
against H1N9, it can be seen that there is less inhibition with the mutant than when 
tested against the wild type, which is the opposite of what was observed with the 
H3N2 viral strain. More assays are required in order to establish an explanation of 
these observations. 
The second experiment (pre-incubation) enabled the examination of whether any 
further association or dissociation of the influenza neuraminidase-inhibitor complex 
occurred upon addition of substrate. By measuring the rate of reaction during a set 
time period it can be seen if there is an increase in the rate of reaction, which 
indicates that there is slow dissociation of the inhibitor. All of the inhibitors tested 
showed a slow dissociation with influenza neuraminidase (results not shown). 
Subsequently, the IC50’s were measured at 60 min with the data shown in Table 11. 
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Table 11 IC50 values obtained for the inhibitors are given in µM. wt – wild type, a No data available. 
Pre-incubation

H1N1 H3N2 H1N9 
Compound wt His274Tyr wt Glu119Val wt Glu119Val 
Zanamivir 
(25) 
0.002 0.002 0.004 0.003 0.003 0.678 
GS4071 
(33) 
0.003 2.4 0.002 0.260 0.003 0.003 
(19) 0.08 0.1 1.4 0.2 1.2 1.2 
(39) 28.1 43.2 150.5 25.8 68.4 77.2 
(37) 41.9 48.5 467.7 76.2 326.1 319.6 
(38) 119.4 ---a 159.0 ---a ---a ---a 
The inhibition results obtained with the 7-N,N-diethylamino derivative (39), although 
better than the ones observed with no pre-incubation (Table 10), still showed poor 
inhibition against all of the influenza viruses tested. The same behaviour, akin to the 
non pre-incubation experiment, was observed with the H3N2 and H1N9 influenza 
virus strains. When tested against H1N1, the inhibition of the wild type and mutant 
(His274Tyr) was comparable. This mutation affects the alkylamino substituent; 
however, there was a minimal loss of inhibition. The 7-N,N-diethylamino derivative 
(39) was designed as an isostere of the pentyloxy ester side chain of GS4071 (33) 
and when comparing the inhibition results between these two inhibitors, it can be 
seen that the loss of inhibition is much greater with GS4071 (33). 
The inhibition results obtained with the 7-N-ethyl-N-methylamino derivative (37) 
were similar to the ones obtained with the 7-N,N-diethylamino derivative (39), with 
an improvement of inhibition between the wild type and mutant of H3N2. Contrary 
to the 7-N,N-diethylamino derivative (39), there is an decline of the IC50 between the 
wild type and mutant of H1N9. More experiments have to be carried in order to 
explain the inhibition results obtained by these two inhibitors. 
The inhibition results obtained with the 7-N-ethyl-N-acetamido derivative (38) are 
limited since the inhibitor was only tested against the wild type of H1N1 and H3N2. 
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6.3.2 Determination of the Ki for the 7-N,N-diethylamino-2,3­
difluorosialic acid (39) 
The influenza virus H1N9 showed a time-dependent inactivation by the 7-N,N­
diethylamino derivative (39), which is expressed by the following equation.

The species E, I and P represent the enzyme, 7-N,N-diethylamino-2,3-difluorosialic 
acid (39) and 7-N,N-diethylamino-3-fluorosialic acid (50), respectively. E – P 
represents the covalent sialoside intermediate, whilst k1 and k2 represent the rate 
constant for the glycosylation and deglycosylation steps.167 
Kinetic studies were performed at 37 ºC in 56 mM Tris.HCl buffer and 4 mM of 
CaCl2 at pH 7.2. The time dependence inactivation of influenza neuraminidase by the 
7-N,N-diethylamino derivative (39) was monitored by incubation of the enzyme 
under the above conditions in the presence of several concentrations (100, 250 µM 
and 2.5 mM) of the inhibitor. Residual enzyme activity was determined at specific 
time points by the addition of an aliquot (20 µL) of the inactivation mixture to an 
assay solution (150 µL) containing 4-nitrophenol-sialic acid (100 µM) (Graph 1). Ki 
was determined by fitting the residual activity versus time to a single exponential 
equation using GraFit version 5.0. 
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Graph 1 Residual activity versus time, giving the initial rate of the reaction and the time at which the 
inhibitor has inhibited the enzyme (steady-state). □ – 100 µM; ◊ – 250 µM; ○ – 2.5 mM of inhibitor 
(39). 
Increasing the concentration of inhibitor increases the rate at which the enzyme is 
inactivated, reaching a steady-state more quickly, where the inhibition becomes 
constant. 
By plotting the residual activity versus time it was possible to determine the initial 
rate for each of the concentrations employed. The inverse of the relative rates was 
then plotted against the inverse of the concentrations, obeying to the 
Lineweaver-Burk equation (Graph 2).168 
1 Ki 1 
= + 
v Vmax [ ] I Vmax 
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Graph 2 Lineweaver-Burk plot, where the intercept at y axis gives the inverse of Vmax and the 
gradient gives Ki/Vmax. 
The results obtained with the 7-N,N-diethylamino-2,3-difluorosialic acid (39) 
showed a Ki of 157 µM. 
6.4 Inhibition results obtained for the 4-epi-N-alkylamino 
Neu5Ac2ene derivatives (42), (43) and (131) against a panel of 
influenza viruses (CSIRO) 
In order to evaluate the inhibitory activity of the synthesised C-4 modified 
compounds, 4-epi-N-methylamino- (42), 4-epi-N-ethylamino- (43) and the 4-epi­
azido Neu5Ac2ene (131) were tested against a series of influenza viruses (CSIRO). 
The influenza viruses used were the H1N1 wild type and His274Tyr mutant; H3N2 
wild type and Glu119Val mutant; H1N9 wild type and Glu119Gly mutant. Inhibitory 
results are given in comparison to the currently approved drugs for the treatment of 
influenza virus, zanamivir (25), the active moiety of oseltamivir (33), as well as to 
the parent 2,3-diflurosialic acid (19). 
As with the C-7 modified compounds, two different experimental conditions were 
used, pre-incubation (30 min) between the inhibitor and the influenza virus prior to 
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the addition of substrate and no pre-incubation, with the inhibitor and substrate being 
added simultaneous to the influenza virus. 
OH 
HO OH HN OH HO OH HN O CO2H 
O CO2H 
AcHN 
AcHN 
42 43 
OH 
O 
HO OH 
AcHN 
CO2H 
N3 
131
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AcHN 
H2N 
CO2H 
O 
HO 
AcHN 
HN 
OH 
OH 
CO2H 
NH 
H2N 
25 33 
All of the inhibitors tested showed a slow association with influenza neuraminidase 
(results not shown). Subsequently, the IC50’s were measured at 60 min with the data 
shown in Table 12. 
The 4-epi-N-methylamino Neu5Ac2ene (42) generally showed lower IC50 values for 
the mutants of influenza virus when comparing with the wild types. For H3N2 and 
H1N9 the reduction in the inhibition was significant, 1 to 2 fold better inhibition with 
the mutant Glu119Val. This mutant targets the presence of a equatorial substituent at 
C-4. With the present inhibitor the substituent has an axial orientation, not being 
affected by this specific mutation. 
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Table 12 IC50 values obtained for the inhibitors are given in µM. wt - wild type. 
No pre-incubation

H1N1 H3N2 H1N9 
Compound wt His274Tyr wt Glu119Val wt Glu119Val 
Zanamivir 
0.008 0.006 0.032 0.052 0.006 0.816 
(25)

GS4071

0.007 2.4 0.005 0.208 0.004 0.005 
(33) 
(42) 77.5 56.7 273.7 70.7 185.5 3.9 
(131) 379.7 301.1 60.6 411.4 44.0 47.1 
The 4-epi-azido-Neu5Ac2ene (131) showed better results for the wild type than the 
mutants, with the exception of the H1N1 His274Tyr mutant. The reason why the IC50 
values are higher for the mutant Glu119Val could be linked to the structure of the 
azide, a linear and rigid structure. 
All of the inhibitors tested showed a slow dissociation with influenza neuraminidase 
(results not shown). Subsequently, the IC50’s were measured at 60 min with the data 
shown in Table 11. 
Table 13 IC50 values obtained for the inhibitors are given in µM. wt – wild type. 
Pre-incubation

H1N1 H3N2 H1N9 
Compound wt His274Tyr Wt Glu119Val Wt Glu119Val 
Zanamivir 
(25) 
0.002 0.002 0.004 0.003 0.003 0.678 
GS4071 
(33) 
0.003 2.4 0.002 0.260 0.003 0.003 
(42) 69.7 57.7 332.9 133.0 193.0 4.5 
(43) 548.3 539.5 3594.5 5469.6 604.2 0.4 
(131) 302.4 249.6 64.3 335.8 47.2 50.2 
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As observed with the no pre-incubation experiment, the 4-epi-N-methylamino 
derivative (42) showed better IC50 values for the mutants than the wild type of the 
influenza viruses. 
The 4-epi-N-methylamino Neu5Ac2ene (43) gave very poor inhibition results, with 
the only exception the inhibition observed for the H1N1 Glu119Val mutant. The 
reason why with H3N2 the difference in inhibition between the wild type and the 
mutant is almost 2 fold poorer and with H1N1 is 3 fold better with the mutant, elude 
us at the present time. 
The inhibition observed for the 4-epi-azido derivative (131) was similar to the one 
observed for the no pre-incubation experiment. 
The 4-epi-N-amino Neu5Ac2ene (96) synthesised by the group of von Itzstein gave a 
Ki of 0.3 µM against influenza neuraminidase N2.97 The 4-epi-N-methylamino 
Neu5Ac2ene (42) gave an IC50 of 332 µM; the 4-epi-N-ethylamino Neu5Ac2ene (43) 
an IC50 of 3595 µM and the 4-epi-N-azido Neu5Ac2ene (131) and IC50 of 64 µM. By 
comparing the inhibition observed against influenza neuraminidase N2, by 
employing the synthesised compounds (42, 43 and 131) with the 4-N-amino 
Neu5Ac2ene (96) becomes apparent the restrictions on the group with an axial 
orientation at C-4. 
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Chapter 7 - Conclusions 
Various approaches to the synthesis of novel 7-N-alkylamino 2,3-difluorosialic acids, 
4-N-alkylamino Neu5Ac2ene’s and 5-N-trifluoroacetamido-2,3-difluorosialic acid 
were investigated. 
Several fluorination conditions were investigated in an attempt to improve the yield 
during the introduction of a fluorine atom at C-2 of the 3-fluorosialic acid (54). 
Unfortunately, none of the trial conditions improved the initial (and literature) 
condition that afforded the desired 2,3-difluorosialic acid (54) in moderate yield 
(45%). This compound served as scaffold for the modifications at the glycerol side 
chain, where through oxidative cleavage and reductive amination the desired 7-N­
alkylamino 2,3-difluorosialic acids were obtained. Problems encountered during the 
oxidative cleavage and reductive amination reactions, caused difficulties in achieving 
the desired aldehyde (46) due to the presence of a vast amount of salts once the 
reductive amination was complete. This hindered the purification of the desired 7-N­
alkylamino compounds. These problems were addressed and resolved by employing 
different scaffolds for the oxidative cleavage and reductive amination (methyl, 
benzyl and pMB sialosides) reactions optimising the experimental conditions. 
For the introduction of the N-alkylamines at C-4 of the Neu5Ac2ene moiety, new 
methodologies had to be developed in order to introduce the target N-alkylamines 
with an axial stereochemistry. For this, palladium chemistry was employed and with 
the aid of an oxazoline (which directed the stereochemistry of the target 
N-alkylamines) a series of N-alkylamines was prepared. Using the same 
methodology, the azide was also introduced, allowing the formation of the 4-epi­
azido (131) as well as the 4-epi-N-amino (126) derivatives. 
The introduction of the N-trifluoroacetamido at C-5 of 3-fluorosialic acid was 
achieved by removing the 5-N-acetamido and introducing the trifluoroacetamido, 
using a literature procedure. Once the 5-N-trifluoroacetamido-3-fluorosialic acid (89) 
was obtained, it was only necessary to introduce the fluorine at C-2 and the target 
compound was achieved. 
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In conclusion, different synthetic methodologies were developed to introduce the 
desired derivatives in the different positions of the 2,3-difluorosialic acid (19). A 
series of C-5 and C-7 2,3-difluorosialic acid derivatives and the C-4 Neu5Ac2ene 
derivatives were successfully prepared. With the methodology developed it is 
possible to introduce a variety of alkylamino substituents in the fore-mentioned 
positions in an attempt to expand the range of compounds to be tested against the 
influenza virus. 
The 7-N-alkylamino 2,3-difluorosialic acid modified inhibitors (37 – 39), as well as 
the Neu5Ac2ene C-4 modified inhibitors (42 – 44), were tested against a series of 
influenza viruses (CSIRO). The 7-N,N-diethylamino, 7-N-ethyl-N-methylamino and 
7-N-ethyl-N-acetamido-2,3-difluorosialic acid (37 – 39) showed a 1000 fold poorer 
inhibition than the currently approved compounds, zanamivir (25) and the active 
moiety of oseltamivir (33). However, the inhibition results obtained showed that the 
inhibitors do not lose activity when tested against clinically identified mutants of 
influenza neuraminidase. 
The biological behaviour of the inhibitors tested was a surprise since the rationale 
behind their design was based on the parent compound, 2,3-difluorosialic acid (19) 
as well as GS4071 (33). Therefore, it was expected that the IC50 values of the 
inhibitors would be comparable to the parent compound. The IC50 values of the 
inhibitors were poor when compared to the parent compound, which might be due to 
a slow association between the inhibitors and the influenza neuraminidase active site. 
For future work, several compounds could be synthesised in an attempt to improve 
the inhibition of influenza neuraminidase. The introduction of cyclic amines at C-7 
could improve the inhibition by reducing the potential rotational freedom of the alkyl 
chain. The synthesis of a dimeric 2,3-difluorosialic acid at C-7, with a 16 carbon 
linker could improve the inhibition results by agglomerating the influenza viruses, 
improving the host defence system. 
The crystal structure obtained for the 7-N,N-diethylamino-2,3-difluorosialic acid (39) 
with the influenza neuraminidase N9, showed the presence of the covalent bond 
formed between Tyr406 and the inhibitor, supporting our proposed catalytic 
mechanism of influenza neuraminidase. 
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In respect with the C-4 modified Neu5Ac2ene, the next step could be the 
development of a synthetic strategy to introduce the fluorines at C-2 and C-3 on the 
amino (126) and azido (131) derivatives. With the fluorines at C-2 and C-3, the 
compounds would target the covalent intermediate sialoside-enzyme that is formed 
during the catalytic mechanism, instead of the transition state. 
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Chapter 8 - Introduction to Chagas’ disease and 
Trypanosoma cruzi 
8.1 Historical perspectives, prevalence and modes of infection 
The parasite Trypanosoma cruzi is the causative agent of Chagas’ disease in humans. 
This disease was first discovered over a century ago by Dr. Carlos Chagas in 
Brazil.169 The disease is endemic to Central and South America, where it is estimated 
that roughly 18 million people are currently infected by the parasite, with a further 
100 million people living in conditions which place them at high risk of becoming 
infected (Figure 25).170 
Figure 25 Geographical distribution of Chagas’ disease in Central and South America.171 
The natural reservoir for the T. cruzi parasite is the reduviid insect, which is endemic 
to most areas of Central and South America. The parasite is found to be present in 
the midgut (stomach) and hindgut (rectum) of the insect (Figure 26).172 
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Figure 26 Reduviid insect, the natural reservoir for the Trypanosoma cruzi parasite.173 
The insect is noctivagous, attacking its prey while they are asleep. The insect, whilst 
taking a blood meal, defecates (with the parasites present in the faeces) near the bite 
wound and upon awakening the mammal often scratches the area of the bite, which 
rubs the faeces into the skin, allowing the parasite to penetrate and initiate the 
infection process.170 There are three common ways of becoming infected with the 
parasite: by direct contact with the reduviid bug (accounts for 80 to 90% of cases); 
through a blood transfusion with infected blood (5 to 20% of infections) or via 
congenital routes (0.5 to 8% of infections).174 
8.2 Life-cycle of the Trypanosoma cruzi parasite and the 
progression of Chagas’ disease 
The life-cycle of the parasite encompasses a variety of developmental stages, which 
occur either in the reduviid insect or in the human host (Figure 27).175 As mentioned 
previously, whilst the insect is taking a blood meal it defecates near the bite, 
depositing the parasites on the skin (step 1). The metacyclic trypomastigotes 
penetrate the skin near the bite wound, infecting cells (step 2). Once inside the cells, 
the metacyclic trypomastigotes differentiate into amastigotes, which are responsible 
for further replication (step 3).172 Following extensive replication in the cell 
cytoplasm, the amastigotes differentiate into trypomastigotes prior to cell rupture.172 
The newly formed trypomastigotes can then either infect neighbouring cells directly 
or enter the bloodstream to infect a variety of cells systematically (step 4). The 
trypomastigotes are able to pass unharmed past the host defence mechanisms. The 
exact reason why this occurs is unclear; however, it is thought to be likely owing to 
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the production of a surface protein, complement regulatory protein (CRP), which is 
known to interfere with complement activation, one of the early stages in host 
defence mechanisms.176 
Figure 27 Life-cycle of the Trypanosoma cruzi parasite in the reduviid insect (red arrows) and in a 
human host (blue arrows).175 
The trypomastigotes present in the human bloodstream can then be re-ingested by a 
reduviid insect, and once in the midgut of the insect the trypomastigotes will 
differentiate into epimastigotes that replicate by binary fusion (step 5 to 7).172 The 
epimastigotes then pass to the hindgut of the insect where they differentiate to 
metacyclic trypomastigotes, and are now ready to begin another cycle of infection 
(step 8) (Figure 27).172 
Chagas’ disease has two distinct phases of infection: the acute phase, which starts 
roughly a week after the host has been infected, lasting usually up to two months; 
and the chronic phase, which persists for life. The majority of symptoms during the 
acute phase are usually mild and are often confused with other diseases. One notable 
exception is a symptom characterised by a sign on the face (the most common site of 
infection), the Romaña sign (a unilateral swelling of the eyelids) that appears at the 
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site of the bite (Figure 28).169,177 In rare cases, more deadly symptoms such as 
myocarditis may also occur. 
Figure 28 Characteristic sign of a reduviid insect bite, called the Romañas’ sign.177 
Roughly two months after infection the chronic phase begins, where it is difficult to 
detect the trypomastigotes in the bloodstream; however, serological tests are positive. 
The chronic phase is further subdivided into three separate stages: the indeterminate; 
the cardiac; and the digestive stages. Up to 70% of all infected patients are part of the 
indeterminate form, where there are no signs of infection or further complications. In 
the remaining cases there is the development of either the cardiac form, which is 
associated with heart conditions (e.g. arrhythmia, cardiac failure) that can be deadly; 
or the digestive form, where there is the formation of megavisceras, more precisely 
megaoesophagus and/or megacolon.169,171,174,178 
8.3 Current treatments for Chagas’ disease 
There are currently only two drugs available for the treatment of Chagas’ disease, 
both of which were discovered in the 1970’s, Nifurtimox (133) produced by Bayer 
and marketed as Lampit®; and Benznidazole (134) which is produced by 
F. Hoffmann-La Roche and marketed as Rochagan®.179 
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Both drugs are administered during the acute phase of the disease as they have 
proven more effective against trypomastigotes (extracellular), as opposed to the 
chronic phase where their effectiveness against amastigotes (intracellular) is 
disputable.174,180-187 
8.3.1 Mode of action of currently approved drugs 
Nifurtimox (133) and Benznidazole (134) are active against Chagas’ disease due to 
the presence of the nitro group, which can be reduced to a nitro anion radical in vivo 
to produce either potential alkylating agents or free radicals (Figure 29).178 Firstly, 
the action of NADPH-cytochrome P450 reductase produces the nitro anion radical 
that takes part in redox cycling with molecular oxygen.178 
Figure 29 Mode of action of a molecule containing a nitro group.178 
The superoxide anion, O2 .-, can generate H2O2 through the action of superoxide 
.­dismutase (SOD). H2O2 and O2 in the presence of Fe3+ can undergo the 
Haber-Weiss reaction to produce a hydroxyl radical (.OH), which is one of the most 
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harmful low molecular weight radical species through binding to lipids, proteins and 
DNA.170,178,188,189 
It has been shown that Trypanosoma cruzi is more sensitive to oxidative stress than 
host cells due to the lack of detoxification mechanisms for oxygen metabolites in the 
parasite, a fact that is exploited by Nifurtimox (133).190,191 On the other hand, it has 
been postulated that Benznidazole (134) acts by covalently binding one or more of its 
nitroreduction intermediates, to inhibit RNA synthesis in the parasite.174,179 It is also 
thought that Benznidazole may be acting on several other processes within the 
parasite, such as interacting with IFN-γ, or inhibiting Trypanosoma cruzi 
NADH-fumarate reductase.188,192-194 
8.3.2 Side-effects associated with current therapies 
As a consequence of their non-selective mechanisms of action, both of the currently 
approved drugs have serious side effects. The common side-effects from Nifurtimox 
(133) generally target the central nervous system and can result in anorexia, loss of 
weight, excitability or sleepiness. It can also cause gastrointestinal problems 
resulting in nausea, vomiting, and occasional intestinal colic and diarrhoea.170,174 
Benznidazole (134) causes similar side effects to Nifurtimox (133), as well as 
additional effects which are more serious in nature. These can be divided into three 
groups: hypersensibility, dermatitis with coetaneous eruptions, articular and 
muscular pain, fever and lymphadenopathy; depression of bone marrow, 
thrombocytopenic purpura and agranulocytosis (the most severe complications 
reported); polyneuropathy, paresthesia and polyneuritis of peripheric nerves. There is 
also speculation that the prolonged use of both drugs can induce 
tumorigenic/carcinogenic events in cells.170,174 
8.4 Novel therapeutic targets for inhibition of Trypanosoma cruzi 
Given the serious problems associated with the currently approved drugs, there is a 
pressing need to develop new and safer drugs able to halt the progression of the 
disease. 
In the 1990’s numerous drug candidates were developed, synthesised and tested 
against Chagas’ disease with little success. Recent advances in the understanding of 
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the biochemistry of the parasite have indentified several potential new targets for 
therapeutic interventions, including the targeting of sterol biosynthesis, 
trypanothione reductase, and cysteine proteases.174,191,195,196 Amongst the several 
enzymes identified as possible targets for chemotherapeutics, one of significant 
importance is Trypanosoma cruzi trans-sialidase.197 This enzyme is present on the 
cell surface of trypomastigotes and is crucial for cell invasion.198 Although this 
protein is only valid for targeting the acute phase of the disease, it is still an 
important target, as halting the infection of host cells by the trypomastigotes will 
neutralize the disease.197 Trypanosoma cruzi trans-sialidase also plays an important 
additional role in protection of the parasites by shielding them from detection by the 
host immune system.197 
8.5 Trypanosoma cruzi trans-sialidase 
The existence of Trypanosoma cruzi trans-sialidase (TcTS) was first postulated by 
Previato et al and latter supported by Zingales et al.199,200 Zingales et al showed that 
the cell surface of the parasite must possess an enzyme that not only has the 
capability of cleaving sialic acid from host cell glycoconjugates, but must also have 
the ability to transfer sialic acid onto the surface of the parasite.200 These 
observations were latter confirmed by several other researchers.172,201-204 
TcTS and the acceptor of sialic acid, a mucin-like protein, are bound to the surface of 
the parasite by glycosylphosphatidylinositol (GPI) anchors.205 TcTS has two distinct 
enzymatic activities, namely the cleavage of sialic acid from the host cell surface 
glycoconjugates and the transfer of the cleaved sialic acid to an acceptor substrate of 
the parasites mucin like surface proteins (Figure 30).206 TcTS is of the upmost 
importance for the parasite, as the parasite is unable to synthesise sialic acid de novo 
to coat the surface of the trypomastigotes with sialic acid. 
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Figure 30 The role of TcTS on the transfer of sialic acid from a host cell glycoconjugate (blue sphere) 
to a mucin receptor at the surface of the parasite (orange sphere). 
Once the parasite’s surface is coated with sialic acid it can evade the host defence 
mechanisms due to the masking of the terminal sugar moiety (a galactose) of the 
glycoconjugate (Figure 31).172,197,205 Trypanosoma cruzi trans-sialidase can also be 
shed into the bloodstream by the action of phosphatidylinositol-phospholipase 
C (PI-PLC). Once in the blood stream, TcTS is able to interact with different 
biological processes, such as inducing apoptosis in components of the host immune 
system; induction of immunophatology; promoting the desialylation of platelets; and, 
surprisingly, enhancing the regeneration and outgrowth of neurons (Figure 31).207-210 
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Figure 31 Role of Trypanosoma cruzi trans-sialidase on transferring sialic acid from host 
glycoconjugates and its biological effects when it is free from the parasitic surface.205 
8.5.1 Catalytic mechanism 
The catalytic mechanism of Trypanosoma cruzi trans-sialidase is very similar to that 
of influenza neuraminidase (Scheme 38).211,212 In the first step of the mechanism the 
glutamate residue, Glu230, acts as a general base catalyst, deprotonating the 
hydroxyl group of the catalytic tyrosine residue, Tyr342.136 The hydroxyl group of 
the tyrosine residue then acts as a nucleophile, attacking the anomeric position (C-2) 
of the sialic acid residue, forming a covalent sialyl-enzyme intermediate.136 
Departure of the aglycone is assisted through protonation of the glycosidic oxygen 
by a aspartate residue, Asp59.136 In the second step of the mechanism the aspartate 
residue now acts as a general base, deprotonating the C-3 hydroxyl group of an 
acceptor galactoside which acts as a nucleophile, attacking the anomeric position 
(C-2) of the sialic acid, turning over the covalent intermediate.136 As a result, the 
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sialic acid is now transferred from the host cell glycoconjugates to a mucin acceptor 
on the surface of the parasite with an overall retention of anomeric configuration.212 
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Scheme 38 Catalytic mechanism of Trypanosoma cruzi trans-sialidase.212 
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8.5.2 Active site architecture of TcTS 
The crystal structure of Trypanosoma cruzi trans-sialidase was solved in 2002 by 
Buschiazzo et al who showed that the enzyme consists of two domains: an 
N-terminus domain of 371 residues which forms a six bladed β propeller that 
contains the active site; and a C-terminus lectin-like domain, containing 260 
residues, which is not involved in the enzymatic activity (Figure 32).213 In the 
majority of trans-sialidases the C-terminal part possesses a repetitive unit of 12 
amino acids called shed acute phase antigen (SAPA) that generates an early antibody 
response from the human host in the acute and congenital stages of infection.172,214 
Active site 
N terminal catalytic 
domain 
C terminal lectin 
like domain 
Figure 32 A monomeric subunit of TcTS (in Corey-Pauling-Kolton form). Generated with PyMol 
(PDB 1MS4). 
The active site of trans-sialidase contains several highly conserved residues that are 
common to most sialidases, such as the arginine triad (Arg35, Arg245 and Arg314) 
which interact with the carboxylate of sialic acid; the catalytic nucleophile residue, 
Tyr342, and the general acid/base residues Asp59 and Glu230.213 Moreover there are 
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several residues that, although not involved in the catalytic cycle, are required to 
interact with the N-acetyl group and the glycerol side chain, namely Val95, Asp96, 
Trp120 and Leu176 (Figure 33).136,213 
Figure 33 Representation of the catalytic site of Trypanosoma cruzi trans-sialidase with Neu5Ac2ene 
(27) binding to the key amino acids. Generated with LigPlot+ (PDB 1MS8). 
In addition to the sialic acid binding site, there is also a lactose binding site present, 
which will accommodate the galactose moiety. The key residues responsible for the 
trans-sialidase activity are Tyr119, Trp120, Val203, Tyr248 and Trp312 which have 
been seen to regulate the accessibility of the acceptor glycoconjugate to the catalytic 
site.213 Once sialic acid is covalently bound to the enzyme the Tyr119 residue can 
adopt one of two conformations: inside the active site, close to the glycerol moiety of 
sialic acid; or outside the catalytic site creating a slot like cavity with the aid of 
Trp312 residue.206,213 Tyr119 plays an important role in the transfer of the sialic acid 
from the donor to the acceptor substrate, as the mutation Tyr119Ser has been shown 
to abolish the trans-glycosylation activity.215 One other residue that seems crucial for 
effective formation of the acceptor binding site is Pro283, which interacts with 
Trp312 a residue that modulates the acceptor binding site.213,215 A cartoon 
representation of the mode of action of trans-sialidase illustrates how the enzyme, 
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after accepting the donor substrate, alters the architecture of its active site to promote 
binding of the acceptor substrate (Figure 34). 
Figure 34 Cartoon representation of Trypanosoma cruzi trans-sialidase.213 
8.6 The development of novel inhibitors of Trypanosoma cruzi 
trans-sialidase 
In order to inhibit Trypanosoma cruzi trans-sialidase, one can either target the sialic 
acid binding site (by mimicking sialic acid) or the lactose binding site. 
Regarding mimetics of sialic acid as potential inhibitors of TcTS, inhibitors of a 
similar enzyme, influenza neuraminidase, have been tested since both enzymes share 
many of the same active site residues and both process sialic acid as their natural 
substrate (Figure 35). 
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Figure 35 Structures of inhibitors towards the sialic acid binding site.212 
Surprisingly Neu5Ac2en (27) showed only a weak inhibition towards Trypanosoma 
cruzi trans-sialidase with a Ki of 12.3 mM, whilst zanamivir (25), GS4071 (33) and 
peramivir (34) showed no inhibition (> 10 mM) towards the enzyme.212,216,217 Other 
compounds based on a benzoic acid scaffold (135 - 139) showed slightly better levels 
of inhibition, in the order of 0.1 to 1 mM. 212,216 
The use of analogues that can occupy both the sialic acid and lactose binding sites 
(140 - 142) have also been studied (Figure 36).212 
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Figure 36 Structures of inhibitors towards the lactose binding site as well as both binding sites.212 
The GM3 ganglioside analogue (140) showed good inhibition (10 to 100 µM) whilst 
no inhibition was observed for the α-2,3-sialyl-β-thiogalactoside (141).218,219 Lactitol 
(142) on the other hand, was found to have an IC50 of 0.57mM.220,221 
Finally, 2,3-difluorosialic acids have also been investigated as mechanism-based 
inhibitors of TcTS (Figure 37).57,222 
Figure 37 Structures of novel fluorinated inhibitors of Trypanosoma cruzi trans-sialidase.222 
The 2,3-difluorosialic acid (19) has been shown to inhibit TcTS in a time dependent 
manner, forming a covalent bond with Tyr342, although high concentrations are 
necessary to achieve complete inactivation (Ki of 20 mM).57 More recently, Buchini 
et al have shown the C-9 modified 2,3-difluorosialic acids (143 - 144) are inhibitors 
of TcTS, having a Ki/Kd of 2.9 and 3.2 min-1mM-1 respectively.222 The compounds 
were observed to have an interaction between the aryl substituent at C-9 and the 
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lactose binding site residues (Trp312 and Tyr119), hampering the binding of lactose 
into the active site (Figure 38).222 
Figure 38 Representation of the interactions within the active site with the C-9 benzoylamide (143) 
and the amino acid residues. Generated with LigPlot+ (PDB 3B69). 
8.7 Aims of the project 
Considering the results observed by Buchini et al, where the introduction of a large 
group at C-9 of the sialic acid was found to inhibit Trypanosoma cruzi trans-sialidase 
by restricting the access of lactose to the active site, we set out to further probe this 
finding by developing a series of modifications at C-7 of 2,3-difluorosialic acid 
(19).222 Several cyclic amines were introduced at C-7 (145 - 147) in order to probe 
the interaction between the amino acid residues Tyr119 and Trp312 with the cyclic 
amino substituents. It was anticipated that by introducing cyclic amines we could 
reduce the degrees of rotational freedom of the bonds, which may improve the 
binding of the compounds within the active site. In addition, an aromatic C-7 amine 
was developed (147) with the intention of possibly forming π-π interactions between 
the Tyr119, Trp312 and the aromatic substituent. The introduction of this series of 
amines was accomplished by employing the methodology developed previously 
(Chapter 3), and the synthesised compounds were tested against Trypanosoma cruzi 
trans-sialidase. 
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Chapter 9 – Synthesis of 7-N-alkylamino 2,3­
difluorosialic acids and their biological evaluation 
against TcTS and trypomastigotes 
9.1 Prelude 
As described previously (Chapter 8) the 7-N-pyrrolidino (145), 7-N-morpholino 
(146) and 7-N-anilino-2,3-difluorosialic acid (147) were developed as inhibitors of 
Trypanosoma cruzi trans-sialidase. 
The 7-N-morpholino derivative (146) was developed to investigate the available 
space in the glycerol side chain binding pocket. In addition, the presence of the 
oxygen could prove advantageous to the binding of the compound with the potential 
formation of hydrogen bounds with neighbouring amino acid residues, such as 
Gly195. For the 7-N,N-diethylamino-2,3-difluorosialic acid (39) the ethyl groups 
have high degrees of rotational freedom; therefore, the introduction of a pyrrolidine 
group (145) would reduce the rotational freedom of the ethyl groups and the 
difference in binding affinity may be determined. Finally, the 7-N-anilino-2,3­
difluorosialic acid (147) was developed in order to interact with the amino acid 
residues Tyr119 and Trp312 present at the lactose binding site. Buchini et al showed 
that the aromatic substituents at C-9 of 2,3-difluorosialic acid interact with the amino 
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acid residues present in the lactose binding site, preventing efficient binding in this 
222 case.
The 7-N-pyrrolidino (145), 7-N-morpholino (146) and 7-N-anilino-2,3-difluorosialic 
acid (147) were all synthesised using the strategy developed (Chapter 3), by 
performing a oxidative cleavage followed by reductive amination on the 2,3­
difluorosialic acid (48). 
The 2,3-difluorosialic acid (48) was treated with an aqueous solution of sodium 
periodate (0.4 M) in water, and upon the completion of the reaction the solvent was 
removed in vacuo and the C-7 aldehyde (47) was used without further purification. 
The C-7 aldehyde (47) was then treated with the desired alkylamine in methanol, to 
afford a series of 7-N-alkylamine 2,3-difluorosialic acid (84) (Table 14). 
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Table 14 Yields of the different 7-N-alkylamines synthesised (148 – 150). 
i) 0.4M NaIO4, H2O, r.t., 20 min; ii) R1R2NH, NaCNBH3, MeOH, AcOH, r.t., O/N. 
Amine 
Entry	 R1 Product Yield (%) 
NH 
R2 
1 
R1 = R2 = 
42 
2 
R1 = R2 = 
21 
3 
R1 = Ph 
R2 = H 
22 
The final step in order to achieve the desired 7-N-alkylamines 2,3-difluorosialic acids 
was the saponification of each of the methyl esters. This conversion proceeded 
smoothly by using a 1M sodium hydroxide solution in water to afford the final 
targets (145 – 147) in good yield (Table 15). 
137 
Chapter 9 
Table 15 Yields for the saponified final compounds (145 - 147). 
1M NaOH, H2O, 4 ºC, 1h 
Entry Product Yield (%) 
1 Quantitative 
145 
O F 
CO2H 
HO 
N 
F 
AcHN 
2 84 
3 60 
9.2 IC50 determination of the inhibitors (145 – 147) 
The determination of the IC50 of 7-N-pyrrolidino (145), 7-N-morpholino (146) and 
7-N-anilino (147) derivatives was carried out using a 14C radiolabelled lactose. The 
enzyme activity was determined using purified TcTS and it was measured by the 
transfer of sialic acid from 1 mM sialyl-α-(2→3)-lactose to 12 µM [D-glucose-1­
14C]lactose (55 mCi/mmol), in 30 µL containing 0.5 ng of TcTS, 20 mM Hepes-Na 
(pH 7.5), 0.2% BSA and 30 mM NaCl. After 30 min at 25 ºC the reaction was 
stopped by dilution with 1mL of water, QAE-Sephadex was added, and the resin 
washed twice with water. Negatively charged compounds were eluted with 0.8 mL of 
1M NaCl and quantified in a WinSpectral 1414 liquid scintillation counter (Figure 
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39).223 The inhibition of the TcTS implies a lower transfer of sialic acid to the 14C 
radio labelled lactose. The amount of 14C radio labelled lactose was measured with a 
scintillation counter. 
Inhibitor pre­incubated Separation using

with TcTS for 1h Sephadex

Lactose 14C 
Hepes­Na 
BSA 
NaCl 
Reaction time 
30 min 
Stirr 
...... . 
... 
..
.. .
. 
.. ...... ...
........
.... ...
...... . .. 
.
. 
.
. 
.. . 
.. . . . .... . .. . . . . .
. .. .
.
. .. .
........
. .
... .. ... 
.....
.... .... . . ..
. ...... .. .. . 
.. ..
Wash with 1M NaCl 
Centrifuge 
Transfer the supernatant 
Centrifuge 
Wash with water 
Centrifuge 
Quantif ication

using Scintillation counter

Figure 39 Illustration of the procedure for the determination of the IC50. 
The reason for pre-incubation of the inhibitors with TcTS for 1h is to take into 
account the potential for slow binding behaviour of the inhibitors (akin to the 
behaviour observed with influenza neuraminidase). The inhibition data obtained for 
the 7-N-pyrrolidino- (145), 7-N-morpholino- (146) and 7-N-anilino-2,3-difluorosialic 
acid (147) is presented in the following graphs (Graph 3 - Graph 5). 
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Graph 3 IC50 determination for inhibitor 7-N-pyrrolidino-2,3-difluorosialic acid (145). 
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Graph 4 IC50 determination for inhibitor 7-N-morpholino-2,3-difluorosialic acid (146). 
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Graph 5 IC50 determination for inhibitor 7-N-anilino-2,3-difluorosialic acid (147).

The IC50 values are present in Table 16. 
Table 16 IC50 values for the inhibitors (145 – 146). 
Compound IC50 (mM) 
4.1 
35.5 
3.2 
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The IC50 obtained for the 7-N-pyrrolidino (145) and 7-N-anilino derivatives (147) are 
similar, 4.1 and 3.2 mM respectively. These two compounds could be interacting 
with the amino acid residues present in the lactose binding site, Tyr119 and Trp312, 
akin to the compounds synthesised by Buchini et al.222 The 7-N-anilino derivative 
(147) could be involved in π-π interactions with the above mentioned amino acid 
residues, leading to a lower IC50 than the 7-N-pyrrolidino derivative (145). 
The 7-N-morpholino derivative (146) showed an IC50 of 35.5 mM, which could be 
due to the fact that the inhibitor has a lower rate of association with the enzyme, 
requiring longer pre-incubation periods with TcTS. 
The technique employed is prone to experimental errors, since a suspended resin 
with the labelled lactose is used, and when adding the resin it is difficult to ensure 
that the same amount of resin is being added. In addition, during the washing of the 
resin it is probable that some of the resin is lost. These types of errors will reduce the 
amount of 14C radio labelled lactose present in solution. 
9.3 Evaluation of the ability of the inhibitors to prevent the 
infection of cells by trypomastigotes 
The in vitro inhibition of infectivity assay is based on the principle that if the 
inhibitors are effective they will halt the infection of host cells by the 
trypomastigotes. 
Vero cells were inserted in a 24-well plate (104 cells/well) fitted with a sterile 
12-mm-diameter glass cover slip in 500 µL 10% FBS-MEM and used after 24h of 
growth (Stage I, Figure 40). Before infection, the medium was removed and the cells 
washed twice with PBS. Different concentrations of inhibitor were added followed 
by 0.2% BSA-MEM. Prior to incubation, trypomastigotes (100 parasites/cell) were 
added and the plate was examined under microscope to ensure that both cells and 
parasites were well, and that the introduction of the inhibitor did not produce 
secondary effects, such as death of the cells and/or parasites (Stage II, Figure 40). 
Once the inspection was complete, the plate was incubated for 20h, at a constant 
temperature of 37 ºC under 5% CO2. The plate was re-examined before changing the 
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medium to ensure that both cells and parasites were alive after the incubation period 
and that the inhibitor was not cytotoxic. 
 
Glass plate 
Vero cells Remove the medium 
BSA­MEM 
Trypomastigotes 
FBS­MEM Inhibitor 
Incubate for 24h 
Stage I Stage II 
Incubate 
for 20h 
Remove the glass plate Remove the medium 
FBS­MEM 
Incubate for 72h 
Stage IV Stage III 
 
Figure 40 Illustration of the assay for the inhibition of trypomastigotes assay, with the key steps 
shown. 
 
After removing the parasites, the wells were washed with PBS and maintained with 
3% FBS-MEM (Stage III, Figure 40). After the changing of the medium, the plate 
was examined again at the microscope to certify that the cells were not removed 
during the procedure. The plate was introduced again in the incubator for a final 72h 
incubation period. The cells should stick to the glass plate during the initial 20h; 
however, if any anomaly occurs during this period (e.g. the inhibitor proved toxic) 
the cells and parasite will die, hence not adhering to the glass plate. After 72h 
incubation, the medium was removed and the wells washed with PBS to remove any 
free particles (e.g. dead cells, some parasites that survived the previous wash) several 
times (Stage IV, Figure 40). After the washings, the glass plates were conditioned for 
visualisation by the addition of dyes, firstly may-Grünwald (250 µL). It was left to 
stand for 5 min, after which water (250 µL) was added and left to stand for a further 
1 min. After removal of the liquid another dye, Giemsa (1/4 dilution with water, 
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600 µL) was added and left to stand for 5 min. The role of the dies is to stain and fix 
the cells and amastigotes (present in the cytoplasm), and ultimately to close the cell 
membrane, making it impermeable. After this time the glass support was carefully 
removed, dipped in water to remove the excess of dye and dried (Stage IV, Figure 
40). The plate supports were mounted with DPX mountant onto a glass support plate. 
The number of infected cells was counted (by eye) and the results expressed as the 
average of the percentage of infected cells in respect with the healthy ones. 
When comparing both assays it is possible to see some deviation in the results, which 
could be related to experimental errors. A possible experimental error can occur 
during the processing of the data, since the data is obtained by visually counting the 
healthy cells versus the infected ones (Figure 41). 
Figure 41 Example of an image from one of the experiments. The presence of infected cells (circle) 
and healthy cells (square) is evident. The dots inside the cells are amastigotes. 
Sometimes the distinction of the cell membrane is complicated due to the high 
number of cells present; this can cause complications in establishing the correct 
number of cells present. One other problem could be the presence of impurities on 
the glass support arising from the washings of the dyes. 
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The infectivity assay was performed twice and the results for both assays are 
presented (Graph 6). The values presented are an average of the duplicates performed 
for each assays. 
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Graph 6 Rate of infection at different concentrations of the inhibitors (145) – (147). Infectivity is the 
ratio between infected and healthy cells. 
At 0.1 mM the values of infection were similar to the ones observed in the control; 
therefore, none of the inhibitors showed any inhibitory activity (Graph 6). At 5 mM 
the 7-N-anilino derivative (147) showed a big reduction in the infection of cells by 
the trypomastigotes, unfortunately the cause for such reduction is linked with a 
possible toxicity of the compound, which could be seen by the reduced number of 
cells (and parasites) present in the wells when compared with the control. Although 
the small rate of infection is clearly very promising, it is important to consider the 
possible toxicity of the inhibitor when analysing the results. The 7-N-pyrrolidino 
(145) and 7-N-morpholino (146) derivatives at 5 mM showed a reduction in the total 
number of cells infected, although the number of cells observed was lower than the 
ones present in the control (Graph 6). At this concentration both compounds show a 
potentially inhibitory behaviour, with the levels of infection decreasing when 
compared with the control. 
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Chapter 10 - Conclusions 
In Part Two of this thesis, the synthesis of several C-7 cyclic N-alkylamines 
(145 - 147) was achieved and the compounds tested against trypomastigotes and 
Trypanosoma cruzi trans-sialidase. 
The 7-N-pyrrolidino and 7-N-anilino derivatives (145 and 147) showed IC50 values 
of 4.1 and 3.5 mM whilst the 7-N-morpholino derivative (146) showed an IC50 of 36 
mM against TcTS. The 7-N-anilino derivative (147) appears to interact with the 
amino acid residues Tyr119 and Trp312 present in the lactose binding site. 
Unfortunately, upon testing in vitro the 7-N-anilino derivative (147) appeared to be 
cytotoxic at the concentration used (5 mM), killing the cells and parasites present. 
The 7-N-pyrrolidino (145) and the 7-N-morpholino (146) derivative showed poor 
levels of inhibition when used at a concentration of 5 mM. 
The next step would be to develop a longer and bulkier aromatic side chain, in order 
to improve the interactions with the Tyr119 and Trp312. It might be also possible to 
develop a 7-N-anilino derivative that could be linked through a sialosidic bond to a 
modified lactose (e.g. removal of the C-3 hydroxyl of galactose). This compound 
may show increased binding affinity between the inhibitor and the Trypanosoma 
cruzi trans-sialidase with the advantage that the cleaved lactose could not be the 
acceptor for the sialic acid, but might interfere with the amino acids present at the 
lactose binding site. 
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Chapter 11 - Experimental 
11.1 General 
Chemical reagents were purchased from Sigma-Aldrich unless otherwise stated. 
Anhydrous dichloromethane and tetrahydrofuran were obtained by distillation over 
calcium hydride or sodium/benzophenone, respectively. All other solvents were 
purchased from Fisher Scientific and used without further purification. Analytical 
thin layer chromatography (t.l.c.) was performed using silica gel 60 F254 pre-coated 
on aluminium sheets (0.25 mm thickness) and reverse phase analytical tlc was 
performed with RP-18 F254s pre-coated on aluminium sheets (0.27 mm thickness) 
purchased from Merck. Column chromatography was performed on silica gel 60 
(35-70 micron) from Fisher Scientific. Melting points were recorded on a Reichert-
Jung Kofler block apparatus and are uncorrected. Specific rotations were determined 
on an Optical Activity Ltd.: AA-10 automatic polarimeter. 1H, 13C and 19F NMR 
were recorded using a Jeol Delta (270 MHz), Varian Mercury (400 MHz) or Bruker 
Avance III (400 and 500 MHz) spectrometers, with acquisition frequencies of 270, 
400 or 500 for 1H; 100 or 125 for 13C; and 376 or 470 for 19F. J values are given in 
Hz and δ in parts per million (ppm). All 1H and 13C NMR assignments are 
corroborated by gCOSY, gHMBC, gHMQC, and DEPT experiments. Abbreviations 
for splitting patterns are as follows: br, broad; s, singlet; d, doublet; q, quartet; 
t, triplet; and m, multiplet. 
High resolution mass spectrometry was performed using a Bruker MicrOTOFTM 
electrospray ionisation mass spectrometer. Standard work up means diluting the 
reaction residue in the appropriate organic solvent (mentioned), and washing with an 
aqueous saturated sodium bicarbonate solution followed by brine. The organic 
phases were then combined and dried over anhydrous sodium sulfate. 
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11.2 Synthesis

Methyl 5-N-acetamido-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-3-fluoro-D-erythro-α-L­
manno-non-2-ulopyranosonate (53) 
i) Neu5Ac aldolase (90.0 mg, 8 U/mg) was added to a solution of 3-fluoropyruvic 
acid (49) (1.50 g, 11.7 mmol) and N-acetyl-D-mannosamine monohydrate (48) 
(5.18 g, 23.4 mmol) in water (120 mL) and the mixture was left to stand at room 
temperature for 5 days. The reaction was followed using 19F NMR by monitoring the 
disappearance of the signal from β-fluoropyruvic acid (49) at δ -233.3 ppm, and the 
formation of a signal corresponding to the 3-fluorosialic acid (50) at δ -208.3 ppm. 
The reaction mixture was purified by ion exchange chromatography (Dowex 1x2 200 
ion exchange resin, formate form) eluting with 0 → 1 M formic acid. Lyophilisation 
of the eluent gave 3-fluorosialic acid (50) as a colourless, hygroscopic solid which 
was used without further purification. 
ii) Trifluoroacetic acid (2.20 mL, 28.7 mmol) was added to a solution of 
3-fluorosialic acid (50) (3.15 g, 10.2 mmol) in methanol (110 mL) at 4 °C and the 
solution was left to warm to room temperature over night. The mixture was then 
concentrated in vacuo affording the 3-fluorosialic acid methyl ester (52) as a white 
solid (3.36 g) which was used without further purification. 
iii) Acetic anhydride (24.6 mL, 260 mmol) was added to a solution of the crude 
methyl ester (52) (3.36 g, 10.4 mmol) in pyridine (90 mL) at 4 °C and the solution 
was stirred at room temperature for 4 days. The solution was then concentrated in 
vacuo and residual pyridine removed by azeotropic evaporation with toluene to give 
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a brown oil. The oil was subjected to a standard work up (EtOAc) and purified by 
flash chromatography (EtOAc:Hexane 9:1 → EtOAc) to give the per-O-acetylated-3­
fluorosialic acid (53) as a white solid (4.12 g, 72% over 3 steps). m.p. 193-196 ºC 
(Lit. 194 ºC)224 . 1H NMR (270 MHz, CDCl3): δ 1.91 (s, 3H, NHC(O)CH3); 2.03, 
2.10, 2.16, 2.17 (4s, 12H, C(O)CH3); 3.83 (s, 3H, OCH3); 4.08 - 4.25 (m, 3H, H-5, 
H-6, 9); 4.55 (dd, 1H, J8,9’ = 2.5, J9,9’ = 12.4 Hz, H-9’); 4.92 (br dd, 1H, J3,4 = 2.5, 
J3,F3 = 49.0 Hz, H-3); 4.91 – 5.14 (m, 1H, H-8); 5.32 – 5.34 (m, 1H, H-7); 5.54 (ddd, 
1H, J4,F3 = 28.1, J4,5 = 11.0 Hz, H-4). HRMS (ESI +ve) m/z 574.1509 [M+Na]+ 
(C22H30NFO14Na requires 574.1548). Spectroscopic data were analogous to those 
reported in the literature.224 
Methyl 5-N-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-3-fluoro-D-erythro-α-L­
manno-non-2-ulopyranosonate (54) 
A solution of hydrazine acetate (0.936 g, 10.4 mmol) in methanol (10 mL) was added 
to a solution of the per-acetylated 3-fluorosialic acid (53) (1.91 g, 3.46 mmol) in 
dichloromethane (40 mL) at 4 ºC and the solution left to stand at this temperature 
(4h). The solution was then subjected to a standard work up (DCM) and the residue 
purified by flash chromatography (EtOAc:Hexane 9:1 → EtOAc) to yield the 
hemiketal (54) as a white solid (1.43 g, 81%). 1H NMR (270 MHz, CDCl3): δ 1.90 
(s, 3H, NHC(O)CH3); 2.02, 2.07, 2.09, 2.15 (4s, 12H, C(O)CH3); 3.84 (s, 3H, 
OCH3); 4.08 (br dd, 1H, J8,9 = 8.3, J9,9’ = 12.4 Hz, H-9); 4.28 – 4.40 (m, 2H, H-5, H­
6); 4.82 (t, 1H, J8,9’ = 2.5 Hz, H-9’); 4.94 (br dd, 1H, J3,4 = 2.5, J3,F3 = 34.4 Hz, H-3); 
5.23 – 5.39 (m, 2H, H-7, H-8); 5.41 (br dd, 1H, J4,F3 = 28.0 Hz, H-4); 5.52 (br s, 1H, 
OH); 5.97 (d, 1H, J5,NHAc = 9.1 Hz, NH). HRMS (ESI +ve) m/z 510.1612 [M+H]+ 
(C20H29NFO13 requires 510.1623); 532.1435 [M+Na]+ (C20H28NFO13Na requires 
532.1442). Spectroscopic data were analogous to those reported in the literature.225 
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Methyl 5-N-acetamido-4,7,8,9-tetra-O-acetyl-2,3,5-trideoxy-2,3-difluoro-D-erythro­
β-L-manno-non-2-ulopyranosonate (58) 
(Diethylamino)sulphur trifluoride (0.19 mL, 1.47 mmol) was added drop-wise to a 
stirred solution of the hemiketal (54) (500 mg, 0.98 mmol) in dichloromethane 
(20 mL) at -30 ºC and the mixture held at this temperature (30 min). The reaction 
was quenched by the addition of methanol (0.5 mL) then subjected to a standard 
work up (DCM) and the residue purified by flash chromatography (EtOAc:Pet Ether 
7:3 with 3 drops of TFA) to give the per-O-acetylated-2,3-difluorosialic acid (58) as 
a white solid (248 mg, 44%) plus the per-O-acetylated-2,3-difluorosialic acid (59) as 
a colourless oil (175 mg, 35%). Data for (58): 1H NMR (400 MHz, CDCl3): δ 1.91 
(s, 3H, NHC(O)CH3); 2.02, 2.09, 2.09, 2.14 (4s, 12H, C(O)CH3); 3.88 (s, 3H, 
OCH3); 4.06 - 4.18 (m, 2H, H-5, H-9); 4.29 - 4.34 (m, 2H, H-6, H-9’); 5.10 (br dt, 
1H, J3,4 = 2.7, J3,F2 = 5.1, J3,F3 = 53.2 Hz, H-3); 5.28 (br d, 1H, J7,8 = 8.2 Hz, H-7); 
5.35 (ddd, 1H, J8,9 = 2.7, J8,9’ = 5.5 Hz, H-8); 5.43 (br dd, 1H, J4,5 = 10.6, J4,F3 = 25.0 
Hz, H-4); 5.61 (br d, 1H, J5,NHAc = 9.0 Hz, NH); 19F NMR (376 MHz, CDCl3): δ ­
123.31 (br d, 1F, JF2,F3 = 12.0 Hz, F-2); -216.66 (ddd, 1F, JF3,4 = 26.3, 
JF3,3 = 51.3 Hz, F-3). HRMS (ESI +ve) m/z 512.1559 [M+H]+ (C20H28NF2O12 
requires 512.1580); 534.1375 [M+Na]+ (C20H27NF2O12Na requires 534.1375). 
Spectroscopic data were analogous to those reported in the literature.137 
Methyl 5-N-acetamido-4,7,8,9-tetra-O-acetyl-2,3,5-trideoxy-2,3-difluoro-D-erythro­
α-L-manno-non-2-ulopyranosonate (59) 
Deoxofluor® (0.2 mL, 0.5 mmol) was added drop-wise to a stirred solution of the 
hemiketal (54) (50.0 mg, 0.1 mmol) in dichloromethane (3 mL) at -30 ºC and the 
mixture held at this temperature (30 min). The reaction was quenched by the addition 
of methanol (0.5 mL) then subjected to a standard work up (DCM) and the residue 
purified by flash chromatography (EtOAc:Hexane 9:1 → EtOAc) to give the per-O­
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acetylated-2,3-difluorosialic acid (59) as a colourless oil (17.2 mg, 30%). 1H NMR 
(400 MHz, CDCl3): δ 1.90 (s, 3H, NHC(O)CH3); 2.04, 2.06, 2.10, 2.14 (4s, 12H, 
C(O)CH3); 3.87 (s, 3H, OCH3); 4.11 (dd, 1H, J8,9 = 6.3, J9,9’ = 12.5 Hz, H-9); 4.31 
(br d, 1H, J5,6 = 11.3 Hz, H-5); 4.44 (q, 1H, H-6); 4.50 (br dd, 1H, J8,9’ = 2,7 Hz, 
H-9’); 5.11 (br dd, 1H, J3,4 = 2.0, J3,F3 = 50.5 Hz, H-3); 5.26 (br dt, 1H, H-8); 
5.32 - 5.42 (m, 1H, H-4); 5.40 (br dd, 1H, J6,7 = 2.0, J7,8 = 6.5 Hz, H-7); 5.47 (d, 1H, 
J5,NHAc = 9.8 Hz, NH). 19F NMR (376 MHz, CDCl3): δ -122.19 (d, 1F, JF2,F3 = 17.1 
Hz, F-2); -206.67 (ddd, 1F, JF3,4 = 27.6, JF3,3 = 47.4 Hz, F-3). HRMS (ESI +ve) m/z 
512.1559 [M+H]+ (C20H28NF2O12 requires 512.1580); 534.1375 [M+Na]+ 
(C20H27NF2O12Na requires 534.1375). 
Methyl (4-fluorobutyl-5-N-acetamido-4,7,8,9-treta-O-acetyl-3,5-dideoxy-3-fluoro-D­
erythro-β-L-manno-non-2-ulopyranosid)onate (64) 
(Diethylamino)sulphur trifluoride (20.0 µL, 0.15 mmol) was added drop-wise to a 
stirred solution of the hemiketal (54) (50 mg, 0.10 mmol) in tetrahydrofuran (2 mL) 
at -30 ºC and the mixture was held at this temperature (1h). The reaction was 
quenched by the addition of methanol (0.5 mL) and solvent removed in vacuo. The 
residue was then subjected to a standard work up (EtOAc) and purified by flash 
chromatography (EtOAc:Hexane 9:1 → EtOAc) to afford the title sialoside (64) as a 
colourless oil (15.0 mg, 26%). 1H NMR (400 MHz, CDCl3): δ 1.60 – 1.68 (m, 2H, H­
3’, 3’’); 1.89 (s, 3H, NHC(O)CH3); 2.03, 2.08, 2.14, 2.15 (4s, 12H, C(O)CH3); 
3.30 - 3.44 (m, 4H, H-1’, 1’’, 2’, 2’’); 3.82 (s, 3H, OCH3); 4.13 - 4.15 (m, 1H, H-9); 
4.20 (br d, 1H, J6,7 = 10.6 Hz, H-6); 4.28 (br dd, 1H, J8,9’ = 2.3, J9,9’ = 12.5 Hz, H-9’); 
4.39 (br t, 1H, J4’,4’’ = 5.5, J4’,F4’ = 11.7 Hz, H-4’); 4.51 (br t, 1H, J4’’,F4’ = 12.1 Hz, 
H-4’’); 4.99 (br d, 1H, J3,F3 = 51.3 Hz, H-3); 5.08 – 5.17 (m, 1H, H-4); 5.26 – 5.31 
(m, 2H, H-5, H-7); 5.43 (ddd, 1H, J8,9 = 5.1, J7,8 = 8.2 Hz, H-8). 13C NMR (100 
MHz, CDCl3): δ 20.67, 20.74, 20.83, 21.08 (C(O)CH3); 23.31 (NHC(O)CH3); 45.30 
(d, J5,F3 = 3.8 Hz, C-5); 53.00 (OCH3); 62.20 (C-9); 65.44 (d, J3’,F4’ = 3.8 Hz, C-3’); 
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67.21 (C-7); 68.00 (C-8); 69.46 (d, J4,F3 = 17.6 Hz, C-4); 70.20 (d, J2’,F4’ = 23.8 Hz, 
C-2’); 70.58 (d, J1’,F4’ = 7.7 Hz, C-1’); 71.21 (C-6); 83.88 (dd, J4’,F3 = 25.3, 
J4’,F4’ = 164.1 Hz, C-4’); 87.47 (d, J3,F3 = 194.0 Hz, C-3); 97.95 (dd, J2,F4’ = 8.4, J2,F3 
= 16.9 Hz, C-2); 166.07 (d, J1,F3 = 3.1 Hz, C-1); 169.92 (NHC(O)CH3); 170.17, 
170.57, 170.61 (C(O)CH3). 19F NMR (376 MHz, CDCl3): δ -215.85 (dt, 1F, 
JF3,4 = 28.9, JF3,3 = 52.6 Hz, F-3); -218.58 to -217.92 (m, 1F, F-4’). HRMS (ESI +ve) 
m/z 584.2196 [M+H]+ (C24H36NF2O13 requires 584.2155); 606.2022 [M+Na]+ 
(C24H35NF2O13Na requires 606.1974). 
Methyl 5-N-acetamido-2,3,5-trideoxy-2,3-difluoro-D-erythro-β-L-manno-non-2­
ulopyranosonate (47) 
A solution of sodium methoxide in methanol (10.0 µL, 0.5M) was added to a 
solution of the per-O-acetylated-2,3-difluorosialic acid (58) (355 mg, 0.69 mmol) in 
methanol (10 mL) at 4 ºC and the solution left to stand overnight at room 
temperature. The solution was then neutralized (Dowex 50WX8, H+ form), filtered, 
then the filtrate concentrated in vacuo to afford the 2,3-difluorosialic acid (47) as a 
off-white solid (236 mg, quantitative). 1H NMR (400 MHz, CDCl3): δ 1.84 (s, 3H, 
NHC(O)CH3); 3.21 (s, 3H, OCH3); 3.32 (br d, 1H, J7,8 = 9.0 Hz, H-7); 3.46 – 3.52 
(m, 2H, H-4, H-9); 3.62 – 3.68 (m, 3H, H-6, H-8, H-9’); 4.03 (br t, 1H, J4,5 = 10.6 
Hz, H-5); 4.91 (d, 1H, J3,F3 = 50.5 Hz, H-3); 7.69 (d, 1H, J5,NHAc = 8.2 Hz, NH). 13C 
NMR (100 MHz, CDCl3): δ 21.97 (NHC(O)CH3); 47.06 (d, J5,F3 = 3.1 Hz, C-5); 
49.31 (OCH3); 53.12 (C-6); 63.49 (C-9); 68.10 (C-7); 69.61 (C-8); 73.51 (d, J4,F3 = 
3.0 Hz, C-4); 87.39 (dd, J3,F2 = 17.6, J3,F3 = 188.6 Hz, C-3); 104.97 (dd, J2,F3 = 17.6, 
J2,F2 = 221.6 Hz, C-2); 165.16 (dd, J1,F3 = 4.6, J1,F2 = 34.5 Hz, C-1); 173.90 
(NHC(O)CH3). 19F NMR (376 MHz, CDCl3): δ -122.80 (d, 1F, JF2,F3 = 11.5 Hz, F-2); 
-219.76 (ddd, 1F, JF3,4 = 27.4, JF3,3 = 50.4 Hz, F-3). HRMS (ESI +ve) m/z 344.1151 
[M+H]+ (C12H20F2N1O8 requires 344.1157); 366.1809 [M+Na]+ (C12H19NF2O8 
requires 366.0976). 
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5-N-Acetamido-2,3,5-trideoxy-2,3-difluoro-D-erythro-β-L-manno-non-2­
ulopyranosonic acid (19) 
A 0.5 M aqueous solution of sodium hydroxide (4 drops) was added to a solution of 
2,3-difluorosialic acid (47) (173 mg, 0.50 mmol) in water (3 mL) at 4 ºC and the 
solution left to warm to room temperature (1h). The solution was then neutralized 
(Dowex 50WX8, H+ form), filtered, then the filtrate concentrated in vacuo to afford 
2,3-difluorosialic acid (19) as a white solid (187 mg, quantitative). m.p. 21 - 25 ºC. 
[α]D -17 (c 0.005 H2O). 1H NMR (400 MHz, D2O): δ 1.85 (s, 3H, NHC(O)CH3); 3.37 
(br d, 1H, J7,8 = 9.0 Hz, H-7); 3.44 (br dd, 1H, J8,9 = 6.7, J9,9’ = 12.5 Hz, H-9); 3.60 
(br d, 1H, J5,6 = 10.6 Hz, H-6); 3.65 – 3.71 (m, 2H, H-8, H-9’); 3.97 (br dd, 1H, 
J4,5 = 10.9, J4,F3 = 26.0 Hz, H-4); 4.09 (t, 1H, J4,5 = 10.8 Hz, H-5); 5.02 (br dt, 1H, 
J3,4 = 2.7, J3,F3 = 51.6 Hz, H-3). 13C NMR (100 MHz, CDCl3): δ 21.14 
(NHC(O)CH3); 46.96 (d, J5,F3 = 3.1 Hz, C-5); 63.03 (C-9); 67.96 (C-7); 69.31 (br dd, 
J4,F2 = 6.1, J4,F3 = 17.6 Hz, C-4); 70.62 (C-8); 72.73 (d, J6,F2 = 4.6 Hz, C-6); 89.06 
(dd, J3,F2 = 18.4, J3,F3 = 184.0 Hz, C-3); 106.77 (dd, J2,F3 = 14.6, J2,F2 = 229.3 Hz, 
C-2); 169.72 (d, J1,F2 = 23.0 Hz, C-1); 175.15 (NHC(O)CH3). 19F NMR (376 MHz, 
CDCl3): δ -121.38 (d, 1F, JF2,F3 = 11.5 Hz, F-2); -218.03 (ddd, 1F, JF3,4 = 27.4, 
JF3,3 = 50.4 Hz, F-3). [α ]20 = -17.4 (c 0.09, H2O). HRMS (ESI -ve) m/z 328.1123 D 
[M-H]- (C11H16NF2O8 requires 328.0844). Spectroscopic data were analogous to 
those reported in the literature.137 
Methyl (methyl 5-N-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-3-fluoro-D­
erythro-α-L-manno-non-2-ulopyranosid)onate (69) 
Sodium hydride (25.0 mg, 1.03 mmol) was added to a solution of the hemiketal (54) 
(500.0 mg, 0.98 mmol) in dimethylformamide (10.0 mL) and the resulting solution 
was stirred for 15 min, after which methyliodide (91.0 µL, 1.47 mmol) was added 
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and the solution stirred for 2h at room temperature. The solution was concentrated in 
vacuo and subjected to a standard work up (EtOAc). The resultant residue was then 
loaded to a flash column (EtOAc:Pet Ether 9:1) affording the per-O-acetylated-3­
fluorosialic acid methyl sialoside (69) as an off white solid (353 mg, 68%). 1H NMR 
(400 MHz, CDCl3): δ 1.88 (s, 3H, NHC(O)CH3); 2.02, 2.07, 2.08, 2.15 (4s, 12H, 
C(O)CH3); 3.29 (s, 3H, OCH3); 3.85 (s, 3H, CO2CH3); 4.03 (dd, 1H, J6,7 = 1.4, 
J5,6 = 10.3 Hz, H-6); 4.15 (dd, 1H, J8,9 = 7.5, J9,9’ = 12.2 Hz, H-9); 4.35 (q, 1H, H-5); 
4.84 – 5.01 (m, 2H, H-3, H-9’); 5.25 – 5.41 (m, 3H, H-4, H-7, H-8). 13C NMR (100 
MHz, CDCl3): δ 15.26, 20.67, 20.78, 21.00 (C(O)CH3); 23.21 (NHC(O)CH3); 45.25 
(C-5); 51.56 (OCH3); 53.07 (CO2CH3); 62.33 (C-9); 68.16 (C-7); 69.15 (d, J4,F3 = 
16.9 Hz, C-4); 71.34 (C-6); 71.77 (C-8); 87.32 (d, J3,F3 = 183.3 Hz, C-3); 98.73 (d, 
J2,F3 = 27.6 Hz, C-2); 165.23 (C-1); 170.03 (NHC(O)CH3); 170.39, 170.60, 170.68, 
170.77 (C(O)CH3). 19F NMR (376 MHz, CDCl3): δ -205.99 (dd, 1F, JF3,4 = 29.0, JF3,3 
= 48.8 Hz, F-3). HRMS (ESI +ve) m/z 524.1755 [M+H]+ (C21H31NFO13 requires 
524.1779); 546.1578 [M+Na]+ (C21H30NFO13Na requires 546.1599). 
Methyl (methyl 5-N-acetamido-3,5-dideoxy-3-fluoro-D-erythro-α-L-manno-non-2­
ulopyranosid)onate (70) 
A solution of sodium methoxide in methanol (10.0 µL, 0.5M) was added to a 
solution of per-O-acetylated-3-fluorosialic acid methyl sialoside (69) (46.0 mg, 0.09 
mmol) in methanol (1 mL) at 4 ºC and the solution stirred overnight at room 
temperature. The solution was then neutralized (Dowex 50WX8, H+ form), filtered 
and the filtrate concentrated in vacuo to afford the 3-fluorosialic acid methyl 
sialoside (70) as a off-white solid (31.0 mg, quantitative). 1H NMR (400 MHz, D2O): 
δ 1.96 (s, 3H, NHC(O)CH3); 3.23 (s, 3H, OCH3); 3.52 (d, 1H, J7,8 = 9.8 Hz, H-7); 
3.60 (dd, 1H, J8,9 = 5.7, J9,9’ = 12.1 Hz, H-9); 3.75 – 3.82 (m, 2H, H-8, 9’); 3.83 (s, 
3H, CO2CH3); 3.87 (d, 1H, J5,6 = 10.6 Hz, H-6); 4.03 (br ddd, 1H, J3,4 = 2.7, J4,5 = 
11.0, J4,F3 = 30.5 Hz, H-4); 4.17 (t, 1H, H-5); 4.89 (br dd, 1H, J3,F3 = 48.9 Hz, H-3). 
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13C NMR (100 MHz, D2O): δ 22.04 (NHC(O)CH3); 47.03 (C-5); 51.19 (OCH3); 
53.84 (CO2CH3); 63.30 (C-9); 67.67 (d, J4,F3 = 17.6 Hz, C-4); 67.81 (C-7); 69.84 (C­
8); 70.51 (C-6); 89.48 (d, J3,F3 = 177.1 Hz, C-3); 98.78 (d, J2,F3 = 26.8 Hz, C-2); 
168.37 (C-1); 174.88 (NHC(O)CH3). 19F NMR (376 MHz, D2O): δ -208.86 (dd, 1F, 
JF3,4 = 30.5, JF3,3 = 48.8 Hz, F-3). HRMS (ESI +ve) m/z 356.1320 [M+H]+ 
(C27H35NFO13 requires 356.1357). 
Methyl (methyl-5-N-acetamido-3,5,7-trideoxy-7-N-ethylamine-3-fluoro-α-L-manno­
hept-2-ulopyranosid)onate (72) 
i) A 0.4 M aqueous solution of sodium periodate (0.5 mL) was added to a solution of 
3-fluorosialic acid methyl sialoside (70) (31 mg, 0.09 mmol) in water (0.5 mL) at 
room temperature and the resulting solution was stirred for 30 min. The mixture was 
then evaporated in vacuo and the aldehyde (71) formed was used without further 
purification. 
ii) A solution of aqueous ethylamine 70% (0.11 mL, 2.0 mmol) in methanol (0.5 mL) 
was acidified to pH 5 with glacial acetic acid, and this solution then added to a 
solution of the crude mixture (above) in methanol (0.5 mL). The mixture was left to 
equilibrate for 1h at room temperature and then sodium cyanoborohydride (57 mg, 
0.9 mmol) dissolved in methanol (0.5 mL) was added to the reaction. The mixture 
was stirred overnight. The reaction mixture was then adsorbed in silica, concentrated 
in vacuo and the residue purified by flash chromatography (EtOAc → 
EtOAc/:MeOH 9:1) to give the 3-fluorosialic acid methyl sialoside (72) as a 
olourless oil (3 mg, 10% over two steps). 1H NMR (270 MHz, CD3OD): δ 1.29 (t, 
3H, J = 7.4 Hz, NHCH2CH3); 1.97 (s, 3H, NHC(O)CH3); 3.25 – 3.66 (m, 7H, H-4, 
H-5, H-6, H-7, H-7’, NHCH2CH3); 3.59 (s, 3H, OCH3); 3.86 (s, 3H, CO2CH3); 4.87 
(br dd, 1H, J3,4 = 2.2, J3,F3 = 49.0 Hz, H-3). HRMS (ESI +ve) m/z 323.1618 [M+H]+ 
(C13H24N2FO6 requires 323.1618). 
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Methyl (benzyl-5-N-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-3-fluoro-D­
erythro-α-L-manno-non-2-ulopyranosid)onate (74) 
Sodium hydride (113 mg, 4.71 mmol) was added to a solution of the of the hemiketal 
(54) (2.00 g, 3.93 mmol) in dimethylformamide (10.0 mL) and the resulting solution 
was stirred for 15 min, after which benzyl bromide (0.56 mL, 4.71 mmol) was added 
and the solution stirred for 2h at room temperature. The reaction was then quenched 
with methanol (5 mL), concentrated in vacuo and subjected to a standard work up 
(EtOAc). The resultant residue was then purified by flash chromatography 
(EtOAc:Pet ether 9:1 → EtOAc) affording the benzyl sialoside (74) as an off-white 
solid (2.08 g, 95%). 1H NMR (400 MHz, CDCl3): δ 1.88 (s, 3H, NH(O)CH3); 1.96, 
2.04, 2.08, 2.16 (4s, 12 H, C(O)CH3); 3.73 (s, 3H, OCH3); 4.10 (br dd, 1H, J6,7 = 1.6, 
J5,6 = 10.9 Hz, H-6); 4.15 (dd, 1H, J8,9 = 7.8, J9,9’ = 10.9 Hz, H-9); 4.37 (q, 1H, 
J5,NHAc = 10.6 Hz, H-5); 4.46 (d, 1H, J = 11.7 Hz, OCH2Ph); 4.65 (d, 1H, OCH2Ph); 
4.91 (dd, 1H, J8,9’ = 2.7 Hz, H-9’); 5.05 (dd, 1H, J3,4 = 2.3, J3,F3 = 49.3 Hz, H-3); 5.22 
(d, 1H, NH); 5.31 – 5.46 (m, 3H, H-4, H-7, H-8); 7.26 – 7.39 (m, 5H, Ph). 13C NMR 
(100 MHz, CDCl3): δ 20.68, 20.79, 20.81, 20.87 (C(O)CH3); 23.21 (NHC(O)CH3); 
45.34 (d, J5,F3 = 2.3 Hz, C-5); 52.98 (OCH3); 62.36 (C-9); 66.17 (OCH2Ph); 68.19 
(C-7); 69.21 (d, J4,F3 = 17.6 Hz, C-4); 71.53 (C-6); 71.60 (C-8); 87.40 (d, 
J3,F3 = 184.0 Hz, C-3); 98.22 (d, J2,F3 = 26.8 Hz, C-2); 127.67 (C Ph); 128.28 (C Ph); 
128.59 (C Ph); 135.63 (Cq Ph); 165.27 (C-1); 170.00 (NHC(O)CH3); 170.38, 170.59, 
170.66, 170.73 (C(O)CH3). 19F NMR (376 MHz, CDCl3): δ -205.84 (dd, 1F, 
JF3,4 = 29.0, JF3,3 = 48.8 Hz, F-3). HRMS (ESI +ve) m/z 600.2061 [M+H]+ 
(C27H35NFO13 requires 600.2092); 622.1869 [M+Na]+ (C27H34NFO13Na requires 
622.1912). 
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Methyl (benzyl-5-N-acetamido-3,5-dideoxy-3-fluoro-D-erythro-α-L-manno-non-2­
ulopyranosid)onate (75) 
Sodium methoxide (180 µL) was added to a solution of the per-O-acetylated-3­
fluorosialic acid benzyl sialoside (74) (787 mg, 1.31 mmol) in methanol (18 mL) at 4 
°C and the mixture left to warm to room temperature (1h). The mixture was then 
neutralized (Dowex 50 WX8 H+ form), filtered and concentrated in vacuo. The 
resultant oil was then dissolved in warm methanol to give 3-fluorosialic acid benzyl 
sialoside (75) as white crystals (533 mg, 95%). 1H NMR (400 MHz, D2O): δ 1.96 (s, 
3H, NHC(O)CH3); 3.58 (d, 1H, J7,8 = 9.8 Hz, H-7); 3.62 (dd, 1H, J8,9 = 5.5, 
J9,9’ = 12.1 Hz, H-9); 3.74 (s, 3H, OCH3); 3.77 – 3.81 (m, 1H, H-9’); 3.89 – 3.92 (m, 
1H, H-8); 4.00 – 4.11 (m, 2H, H-4, H-6); 4.19 (t, 1H, J4,5 = 10.6 Hz, H-5); 4.30 (dd, 
1H, J = 11.0 Hz, OCH2Ph); 4.71 (d, 1H, OCH2Ph); 4.91 (dd, 1H, J3,4 = 2.3, 
J3,F3 = 50.5 Hz, H-3); 7.32 – 7.36 (m, 5H, CH Ph). 13C NMR (100 MHz, CDCl3): δ 
22.06 (NHC(O)CH3); 47.11 (d, J5,F3 = 1.5 Hz, C-5); 53.77 (OCH3); 63.32 (C-9); 
65.99 (OCH2Ph); 67.49 (C-7); 67.68 (d, J4,F3 = 2.3 Hz, C-4); 69.88 (C-8); 70.75 
(C-6); 89.60 (d, J3,F3 = 177.9 Hz, C-3); 98.10 (d, J2,F3 = 27.6 Hz, C-2); 128.80 (m-, o­
, p-C Ph); 135.42 (Cq Ph); 168.41 (C-1); 174.93 (NHC(O)CH3). 19F NMR (376 MHz, 
CDCl3): δ -209.06 (dd, 1F, JF3,4 = 30.5, JF3,3 = 48.8 Hz, F-3). HRMS (ESI +ve) m/z 
432.1644 [M+H]+ (C19H27NFO9 requires 432.1670); 454.1458 [M+Na]+ 
(C19H26NFO9Na requires 454.1489). 
Methyl (benzyl-5-N-acetamido-4-O-acetyl-3,5,7-trideoxy-7-N-ethylacetamido-3­
fluoro-α-L-manno-hept-2-ulopyranosid)onate (77) 
159 
Chapter 11 
i) A 0.4 M aqueous solution of sodium periodate (6.50 mL) was added to a solution 
of 3-fluorosialic acid benzyl sialoside (75) (533 mg, 1.24 mmol) in water (6.5 mL) at 
room temperature and the resulting solution was stirred for 30 min. The mixture was 
then evaporated in vacuo and the aldehyde (76) formed was used without further 
purification. 
ii) A solution of aqueous ethylamine 70% (1.50 mL, 26.5 mmol) in methanol (4 mL) 
was acidified to pH 5 with glacial acetic acid, and this solution then added to a 
solution of the crude mixture (above) in methanol (4 mL). The mixture was left to 
equilibrate for 1h at room temperature and then sodium cyanoborohydride (777 mg, 
12.36 mmol) dissolved in methanol (4 mL) was added to the reaction. The mixture 
was stirred overnight. The reaction mixture was then adsorbed in silica, concentrated 
in vacuo and the residue purified by flash chromatography (EtOAc → 
EtOAc/:MeOH 9:1). 
iii) Acetic anhydride (1.27 mL, 13.4 mmol) was added to the purified residue in 
pyridine (11 mL) at room temperature and the solution was left stirring overnight at 
room temperature. The solution was then concentrated in vacuo, and residual 
pyridine removed by azeotropic evaporation with toluene to give a yellow oil. The 
oil was subjected to a standard work up (EtOAc) and purified by flash 
chromatography (EtOAc:Hexane 9:1 → EtOAc) to give the acetylated-3-fluorosialic 
acid benzyl sialoside (77) as a white solid (215 mg, 36% over three steps). 1H NMR 
(400 MHz, CDCl3): δ 1.24 (t, 3H, J = 7.4 Hz, CH3(O)CNCH2CH3); 1.95 (s, 3H, 
NHC(O)CH3); 2.07 (s, 3H, CH3(O)CNCH2CH3); 2.09 (s, 3H, C(O)CH3); 3.14 (dd, 
1H, J = 7.4, J = 14.1 Hz, CH3(O)CNCH2CH3); 3.44 – 3.67 (m, 2H, H-7, H-7’); 3.74 
(s, 3H, OCH3); 3.95 (d, 1H, J = 14.1 Hz, CH3(O)CNCH2CH3); 4.07 – 4.13 (m, 1H, 
H-6); 4.18 – 4.23 (m, 1H, H-5); 4.25 (d, 1H, J = 11.0 Hz, OCH2Ph); 4.42 (d, 1H, 
OCH2Ph); 4.98 (br dd, 1H, J3,4 = 2.3, J3,F3 = 49.5 Hz, H-3); 5.33 (ddd, 1H, J4,5 = 
10.6, J4,F3 = 29.0 Hz, H-4); 6.06 (d, 1H, J5,NHAc = 9.0 Hz, NH); 7.28 – 7.36 (m, 5H, 
CH Ph). 13C NMR (100 MHz, CDCl3): δ 13.92 (CH3(O)CNCH2CH3); 20.74 
(C(O)CH3); 21.23 (CH3(O)CNCH2CH3); 23.31 (NHC(O)CH3); 45.79 (C-7); 47.60 
(CH3(O)CNCH2CH3); 47.69 (C-5); 52.86 (OCH3); 65.96 (OCH2Ph); 69.30 (d, 
J4,F3 = 17.3 Hz, C-4); 72.21 (C-6); 87.60 (d, J3,F3 = 181.7 Hz, C-3); 97.83 (d, 
J2,F3 = 27.6 Hz, C-2); 128.28 (C Ph); 128.42 (C Ph); 128.58 (C Ph); 135.38 (Cq Ph); 
165.87 (C-1); 170.74 (NHC(O)CH3); 170.77 (CH3(O)CNCH2CH3); 170.84 
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(C(O)CH3). 19F NMR (376 MHz, CDCl3): δ -205.98 (dd, 1F, JF3,4 = 29.0, JF3,3 = 48.8 
Hz, F-3). HRMS (ESI +ve) m/z 483.2134 [M+H]+ (C23H32N2FO8 requires 483.2143); 
505.1954 [M+Na]+ (C23H31N2FO8Na requires 505.1962). 
Methyl 5-N-acetamido-4-O-acetyl-3,5,7-trideoxy-7-N-ethylacetamido-3-fluoro-α-L­
manno-hepta-2-pyranosonate (79) 
Glacial acetic acid was added to a solution of acetylated-3-fluorosialic acid benzyl 
sialoside (77) (100 mg, 0.21 mmol) in tetrahydrofuran (10 mL) until pH 4 and then 
palladium on charcoal (30.0 mg, 10 wt. %) was added to the reaction and the reaction 
was put under a hydrogen gas atmosphere (10 days). The mixture was filtered 
through Celite®, washed with methanol and the filtrate concentrated in vacuo. The 
residue was purified by flash chromatography (EtOAc → EtOAc:MeOH 9:1) to 
afford the hemiketal (79) as a white solid (39.4 mg, 48%). 1H NMR (400 MHz, 
CDCl3): δ 1.18 (t, 3H, J = 7.4 Hz, CH3(O)CNCH2CH3); 1.99 (s, 3H, NHC(O)CH3); 
2.06 (s, 3H, CH3(O)CNCH2CH3); 2.10 (s, 3H, C(O)CH3); 3.08 (dd, 1H, J = 7.4, J = 
14.1 Hz, CH3(O)CNCH2CH3); 3.35 – 3.65 (m, 3H, H-5, H-7, H-7’); 3.83 (s, 3H, 
OCH3); 3.90 (d, 1H, J = 14.1 Hz, CH3(O)CNCH2CH3); 4.22 – 4.28 (m, 1H, H-6); 
4.94 (br dd, 1H, J3,4 = 2.3, J3,F3 = 50.1 Hz, H-3); 5.35 – 5.44 (m, 1H, H-4); 6.50 (d, 
1H, J5,NHAc = 8.6 Hz, NH). 13C NMR (100 MHz, CDCl3): δ 13.64 
(CH3(O)CNCH2CH3); 20.79 (NHC(O)CH3); 21.04 (CH3(O)CNCH2CH3); 23.18 
(C(O)CH3); 46.18 (C-7); 47.61 (C-5); 48.25 (CH3(O)CNCH2CH3); 53.10 (OCH3); 
69.53 (d, J4,F3 = 17.6 Hz, C-4); 71.24 (C-6); 87.32 (d, J3,F3 = 184.8 Hz, C-3); 94.21 
(d, J2,F3 = 25.3 Hz, C-2); 167.62 (C-1); 171.07 (NHC(O)CH3); 171.12 
(CH3(O)CNCH2CH3); 171.29 (C(O)CH3). 19F NMR (376 MHz, CDCl3): δ -205.09 
(dd, 1F, JF3,4 = 29.0, JF3,3 = 50.3 Hz, F-3). HRMS (ESI +ve) m/z 393.1674 [M+H]+ 
(C16H26N2FO8 requires 393.1673); 415.1484 [M+Na]+ (C16H25N2FO8Na requires 
415.1493). 
161 
Chapter 11

Methyl 5-N-acetamido-4-O-acetyl-2,3,5,7-tetradeoxy-7-N-ethylacetamido-2,3­
difluoro-β-L-manno-hept-2-pyranosonate (80) 
(Diethylamino)sulphur trifluoride (20.0 µL, 0.15 mmol) was added drop-wise to a 
stirred solution of the hemiketal (79) (39.4 mg, 0.10 mmol) in dichloromethane (2 
mL) at -30 ºC and the mixture held at this temperature (30 min). The reaction was 
quenched by the addition of methanol (40.0 µL) and then subjected to a standard 
work up (DCM) and the residue purified by flash chromatography (EtOAc:Hexane 
9:1 → EtOAc) to give the 2,3-difluorosialic acid benzyl sialoside (80) as a white 
solid (19.00 mg, 50%).1H NMR (400 MHz, CDCl3): δ 1.18 (t, 3H, J = 7.0 Hz, 
CH3(O)CNCH2CH3); 1.96 (s, 3H, NHC(O)CH3); 2.11 (s, 3H, CH3(O)CNCH2CH3); 
2.11 (s, 3H, C(O)CH3); 3.30 (dd, 1H, J6,7 = 6.3, J7,7’ = 14.5 Hz, H-7); 3.48 (q, 2H, 
J = 5.4 Hz, CH3OCNCH2CH3); 3.81 (d, 1H, J7,7’ = 14.5 Hz, H-7’); 3.88 (s, 3H, 
OCH3); 4.04 – 4.08 (m, 2H, H-5, H-6); 5.13 (ddt, 1H, J3,4 = 2.3, J3,F2 = 3.9, J3,F3 = 
50.5 Hz, H-3); 5.43 (dd, 1H, J4,F2 = 6.7, J4,F3 = 26.2 Hz, H-4); 6.33 (d, 1H, J5,NHAc = 
7.4 Hz, NH). 13C NMR (100 MHz, CDCl3): δ 14.18 (CH3(O)CNCH2CH3); 20.68 
(NHC(O)CH3); 21.24 (CH3(O)CNCH2CH3); 23.36 (C(O)CH3); 45.82 (C-7); 47.44 
(d, J5,F3 = 3.1 Hz, C-5); 47.50 (CH3(O)CNCH2CH3); 53.63 (OCH3); 68.71 (dd, J4,F2 = 
6.1, J4,F3 = 16.9 Hz, C-4); 74.16 (d, J6,F2 = 3.1 Hz, C-6); 85.52 (dd, J3,F2 = 19.9, J3,F3 
= 192.5 Hz, C-3); 104.73 (dd, J2,F3 = 17.6, J2,F2 = 223.1 Hz, C-2); 164.58 (dd, J1,F3 = 
3.8, J1,F2 = 30.7 Hz, C-1); 170.33(NHC(O)CH3); 171.00 (CH3(O)CNCH2CH3); 
171.54 (C(O)CH3). 19F NMR (376 MHz, CDCl3): δ -122.37 (d, 1F, JF2,F3 = 12.2 Hz, 
F2); -217.11 (ddd, 1F, JF3,4 = 25.9, JF3,3 = 50.4 Hz, F-3). HRMS (ESI +ve) m/z 
395.1620 [M+H]+ (C16H24N2F2O7 requires 395.1630); 417.1437 [M+Na]+ 
(C16H23N2F2O7Na requires 417.1449). 
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Methyl (benzyl-5-N-acetamido-4-O-acetyl-3,5,7-trideoxy-7-N,N-diethylamine-3­
fluoro-α-L-manno-hept-2-pyranosid)onate (78) 
i) A 0.4 M aqueous solution of sodium periodate (4.9 mL) was added to a solution of 
3-fluorosialic acid benzyl sialoside (75) (500 mg, 1.16 mmol) in water (4.9 mL) at 
room temperature and the solution was stirred for 30 min. The solution was 
concentrated in vacuo and the crude residue was used without further purification. 
ii) A solution of diethylamine (1.81 mL, 17.4 mmol) in methanol (5 mL) was 
acidified to pH 5 with glacial acetic acid, and this solution was then added to a 
solution of the crude mixture (above) in methanol (5 mL). The solution was stirred 
for 4h at room temperature, then sodium cyanoborohydride (364 mg, 5.79 mmol) 
was added and the mixture was left stirring overnight. Water (5 mL) and methanol 
(5 mL) were added, the volume of solution reduced to 5 mL and applied to a reverse 
phase column (Water → Water:MeOH 1:1). 
iii) Acetic anhydride (0.53 mL, 5.63 mmol) was added to a solution of the residue 
(200 mg, 0.47 mmol) in pyridine (4 mL) and the reaction was stirred overnight at 
room temperature. The solution was then concentrated in vacuo and residual pyridine 
removed by azeotropic evaporation with toluene (3 times) to afford a yellow oil. The 
oil was then subjected to a standard work up (EtOAc) and then purified by flash 
chromatography (EtOAc:Pet Ether 8:2 → EtOAc:MeOH 9:1) to afford the 7-N,N­
diethylamino-3-fluorosialic acid benzyl sialoside (78) as an off-white solid (11.0 mg, 
2% over three steps). 1H NMR (400 MHz, CD3OD): δ 1.10 (t, 6H, J = 7.0 Hz, 
N(CH2CH3)2)); 1.92 (s, 3H, NHC(O)CH3); 2.06 (s, 3H, C(O)CH3); 2.74 (q, 4H, 
J = 14.4 Hz, N(CH2CH3)2); 2.81 – 2.89 (m, 2H, H-7, H-7’); 3.78 (s, 3H, OCH3); 
3.98 - 4.02 (m, 1H, H-6); 4.12 (t, 1H, J4,5 = 10.5 Hz, H-5); 4.42 (d, 1H, J = 11.1 Hz, 
OCH2Ph); 4.75 (d, 1H, OCH2Ph); 5.04 (br dd, J3,4 = 2.6, J3,F3 = 49.8 Hz, H-3); 5.32 
(br ddd, 1H, J4,F3 = 28.7 Hz, H-4); 7.31 – 7.40 (m, 5H, Ph). 13C NMR (100 MHz, 
CD3OD): δ 11.75 (N(CH2CH3)2); 20.54 (C(O)CH3); 22.67 (NHC(O)CH3); 48.32 (d, 
J5,F3 = 1.5 Hz, C-5); 48.93 (N(CH2CH3)2); 53.42 (OCH3); 54.31 (C-7); 67.41 
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(OCH2Ph); 70.71 (d, J4,F3 = 17.7 Hz, C-4); 73.12 (C-6); 88.65 (d, J3,F3 = 180.6 Hz, 
C-3); 99.42 (d, J2,F3 = 26.5 Hz, C-2); 129.02 (C Ph); 129.23 (C Ph); 129.53 (C Ph); 
137.57 (Cq Ph); 167.49 (C-1); 171.68 (NHC(O)CH3); 173.72 (C(O)CH3). 19F NMR 
(376 MHz, CD3OD): δ -208.80 (dd, 1F, JF3,4 = 29.0, JF3,3 = 50.4 Hz, F-3). HRMS 
(ESI +ve) m/z 469.2359 [M+H]+ (C23H34N2FO7 requires 469.2350); 491.2173 
[M+Na]+ (C23H33N2FO7Na requires 491.2169). 
Methyl 5-N-acetamido-4-O-acetyl-3,5,7-trideoxy-7-N,N-diethylamine-3-fluoro-α-L­
manno-hept-2-pyranosonate (152) 
Glacial acetic acid was added to a solution of 7-N-diethylamine-3-fluorosialic acid 
benzyl sialoside (78) (150 mg, 0.32 mmol) in tetrahydrofuran (15 mL) until pH 4, 
and then palladium on charcoal (40.0 mg, 10 wt. %) was added to the reaction and 
the reaction was put under a hydrogen gas atmosphere (10 days). The mixture was 
filtered through Celite®, washed with methanol and the filtrate concentrated in vacuo. 
The residue was purified by flash chromatography (EtOAc → EtOAc:MeOH 9:1) to 
afford the 7-N-diethylamine-3-fluorosialic acid (152) as an off-white solid (39.6 mg, 
31%). 1H NMR (400 MHz, CD3OD): δ 1.17 (t, 6H, J = 7.2 Hz, N(CH2CH3)2)); 1.95 
(s, 3H, NHC(O)CH3); 2.08 (s, 3H, C(O)CH3); 2.92 – 3.06 (m, 4H, N(CH2CH3)2); 
3.15 – 3.23 (m, 2H, H-7, 7’); 3.35 (s, 3H, OCH3); 4.08 – 4.13 (m, 1H, H-5); 
4.23 - 4.38 (m, 1H, H-6); 5.03 (br dd, J3,4 = 2.4, J3,F3 = 49.6 Hz, H-3); 5.40 (br ddd, 
1H, J4,5 = 10.8, J4,F3 = 28.0 Hz, H-4). 13C NMR (400 MHz, CD3OD): δ 10.56 
(N(CH2CH3)2); 20.65 (C(O)CH3); 22.82 (NHC(O)CH3); 48.02 (N(CH2CH3)2); 48.14 
(C-5); 53.93 (OCH3); 54.17 (C-7); 66.82 (C-6); 70.38 (d, J4,F3 = 17.1 Hz, C-4); 89.60 
(d, J3,F3 = 179.5 Hz, C-3); 96.74 (d, J2,F3 = 27.5 Hz, C-2); 169.56 (C-1); 171.84 
(NHC(O)CH3); 174.07 (C(O)CH3). 19F NMR (470 MHz, CD3OD): δ -209.00 (dd, 1F, 
JF3,4 = 29.6, JF3,3 = 49.4 Hz, F-3). HRMS (ESI +ve) m/z 379.1884 [M+H]+ 
(C16H28N2FO7 requires 379.1881); 401.1696 [M+Na]+ (C16H27N2FO7Na requires 
401.1700). 
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Attempted synthesis of methyl (benzyl-5-N-acetamido-4-O-acetyl-7-N,N­
diethylamine-3,5,7-trideoxy-3-fluoro-α-L-manno-hept-2-pyranosid)onate (78) where 
the product obtained was methyl (benzyl-5-N-acetamido-4,7-di-O-acetyl-3,5­
dideoxy-3-fluoro-α-L-manno-hept-2-pyranosid)onate (153) 
i) A 0.4 M aqueous solution of sodium periodate (4.9 mL) was added to a solution of 
3-fluorosialic acid benzyl sialoside (75) (500 mg, 1.16 mmol) in water (4.9 mL) at 
room temperature and the solution was stirred for 30 min. The solution was 
concentrated in vacuo and the crude residue was used without further purification. 
ii) A solution of diethylamine (1.81 mL, 17.4 mmol) in methanol (5 mL) was 
acidified to pH 5 with glacial acetic acid, and this solution was added to a solution of 
the crude mixture (above) in methanol (5 mL). The solution was stirred for 4h at 
room temperature, then sodium cyanoborohydride (364 mg, 5.79 mmol) was added 
and the mixture was left stirring overnight. Water (5 mL) and methanol (5 mL) were 
added, the volume of solution reduced to 5 mL. This solution was applied to a 
reverse phase column and eluted with Water → Water:MeOH 1:1. 
iii) Acetic anhydride (0.53 mL, 5.63 mmol) was added to a solution of the residue 
obtained (200 mg, 0.47 mmol) in pyridine (4 mL) and the reaction was stirred 
overnight at room temperature. The solution was then concentrated in vacuo and 
residual pyridine removed by azeotropic evaporation with toluene (3 times) to afford 
a yellow oil. The oil was subjected to a standard work up (EtOAc) and then purified 
by flash chromatography (EtOAc:Pet Ether 8:2) to afford the 7-O-acetyl-3­
fluorosialic acid benzyl sialoside (153) as an off-white solid (170 mg, 21% over three 
steps). 1H NMR (400 MHz, CDCl3): δ 1.92 (s, 3H, NHC(O)CH3); 2.10 (s, 6H, 
C(O)CH3); 3.78 (s, 3H, OCH3); 3.79 - 3.83 (m, 1H, H-6); 4.24 – 4.33 (m, 2H, H-7, 
H-7’); 4.37 – 4.45 (m, 2H, OCH2Ph, H-5); 4.57 (d, 1H, J = 11.4 Hz, OCH2Ph); 5.00 
(br dd, J3,4 = 2.6, J3,F3 = 49.2 Hz, H-3); 5.28 (ddd, 1H, J4,5 = 11.1, J4,F3 = 28.4 Hz, H­
4); 5.42 (d, 1H, J5,NHAc = 9.4 Hz, NH); 7.25 – 7.39 (m, 5H, Ph). 13C NMR (100 
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MHz, CDCl3): δ 20.75, 20.89 (C(O)CH3); 23.20 (NHC(O)CH3); 46.56 (d, J5,F3 = 2.2 
Hz, C-5); 53.07 (OCH3); 63.22 (C-7); 66.27 (OCH2Ph); 69.21 (d, J4,F3 = 17.0 Hz, 
C-4); 72.15 (C-6); 87.52 (d, J3,F3 = 182.8 Hz, C-3); 98.17 (d, J2,F3 = 27.3 Hz, C-2); 
128.13 (C Ph); 128.45 (C Ph); 128.62 (C Ph); 135.62 (Cq Ph); 165.65 (C-1); 170.21 
(NHC(O)CH3); 170.89, 171.23 (C(O)CH3). 19F NMR (376 MHz, CDCl3): δ -205.65 
(dd, 1F, JF3,4 = 28.9, JF3,3 = 50.0 Hz, F-3). m/z found (ESI): 456.1660 [M+H]+, 
C21H27F1N1O9 requires 456.1670; 478.1477 [M+Na]+, C21H26F1N1O9Na requires 
478.1489. HRMS (ESI +ve) m/z 456.1651 [M+H]+ (C21H27NFO9 requires 456.1670); 
478.1467 [M+Na]+ (C21H26NFO9Na requires 478.1489). 
Methyl 5-N-acetamido-4,7-di-O-acetyl-3,5-dideoxy-3-fluoro-α-L-manno-hept-2­
pyranosonate (154) 
Glacial acetic acid was added to a solution of 4,7-di-O-acetyl-3-fluorosialic acid 
benzyl sialoside (153) (170 mg, 0.37 mmol) in tetrahydrofuran (20 mL) until pH 4 
and then palladium on carbon (60 mg, 10 wt. %) was added. An atmosphere of 
hydrogen gas was created with the use of a balloon and the reaction was left stirring 
for 6 days. The mixture was filtered through Celite®, washed with ethyl acetate and 
the filtrate concentrated in vacuo. The residue was applied to a chromatographic 
column (EtOAc) affording 4,7-di-O-acetyl-3-fluorosialic acid (154) as an off-white 
solid (92.3 mg, 68%). 1H NMR (400 MHz, CDCl3): δ 1.91 (s, 3H, NHC(O)CH3); 
2.06, 2.07 (2s, 6H, C(O)CH3); 3.81 (s, 3H, OCH3); 4.14 – 4.19 (m, 2H, H-6, H-7); 
4.25 – 4.35 (m, 2H, H-5, H-7’); 4.94 (br dd, 1H, J3,4 = 2.3, J3,F3 = 50.1 Hz, H-3); 5.35 
(br ddd, 1H, J4,5 = 10.8, J4,F3 = 28.4 Hz, H-4). 13C NMR (100 MHz, CDCl3): δ 20.57, 
20.73 (C(O)CH3); 22.66 (NHC(O)CH3); 46.72 (d, J5,F3 = 2.2 Hz, C-5); 53.31 
(OCH3); 64.20 (C-7); 70.99 (d, J4,F3 = 17.0 Hz, C-4); 71.61 (C-6); 88.81 (d, 
J3,F3 = 182.1 Hz, C-3); 95.71 (d, J2,F3 = 25.8 Hz, C-2); 169.39 (C-1); 171.77, 172.62 
(C(O)CH3); 173.58 (NHC(O)CH3). 19F NMR (376 MHz, CDCl3): δ -208.41 (dd, 1F, 
JF3,4 = 27.7, JF3,3 = 49.2 Hz, F-3). HRMS (ESI +ve) m/z 366.1208 [M+H]+ 
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(C14H21F1N1O9 requires 366.1200); 388.1022 [M+Na]+ (C21H26F1N1O9Na requires 
388.1020). 
Methyl (p-methoxybenzyl-5-N-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-3­
fluoro-D-erythro-α-L-manno-non-2-ulopyranosid)onate (81) 
Sodium hydride (14.0 mg, 0.59 mmol) was added to a solution of hemiketal (54) 
(250 mg, 0.49 mmol) in dimethylformamide (7 mL) and the reaction was stirred for 
15 min, after which para-methoxybenzyl chloride (0.14 mL, 0.98 mmol) was added 
and the solution stirred for 2h at room temperature. The solution was quenched with 
methanol (1 mL) and then concentrated in vacuo and subjected to a standard work up 
(EtOAc). The residue was purified by flash chromatography (EtOAc:Pet ether 2:8 → 
EtOAc) to give the per-O-acetylated-3-fluorosialic acid para-methoxybenzyl 
sialoside (81) as an off-white solid (266 mg, 86%). 1H NMR (400 MHz, CDCl3): δ 
1.87 (s, 3H, NHC(O)CH3); 2.00, 2.04 2.06, 2.16 (4s, 12H, C(O)CH3); 3.75 (s, 3H, 
OCH3); 3.80 (s, 3H, OCH2PhOCH3); 4.08 – 4.18 (m, 2H, H-6, H-9); 4.35 – 4.43 (m, 
2H, OCH2PhOCH3, H-5); 4.58 (d, 1H, J = 11.4 Hz, OCH2PhOCH3); 4.92 – 4.94 (m, 
1H, H-9’); 5.00 (br dd, J3,4 = 2.1, J3,F3 = 41.3 Hz, H-3); 5.31 – 5.41 (m, 4H, NH, H-4, 
H-7, H-8); 6.89 (d, 2H, J = 8.8 Hz, H Ph ); 7.26 (d, 2H, H Ph). 13C NMR (100 MHz, 
CDCl3): δ 20.66, 20.77, 20.79, 20.93 (C(O)CH3); 23.16 (NHC(O)CH3); 45.20 (C-5); 
52.96 (CO2CH3); 55.29 (OCH2PhOCH3); 62.42 (C-9); 66.03 (OCH2PhOCH3); 68.31 
(C-7); 69.27 (d, J4,F3 = 17.0 Hz, C-4); 71.61 (C-6); 71.87 (C-8); 87.40 (d, 
J3,F3 = 183.5 Hz, C-3); 98.16 (d, J2,F3 = 27.3 Hz, C-2); 113.98 (C Ph); 127.67 (Cq 
Ph); 129.51 (C Ph); 159.66 (Cq Ph); 165.40 (C-1); 170.01 (NHC(O)CH3); 170.35, 
170.59, 170.74 (C(O)CH3). 19F NMR (376 MHz, CDCl3): δ -206.26 (dd, JF3,4 = 28.9, 
JF3,3 = 50.0 Hz, F-3). HRMS (ESI +ve) m/z 630.2179 [M+H]+ (C28H37NFO14 requires 
630.2198); 652.2009 [M+Na]+ (C28H36NFO14Na requires 652.2018). 
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Methyl (p-methoxybenzyl-5-N-acetamido-3,5-dideoxy-3-fluoro-D-erythro-α-L­
manno-non-2-ulopyranosid)onate (82) 
A 0.5 M solution of sodium methoxide in methanol (0.06 mL) was added to a 
solution of per-O-acetylated-3-fluorosialic acid para-methoxybenzyl sialoside (81) 
(266 mg, 0.42 mmol) in methanol (6 mL) at 4 ºC and the solution stirred overnight at 
room temperature. The solution was then neutralized (Dowex 50WX8, H+ form), 
filtered and the filtrate concentrated in vacuo to afford the 3-fluorosialic acid para­
methoxybenzyl sialoside (82) as an off-white solid (156.3 mg, 81%). 1H NMR (400 
MHz, CDCl3): δ 1.99 (s, 3H, NHC(O)CH3); 3.58 (br dd, 1H, J6,7 = 1.2, J7,8 = 9.7 Hz, 
H-7); 3.71 (br dd, 1H, J8,9 = 5.0, J9,9’ = 11.4 Hz, H-9); 3.78 (s, 3H, OCH2PhOCH3); 
3.81 (s, 3H, OCH3); 3.85 (br dd, 1H, J8,9’ = 2.9 Hz, H-9); 3.93 – 3.99 (m, 1H, H-8); 
4.01 – 4.09 (m, 2H, H-4, H-6); 4.18 (d, 1H, J = 10.0 Hz, OCH2PhOCH3); 4.24 (t, 1H, 
J5,NHAc = 10.5 Hz, H-5); 4.79 – 4.92 (m, 2H, OCH2PhOCH3, H-3); 6.85 (d, 2H, J = 
8.8 Hz, H Ph); 7.31 (d, 2H, H Ph). 13C NMR (100 MHz, CDCl3): δ 22.68 
(NHC(O)CH3); 48.37 (C-5); 53.40 (CO2CH3); 55.70 (OCH2PhOCH3); 65.24 (C-9); 
66.62 (OCH2PhOCH3); 69.17 (d, J4,F3 = 18.4 Hz, C-4); 69.93 (C-7); 71.44 (C-8); 
72.57 (C-6); 91.30 (d, J3,F3 = 179.1 Hz, C-3); 99.63 (d, J2,F3 = 27.3 Hz, C-2); 114.67 
(C Ph); 129.93 (Cq Ph); 131.39 (C Ph); 161.14 (Cq Ph); 168.91 (C-1); 174.87 
(NHC(O)CH3). 19F NMR (376 MHz, CDCl3): δ -210.36 (dd, JF3,4 = 30.3, JF3,3 = 50.0 
Hz, F-3). HRMS (ESI +ve) m/z 462.1768 [M+H]+ (C20H29NFO10 requires 462.1775); 
484.1577 [M+Na]+ (C20H28NFO10Na requires 484.1595). 
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Attempted synthesis of methyl (p-methoxybenzyl-5-N-acetamido-4-O-acetyl-7-N,N­
diethylamino-3-fluoro-3,5,7-trideoxy-α-L-manno-oct-2-ulopyranosid)onate (155) 
where the product obtained was methyl (p-methoxybenzyl-5-N-acetamido-4,7-di-O­
acetyl-3,5-dideoxy-3-fluoro-α-L-manno-hept-2-pyranosid)onate (83) 
i) A 0.4 M aqueous solution of sodium periodate (8.5 mL) was added to a solution of 
3-fluorosialic acid para-methoxybenzyl sialoside (82) (750 mg, 1.63 mmol) in water 
(8.5 mL) at room temperature and the solution was stirred for 30 min. The solution 
was concentrated in vacuo and the crude residue was used without further 
purification. 
ii) A solution of diethylamine (3.38 mL, 32.51 mmol) in methanol (5 mL) was 
acidified to pH 5 with glacial acetic acid, and this solution then added to a solution of 
the crude mixture (above) in methanol (10 mL). The solution was stirred for 4h at 
room temperature, then sodium cyanoborohydride (511 mg, 8.13 mmol) was added 
and the mixture was left stirring overnight. The solution was then concentrated in 
vacuo and the crude residue was used without further purification. 
iii) Acetic anhydride (1.55 mL, 16.43 mmol) was added to a solution of the crude 
mixture (above) in pyridine (14 mL) and stirred overnight at room temperature. The 
solution was then concentrated in vacuo and residual pyridine removed by azeotropic 
evaporation with toluene (3 times) to afford a yellow oil. The oil was then subjected 
to a standard work up (EtOAc) and then purified by flash chromatography (EtOAc 
→ EtOAc:MeOH 9:2) to afford the 7-O-acetyl-3-fluorosialic acid para­
methoxybenzyl sialoside (83) as a off-white solid (76 mg, 10% over three steps). 
Mp 87 – 92 ºC. 1H NMR (400 MHz, CDCl3): δ 1.92 (s, 3H, NHC(O)CH3); 2.10, 
2.11 (2s, 6H, C(O)CH3); 3.80 (s, 3H, OCH2PhOCH3); 3.81 (s, 3H, OCH3); 
3.79 - 3.83 (m, 1H, H-6); 4.25 – 4.51 (m, 5H, OCH2PhOCH3, H-5, H-7, H-7’); 4.98 
(br dd, J3,4 = 2.6, J3,F3 = 49.2 Hz, H-3); 5.26 (br ddd, 1H, J4,5 = 11.1, J4,F3 = 28.7 Hz, 
H-4); 5.47 (d, 1H, J5,NHAc = 9.4 Hz, NH); 6.89 (d, 2H, J = 8.8 Hz, H Ph); 7.22 (d, 2H, 
H Ph). 13C NMR (100 MHz, CDCl3): δ 20.74, 20.90 (C(O)CH3); 23.19 
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(NHC(O)CH3); 46.58 (d, J5,F3 = 2.2 Hz, C-5); 53.07 (CO2CH3); 55.32 
(OCH2PhOCH3); 63.27 (C-7); 66.08 (OCH2PhOCH3); 69.21 (d, J4,F3 = 17.0 Hz, 
C-4); 72.05 (C-6); 87.56 (d, J3,F3 = 182.8 Hz, C-3); 98.11 (d, J2,F3 = 27.3 Hz, C-2); 
113.99 (C Ph); 127.71 (Cq Ph); 129.94 (C Ph); 159.77 (Cq Ph); 165.79 (C-1); 170.24 
(NHC(O)CH3); 170.93, 171.23 (C(O)CH3). 19F NMR (376 MHz, CDCl3): δ -205.67 
(dd, 1F, JF3,4 = 29.0, JF3,3 = 49.2 Hz, F-3). HRMS (ESI +ve) m/z 486.1783 [M+H]+ 
(C22H29NFO10 requires 486.1775); 508.1607 [M+Na]+ (C22H28NFO10Na requires 
508.1595). 
Methyl 5-N-acetamido-2,3,5,7-tetradeoxy-7-N-ethyl-N-methylamino-2,3-difluoro-β­
L-manno-hept-2-pyranosonate (85) 
i) A 0.4 M aqueous solution of sodium periodate (3.1 mL) was added to a solution of 
2,3-difluorosialic acid (47) (250 mg, 0.73 mmol) in water (3.1 mL) at room 
temperature and the solution was stirred for 30 min. Cold tetrahydrofuran (15 mL) 
was added and the solution was cooled to 4 ºC for 15 min, filtered and the filtrate 
then concentrated in vacuo and used without further purification. 
ii) A solution of ethylmethylamine (0.94 mL, 10.9 mmol) in methanol (5 mL) was 
acidified to pH 5 with glacial acetic acid, and this solution then added to a solution of 
the crude mixture (above) in methanol (5 mL). The solution was stirred for 4h at 
room temperature, then sodium cyanoborohydride on polymer support (1.13 g, 3.64 
mmol) was added and the mixture was stirred overnight. The mixture was filtered 
and the filtrate evaporated to dryness and then purified using flash chromatography 
(EtOAc:Pet Ether 7:3) to afford the 7-N-ethyl-N-methylamino-2,3-difluorosialic acid 
(85) as a colourless oil (25.5 mg, 11% over 2 steps). 1H NMR (400 MHz, CD3OD): δ 
1.07 (t, 3H, J = 7.0 Hz, CH3NCH2CH3); 2.01 (s, 3H, NHC(O)CH3); 2.33 (d, 3H, 
J = 1.2 Hz, CH3NCH2CH3); 2.53 – 2.61 (m, 3H, H-7, CH3NCH2CH3); 2.70 (dd, 1H, 
J6,7’ = 7.9, J7,7’ = 13.7 Hz, H-7’); 3.87 (s, 2H, exchanging with solvent, OCH3); 4.21 
– 4.26 (m, 2H, H-4, 5); 4.73 – 4.76 (m, 1H, H-6); 5.02 (br ddd, 1H, J3,4 = 3.6, 
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J3,F2 = 23.1, J3,F3 = 46.9 Hz, H-3). 13C NMR (100 MHz, CD3OD): δ 10.35 
(CH3NCH2CH3); 20.93 (NHC(O)CH3); 40.78 (CH3NCH2CH3); 51.27 
(CH3NCH2CH3); 52.52 (OCH3); 52.70 (d, J5,F3 = 5.4 Hz, C-5); 55.67 (C-7); 66.63 
(dd, J4,F2 = 1.2, J4,F3 = 16.9 Hz, C-4); 66.81 (d, J6,F2 = 2.3 Hz, C-6); 84.57 (dd, 
J3,F2 = 24.5, J3,F3 = 192.5 Hz, C-3); 105.92 (dd, J2,F3 = 23.8, J2,F2 = 249.2 Hz, C-2); 
165.22 (d, J1,F2 = 33.0 Hz, C-1); 172.33 (NHC(O)CH3). 19F NMR (376 MHz, 
CD3OD): δ -137.46 (t, 1F, JF2,F3 = 22.9 Hz, F-2); -214.43 (ddt, 1F, JF3,4 = 4.6, 
JF3,3 = 42.7 Hz, F-3). HRMS (ESI +ve) m/z 325.1570 [M+H]+ (C13H23N2F2O5 
requires 325.1575); 347.1397 [M+Na]+ (C13H22N2F2O5Na requires 347.1394). 
5-N-Acetamido-2,3,5,7-tetradeoxy-7-N-ethyl-N-methylamino-2,3-difluoro-β-L­
manno-hept-2-pyranosonic acid (37) 
A 0.5 M solution of sodium hydroxide (1 drop) was added to a solution of 7-N-ethyl-
N-methylamino-2,3-difluorosialic acid (85) (12.1 mg, 0.04 mmol) in water (0.5 mL) 
at 4 ºC and the solution left to warm to room temperature for 2h. The solution was 
then neutralized (Dowex 50WX8, H+ form), filtered and the filtrate concentrated in 
vacuo to afford 7-N-ethyl-N-methylamino-2,3-difluorosialic acid (37) as a yellow 
solid (7.0 mg, 50%). m.p. 30 ºC (hygroscopic). 1H NMR (400 MHz, CD3OD): δ 1.33 
(t, 3H, J = 7.4 Hz, CH3NCH2CH3); 2.04 (s, 3H, NHC(O)CH3); 2.89 (s, 3H, 
CH3NCH2CH3); 3.25 – 3.34 (m, 4H, obscured by solvent peak, CH3NCH2CH3, H-7, 
H-7’); 4.16 – 4.19 (m, 1H, H-4); 4.29 – 4.29 (m, 1H, H-5); 4.85 (s, 1H, obscured by 
HDO peak, H-6); 4.97 (ddd, 1H, J3,4 = 3.5, J3,F2 = 22.3, J3,F3 = 43.0 Hz, H-3). 
13C NMR (100 MHz, CD3OD): δ 7.77 (CH3NCH2CH3); 21.16 (NHC(O)CH3); 38.19 
(CH3NCH2CH3); 47.86 (CH3NCH2CH3); 51.70 (d, J5,F3 = 6.1 Hz, C-5); 54.82 (C-7); 
63.62 (C-6); 66.98 (d, J4,F3 = 17.7 Hz, C-4); 84.99 (dd, J3,F2 = 25.3, J3,F3 = 190.2 Hz, 
C-3); 106.32 (dd, J2,F3 = 24.5, J2,F2 = 173.2 Hz, C-2); 169.01 (d, J1,F2 = 26.8 Hz, C-1); 
172.27 (NHC(O)CH3). 19F NMR (376 MHz, CD3OD): δ -135.36 (t, 1F, JF2,F3 = 21.3 
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Hz, F-2); -213.91 (dd, 1F, JF3,3 = 44.3 Hz, F-3). [α ]20 = +56.0 (c 0.05, H2O). HRMS D 
(ESI -ve) m/z 309.1276 [M-H]- (C12H20N2F2O5 requires 309.1262). 
Methyl 5-N-acetamido-2,3,5,7-tetradeoxy-7-N-ethylacetamido-2,3-difluoro-β-L­
manno-hept-2-pyranosonate (80) 
i) A 0.4 M solution of sodium periodate (2.7 mL) was added to a solution of 
2,3-difluorosialic acid (47) (212 mg, 0.62 mmol) in water (2.7 mL) at room 
temperature and the solution was stirred for 30 min. Cold tetrahydrofuran (15 mL) 
was added and the solution was cooled to 4 ºC for 15 min, filtered and the filtrate 
was concentrated in vacuo and used without further purification. 
ii) A solution of ethylamine (0.61 mL, 9.26 mmol) in methanol (5 mL) was acidified 
to pH 5 with glacial acetic acid, and this solution then added to a solution of the 
crude mixture (above) in methanol (5 mL). The solution was stirred for 4h at room 
temperature, then sodium cyanoborohydride on polymer support (962 mg, 3.09 
mmol) was added and the mixture was left stirring overnight. The mixture was 
filtered and the filtrate evaporate to dryness and then purified by flash 
chromatography (EtOAc:MeOH 7:3) to afford the 7-N-ethylamino-2,3-difluorosialic 
acid as an oil. 
iii) Acetic anhydride (0.59 mL, 6.2 mmol) was added to a solution of the crude 
mixture (above) in pyridine (3 mL) and stirred overnight at room temperature. The 
solution was then concentrated in vacuo and residual pyridine removed by azeotropic 
evaporation with toluene (3 times) to afford a yellow oil. The oil was then subjected 
to a standard work up (EtOAc) and then purified by flash chromatography (EtOAc 
→ EtOAc:MeOH 9:2) to afford the 4-O-acetyl-7-N-ethylacetamido-2,3-difluorosialic 
acid as a off-white solid. 
iv) A 0.5 M solution of sodium methoxide in methanol (0.06 mL) was added to a 
solution of 4-O-acetyl-7-N-ethylacetamido-2,3-difluorosialic acid (266 mg, 0.42 
mmol) in methanol (6 mL) at 4 ºC and the solution stirred overnight at room 
172 
Chapter 11

temperature. The solution was then neutralized (Dowex 50WX8, H+ form), filtered 
and the filtrate concentrated in vacuo to afford the 7-N-ethylacetamido-2,3­
difluorosialic acid (80) as an off-white solid (11 mg, 22% over 4 steps). m.p. 30 ºC 
(hygroscopic). 1H NMR (400 MHz, CD3OD): δ 1.14 (t, 3H, J = 7.0 Hz, 
CH3C(O)NCH2CH3); 2.02 (s, 3H, NHC(O)CH3); 2.16 (s, 3H, CH3C(O)NCH2CH3); 
3.21 (q, 1H, J = 7.0, J = 14.4 Hz, CH3C(O)NCH2CH3); 3.37 – 4.14 (m, 6H, H-4, H-5, 
H-6, H-7, H-7’, CH3C(O)NCH2CH3); 3.88 (s, 3H, OCH3); 5.04 – 5.19 (m, 1H, H-3). 
13C NMR (100 MHz, CD3OD): δ 10.31 (CH3C(O)NCH2CH3); 22.40 (NHC(O)CH3); 
23.50 (CH3C(O)NCH2CH3); 49.24 (CH3C(O)NCH2CH3) 52.16 (C-7); 51.64 (C-5); 
53.99 (OCH3); 66.99 (d, J4,F3 = 16.7 Hz, C-4); 67.35 (d, J6,F2 = 2.4 Hz, C-6); 86.89 
(dd, J3,F2 = 23.7, J3,F3 = 191.6 Hz, C-3); 107.43 (dd, J2,F3 = 24.6, J2,F2 = 250.0 Hz, 
C-2); 167.89 (d, J1,F2 = 28.9 Hz, C-1); 173.80 (NHC(O)CH3); 174.59 
(CH3C(O)NCH2CH3). 19F NMR (376 MHz, CD3OD): δ -123.80 (d, 1F, JF2,F3 = 12.2 
Hz, F-2); -220.72 (ddd, 1F, JF3,4 = 27.5, JF2,F3 = 12.2, JF3,3 = 50.4 Hz, F-3). HRMS 
(ESI +ve) m/z 375.1338 [M+Na]+ (C14H22N2F2O6Na requires 375.1344). 
5-N-Acetamido-2,3,5,7-tetradeoxy-7-N-ethylacetamido-2,3-difluoro-β-L-manno­
hept-2-pyranosonic acid (38) 
A 0.5 M solution of sodium hydroxide (2 drops) was added to a solution of 7-N­
ethylacetamido-2,3-difluorosialic acid (80) (10.0 mg, 0.03 mmol) in water (0.5 mL) 
at 4 ºC and the solution left to warm to room temperature (1h). The solution was then 
neutralized (Dowex 50WX8, H+ form), filtered and the filtrate concentrated in vacuo 
to afford 7-N-ethylacetamido-2,3-difluorosialic acid (38) as a white solid (7.8 mg, 
76%). m.p. 30 ºC (hygroscopic). 1H NMR (400 MHz, D2O): δ 1.05 (t, 3H, J = 7.0 
Hz, CH3C(O)NCH2CH3); 1.79 (s, 3H, NHC(O)CH3); 1.92 (s, 3H, 
CH3C(O)NCH2CH3); 3.25 – 3.95 (m, 7H, H-4, H-5, H-6, H-7, H-7’, 
CH3C(O)NCH2CH3); 4.98 (br d, 1H, J3,F3 = 52.4 Hz, H-3). 13C NMR (100 MHz, 
CD3OD): δ 11.13 (CH3C(O)NCH2CH3); 21.54 (NHC(O)CH3); 24.56 
173 
Chapter 11

(CH3C(O)NCH2CH3); 48.76 (CH3C(O)NCH2CH3) 51.34 (C-7); 50.76 (C-5); 67.67 
(d, J4,F3 = 16.5 Hz, C-4); 66.76 (d, J6,F2 = 2.2 Hz, C-6); 87.54 (dd, J3,F2 = 23.9, J3,F3 = 
190.9 Hz, C-3); 108.33 (dd, J2,F3 = 24.2, J2,F2 = 251.0 Hz, C-2); 168.23 (d, J1,F2 = 
29.0 Hz, C-1); 174.76 (NHC(O)CH3); 175.02 (CH3C(O)NCH2CH3). 19F NMR (376 
MHz, CD3OD): δ -120.13 (d, 1F, JF2,F3 = 10.7 Hz, F-2); -217.13 – 216.83 (m, 1F, 
[ ]20 F-3). α D = +10.5 (c 0.08, H2O). HRMS (ESI -ve) m/z 337.1239 [M-H]­
(C13H19N2F2O6 requires 337.1211). 
Methyl 5-N-acetamido-2,3,5,7-tetradeoxy-7-N,N-diethylamino-2,3-difluoro-β-L­
manno-hept-2-pyranosonate (68) 
i) A 0.4 M solution of sodium periodate (2.7 mL) was added to a solution of 
2,3-difluorosialic acid (47) (212 mg, 0.62 mmol) in water (2.7 mL) at room 
temperature and the solution was stirred for 30 min. Cold tetrahydrofuran (15 mL) 
was added and the solution was cooled to 4 ºC for 15 min, filtered and the filtrate 
was concentrated in vacuo and used without further purification. 
ii) A solution of diethylamine (0.96 mL, 9.26 mmol) in methanol (5 mL) was 
acidified to pH 5 with glacial acetic acid, and this solution then added to a solution of 
the crude mixture (above) in methanol (5 mL). The solution was stirred for 4h at 
room temperature, then sodium cyanoborohydride on polymer support (962 mg, 3.09 
mmol) was added and the mixture was left stirring overnight. The mixture was 
filtered and the filtrate evaporate to dryness and then purified by flash 
chromatography (EtOAc:Pet Ether 7:3) to afford the 7-N,N-diethylamino-2,3­
difluorosialic acid (68) as an off-white solid (37.9 mg, 18% over 2 steps). m.p. 30 ºC 
(hygroscopic). 1H NMR (400 MHz, CD3OD): δ 1.08 (t, 6H, J = 7.0 Hz, 
N(CH2CH3)2); 2.01 (s, 3H, NHC(O)CH3); 2.67 – 2.85 (m, 5H, N(CH2CH3)2, H-7); 
3.09 – 3.15 (m, 1H, H-7’); 3.87 (s, 3H, OCH3); 4.25 – 4.26 (m, 2H, H-4, H-5); 4.74 
(t, 1H, J6,7 = 5.9 Hz, H-6); 5.02 (ddd, J3,4 = 2.7, J3,F2 = 25.8, J3,F3 = 46.1 Hz, H-3). 
13C NMR (100 MHz, CD3OD): δ 11.21 (N(CH2CH3)2); 22.40 (NHC(O)CH3); 50.24 
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(N(CH2CH3)2) 53.16 (C-7); 53.94 (C-5); 53.99 (OCH3); 67.99 (d, J4,F3 = 16.8 Hz, 
C-4); 68.25 (d, J6,F2 = 2.3 Hz, C-6); 85.90 (dd, J3,F2 = 23.8, J3,F3 = 191.7 Hz, C-3); 
107.32 (dd, J2,F3 = 24.5, J2,F2 = 249.9 Hz, C-2); 166.60 (d, J1,F2 = 29.1 Hz, C-1); 
173.80 (NHC(O)CH3). 19F NMR (376 MHz, CD3OD): δ -137.21 to -137.34 (m, 1F, 
F-2); -214.41 (ddt, 1F, JF3,4 = 6.1, JF2,F3 = 19.8, JF3,3 = 44.2 Hz, F-3). HRMS 
(ESI +ve) m/z 339.1731 [M+H]+ (C14H25N2F2O5 requires 339.1732); 361.1556 
[M+Na]+ (C14H24N2F2O5Na requires 361.1551). 
5-N-Acetamido-2,3,5,7-tetradeoxy-7-N,N-diethylamino-2,3-difluoro-β-L-manno­
hept-2-pyranosonic acid (39) 
A 0.5 M solution of sodium hydroxide (2 drops) was added to a solution of 7-N,N­
diethylamino-2,3-difluorosialic acid (68) (20.0 mg, 0.06 mmol) in water (0.5 mL) at 
4 ºC and the solution left to warm to room temperature (1h). The solution was then 
neutralized (Dowex 50WX8, H+ form), filtered and the filtrate concentrated in vacuo 
to afford 7-N,N-diethylamino-2,3-difluorosialic acid (39) as a white solid (11.8 mg, 
67%). m.p. 30 ºC (hygroscopic). 1H NMR (400 MHz, D2O): δ 1.16 (q, 6H, J = 7.4, 
= 13.7 Hz, N(CH2CH3)2); 1.92 (s, 3H, NHC(O)CH3); 3.09 – 3.28 (m, 6H, 
N(CH2CH3)2, H-7, H-7’); 4.18 – 4.20 (m, 1H, H-5); 4.21 – 4.25 (m, 1H, H-4); 
4.71 - 4.74 (m, 1H, H-6); 4.92 (ddd, 1H, J3,4 = 3.9, J3,F2 = 23.8, J3,F3 = 46.1 Hz, H-3). 
13C NMR (100 MHz, D2O): δ 7.71 (N(CH2CH3)2); 7.92 (N(CH2CH3)2); 21.61 
(NHC(O)CH3); 47.33 ((N(CH2CH3)2); 49.06 (N(CH2CH3)2); 51.48 (d, J5,F3 = 6.2 Hz, 
C-5); 51.64 (C-7); 63.78 (d, J6,F2 = 3.0 Hz, C-6); 66.27 (d, J4,F3 = 16.9 Hz, C-4); 
84.45 (dd, J3,F2 = 24.6, J3,F3 = 189.4 Hz, C-3); 106.44 (dd, J2,F3 = 25.3, J2,F2 = 246.9 
Hz, C-2); 169.78 (d, J1,F2 = 28.3 Hz, C-1); 174.46 (NHC(O)CH3). 19F NMR 
(376 MHz, D2O): δ -134.29 (t, 1F, JF2,F3 = 21.4 Hz, F-2); -213.02 (ddt, 1F, JF3,4 = 4.6, 
JF3,3 = 42.7 Hz, F-3). [α ]20 = +20.9 (c 0.07, H2O). HRMS (ESI -ve) m/z 323.1429 D 
[M-H]- (C13H21N2F2O5 requires 323.1419). 
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Methyl 5-N-acetamido-7-N-anilino-2,3,5,7-tetradeoxy-2,3-difluoro-β-L-manno-hept­
2-pyranosonate (150) 
i) A 0.4 M aqueous solution of sodium periodate (2.7 mL) was added to a solution of 
2,3-difluorosialic acid (47) (220 mg, 0.64 mmol) in water (2.7 mL) at room 
temperature and the solution was stirred for 30 min. Cold tetrahydrofuran (10 mL) 
was added and the solution cooled to 4 ºC for 15 min, filtered and the filtrate then 
concentrated in vacuo and used without further purification. 
ii) A solution of aniline (0.88 mL, 9.61 mmol) in methanol (5.0 mL) was acidified to 
pH 5 with glacial acetic acid, and this solution then added to a solution of the crude 
mixture (above) in methanol (5.0 mL). The mixture was stirred for 4h at room 
temperature, then sodium cyanoborohydride on polymer support (1.28 g, 3.20 mmol) 
was added and the mixture left stirring overnight. The mixture was filtered and the 
filtrate evaporated to dryness and then purified using flash chromatography 
(EtOAc:Pet Ether 7:3) to afford the 7-N-anilino-2,3-difluorosialic acid (150) as a 
yellow solid (25.5 mg, 27% over 2 steps). m p. 82-86 °C. 1H NMR (400 MHz, 
CDCl3): δ 1.97 (s, 3H, NHC(O)CH3); 3.29 – 3.39 (m, 2H, H-7); 3.91 (s, 3H, OCH3); 
4.43 - 4.45 (m, 2H, H-4, H-5); 4.79 (t, 1H, J5,6 = 5.8 Hz, H-6); 5.00 (ddd, 1H, J3,4 = 
3.1, J3,F2 = 22.0, J3,F3 = 43.5 Hz, H-3); 6.47 (d, 1H, J5,NHAc = 7.2 Hz, NH); 6.62 (d, 
2H, J = 7.6 Hz, H Ph); 6.75 (t, 1H, J = 14.8 Hz, H Ph); 7.17 (t, 2H, H Ph). 13C NMR 
(100 MHz, CDCl3): δ 23.07 (NHC(O)CH3); 43.94 (C-7); 52.12 (d, J5,F3 = 5.9 Hz, C­
5); 53.84 (OCH3); 66.74 (d, J4,F3 = 16.2 Hz, C-4); 67.81 (C-6); 84.58 (dd, J3,F2 = 
24.3, J3,F3 = 192.4 Hz, C-3); 105.91 (dd, J2,F3 = 24.3, J2,F2 = 252.1 Hz, C-2); 113.37 
(C Ph); 118.50 (C Ph); 129.38 (C Ph); 147.14 (Cq Ph); 165.32 (d, J1,F2 = 30.2 Hz, C­
1); 171.15 (NHC(O)CH3). 19F NMR (376 MHz, CDCl3): δ -136.69 (t, 1F, JF2,F3 = 
20.2 Hz, F-2); -213.75 (ddt, 1F, JF3,4 = 5.0, JF3,3 = 44.1 Hz, F-3). HRMS (ESI +ve) 
m/z 359.1409 [M+H]+ (C16H21N2F2O5 requires 359.1419); 381.1233 [M+Na]+ 
(C16H20N2F2O5Na requires 381.1238). 
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5-N-Acetamido-7-N-anilino-2,3,5,7-tetradeoxy-2,3-difluoro-β-L-manno-hept-2­
pyranosonic acid (147) 
A 0.5 M aqueous solution of sodium hydroxide (4 drops) was added to a solution of 
7-N-anilino-2,3-difluorosialic acid (150) (17.4 mg, 0.05 mmol) in water (0.5 mL) at 
4 ºC and the solution left to warm to room temperature (1h). The solution was then 
neutralized (Dowex 50WX8, H+ form), filtered and the filtrate concentrated in vacuo 
to afford 7-N-anilino-2,3-difluorosialic acid (147) as a light brown solid (10.0 mg, 
60%). m.p. 36-40 ºC. 1H NMR (400 MHz, CD3OD): δ 2.03 (s, 3H, NHC(O)CH3); 
3.24 – 3.26 (m, 2H, H-7, H-7’); 4.18 – 4.20 (m, 1H, H-4); 4.31 – 4.33 (m, 1H, H-5); 
4.65 (dt, J6,7 = 1.2, J5,6 = 6.3 Hz, H-6); 4.91 (ddd, 1H, J3,4 = 3.9, J3,F2 = 23.0, 
J3,F3 = 43.3 Hz, H-3); 6.62 (d, 2H, J = 7.8 Hz, H Ph); 7.09 (t, 3H, H Ph). 13C NMR 
(100 MHz, CD3OD): δ 22.58 (NHC(O)CH3); 44.86 (C-7); 53.36 (d, J5,F3 = 3.9 Hz, 
C-5); 68.22 (C-6); 68.74 (d, J4,F3 = 16.9 Hz, C-4); 87.55 (dd, J3,F2 = 26.8, 
J3,F3 = 187.8 Hz, C-3); 107.36 (dd, J2,F3 = 25.1, J2,F2 = 247.5 Hz, C-2); 114.05 (C Ph); 
118.28 (C Ph); 130.08 (C Ph); 149.58 (Cq Ph); 171.76 (d, J1,F2 = 27.6 Hz, C-1); 
173.53 (NHC(O)CH3). 19F NMR (376 MHz, CD3OD): δ -135.38 (t, 1F, JF2,F3 = 21.4 
Hz, F-2); -213.89 (dd, 1F, JF3,3 = 42.7 Hz, F-3). [α ]20 = +72.7 (c 0.04, H2O). HRMS D 
(ESI -ve) m/z 343.1121 [M-H]- (C15H17N2F2O5 requires 343.1106). 
Methyl 5-N-acetamido-2,3,5,7-tetradeoxy-2,3-difluoro-7-N-morphonlino-β-L­
manno-hept-2-pyranosonate (149) 
i) A 0.4 M aqueous solution of sodium periodate (3.1 mL) was added to a solution of 
2,3-difluorosialic acid (47) (250 mg, 0.73 mmol) in water (3.1 mL) at room 
temperature and the solution was stirred for 30 min. Cold tetrahydrofuran (15 mL) 
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was added and the solution cooled to 4 ºC for 15 min, filtered and the filtrate then 
concentrated in vacuo and used without further purification. 
ii) A solution of morpholine (0.96 mL, 10.9 mmol) in methanol (5 mL) was acidified 
to pH 5 with glacial acetic acid, and this solution then added to a solution of the 
crude mixture (above) in methanol (5 mL). The mixture was stirred for 4h at room 
temperature, then sodium cyanoborohydride on polymer support (1.13 g, 3.64 mmol) 
was added and the mixture was left stirring overnight. The mixture was filtered and 
the filtrate evaporated to dryness and then purified using flash chromatography 
(EtOAc:Pet Ether 7:3) to afford the 7-N-morpholino-2,3-difluorosialic acid (149) as a 
light yellow solid (53.4 mg, 21% over 2 steps). m.p. 30 ºC (hygroscopic). 1H NMR 
(400 MHz, CD3OD): δ 2.01 (s, 3H, NHC(O)CH3); 2.44 – 2.67 (m, 6H, N(CH2)2, 
H-7, H-7’); 3.67 (t, 4H, J = 4.6 Hz, O(CH2)2); 3.87 (s, 3H, OCH3); 4.24 – 4.26 (m, 
2H, H-4, H-5); 4.72 – 4.75 (m, 1H, H-6); 5.01 (br ddd, J3,4 = 2.8, J3,F2 = 22.7, J3,F3 = 
43.0 Hz, H-3). 13C NMR (100 MHz, CD3OD): δ 22.37 (NHC(O)CH3); 53.96 
(OCH3); 54.01 (C-5); 55.03 (N(CH2)2); 59.05 (C-7); 67.70 (O(CH2)2); 68.03 (d, J4,F3 
= 15.4 Hz, C-4); 68.18 (d, J6,F2 = 3.1 Hz, C-6); 86.02 (dd, J3,F2 = 23.8, J3,F3 = 191.7 
Hz, C-3); 107.35 (dd, J2,F3 = 24.5, J2,F2 = 249.2 Hz, C-2); 166.63 (d, J1,F2 = 32.2 Hz, 
C-1); 173.67 (NHC(O)CH3). 19F NMR (376 MHz, CD3OD): δ -137.92 (t, 1F, JF2,F3 = 
21.4 Hz, F-2); -214.98 (m, 1F, F-3). HRMS (ESI +ve) m/z 353.1541 [M+H]+ 
(C14H23N2F2O6 requires 353.1524); 375.1368 [M+Na]+ (C14H22N2F2O6Na requires 
375.1344). 
5-N-Acetamido-2,3,5,7-tetradeoxy-2,3-difluoro-7-N-morpholino-β-L-manno-hept-2­
pyranosonic acid (146) 
A 0.5 M aqueous solution of sodium hydroxide (4 drops) was added to a solution of 
7-N-morpholino-2,3-difluorosialic acid (149) (112 mg, 0.32 mmol) in water (2 mL) 
at 4 ºC and the solution was left to warm to room temperature (1h). The solution was 
then neutralized (Dowex 50WX8, H+ form), filtered and the filtrate concentrated in 
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vacuo to afford 7-N-morpholino-2,3-difluorosialic acid (146) as a light brown solid 
(90.1 mg, 84%). m.p. 30 ºC (hygroscopic). 1H NMR (400 MHz, CD3OD): δ 20.3 
(s, 3H, NHC(O)CH3); 2.80 – 2.94 (m, 6H, N(CH2)2, H-7, H-7’); 3.77 – 3.78 (m, 4H, 
O(CH2)2); 4.16 – 4.17 (m, 1H, H-4); 4.28 (br s, 1H, H-5); 4.81 – 4.89 (m, 1H, H-6); 
4.90 - 5.01 (m, 1H, H-3). 13C NMR (100 MHz, CD3OD): δ 22.58 (NHC(O)CH3); 
53.72 (d, J5,F3 = 5.4 Hz, C-5); 54.47 (N(CH2)2); 59.17 (C-7); 66.02 (C-6); 66.37 
(O(CH2)2); 68.42 (d, J4,F3 = 16.9 Hz, C-4); 86.91 (dd, J3,F2 = 26.0, J3,F3 = 189.3 Hz, 
C-3); 108.40 (dd, J2,F3 = 25.4, J2,F2 = 246.2 Hz, C-2); 171.00 (d, J1,F2 = 26.9 Hz, C-1); 
173.42 (NHC(O)CH3). 19F NMR (376 MHz, CD3OD): δ -135.13 (s, 1F, F-2); -213.62 
(dd, 1F, JF2,F3 = 19.9, JF3,3 = 42.8 Hz, F-3). [α ]20 = +66.7 (c 0.09, H2O). HRMS (ESI D 
-ve) m/z 337.1217 [M-H]- (C13H19N2F2O6 requires 337.1211). 
Methyl 5-N-acetamido-2,3,5,7-tetradeoxy-7-N-pyrrolidino-2,3-difluoro-β-L-manno­
hept-2-pyranosonate (148) 
i) A 0.4 M aqueous solution of sodium periodate (3.1 mL) was added to a solution of 
2,3-difluorosialic acid (47) (250 mg, 0.73 mmol) in water (3.1 mL) at room 
temperature and the solution was stirred for 30 min. Cold tetrahydrofuran (15 mL) 
was added and the solution was cooled to 4 ºC for 15 min, filtered and the filtrate 
then concentrated in vacuo and used without further purification. 
ii) A solution of diethylamine (0.9 mL, 10.92 mmol) in methanol (5 mL) was 
acidified to pH 5 with glacial acetic acid, and this solution added to a solution of the 
crude mixture (above) in methanol (5 mL). The mixture was stirred for 4h at room 
temperature, then sodium cyanoborohydride on polymer support (1.133 g, 3.64 
mmol) was added and the mixture was left stirring overnight. The mixture was 
filtered and the filtrate evaporated to dryness and then purified by flash 
chromatography (EtOAc:MeOH 1:0 → EtOAc:MeOH 8:2) to afford the 7-N­
pyrrolidino-2,3-difluorosialic acid (148) as an off-white solid (104.6 mg, 42% over 2 
steps). m.p. 30 ºC (hygroscopic). 1H NMR (400 MHz, CD3OD): δ 2.04 (s, 3H, 
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NHC(O)CH3); 2.06 (s, 4H, N(C2H4)(C2H4)); 3.28 – 3.39 (m, 6H, N(C2H4)(C2H4), 
H-7, 7’); 3.89 (s, 1H exchanging with the solvent, OCH3); 4.25 – 4.28 (m, 1H, H-5); 
4.30 – 4.31 (m, 1H, H-4); 4.92 (dt, 1H, J6,7 = 2.4, J5,6 = 9.0 Hz, H-6); 5.04 – 5.22 
(ddd, obscured by the HDO peak, J3,4 = 3.5, J3,F2 = 22.7 Hz, H-3). 13C NMR 
(100 MHz, CD3OD): δ 22.47 (NHC(O)CH3); 23.90 (N(C2H4)(C2H4)); 53.51 (d, J4,F3 
= 6.2 Hz, C-4); 55.55 (C-7); 67.83 (d, J6,F2 = 3.8 Hz, C-6); 67.92 (d, J5,F3 = 10.0 Hz, 
C-5); 85.47 (dd, J3,F2 = 23.0, J3,F3 = 191.7 Hz, C-3); 106.85 (dd, J2,F3 = 24.6, 
J2,F2 = 250.0 Hz, C-2); 165.90 (d, J1,F2 = 31.4 Hz, C-1); 173.90 (NHC(O)CH3). 
19F NMR (376 MHz, CD3OD): δ -136.63 (m, 1F, F-2); -214.15 (ddt, JF3,4 = 6.1, JF2,F3 
= 18.3, JF3,3 = 42.7 Hz, 1F, F-3). HRMS (ESI +ve) m/z 337.1565 [M+H]+ 
(C14H23N2F2O5 requires 337.1575); 359.1376 [M+Na]+ (C14H22N2F2O5Na requires 
359.1394). 
5-N-Acetamido-2,3,5,7-tetradeoxy-7-N-pyrrolidino-2,3-difluoro-β-L-manno-hept-2­
pyranosonic acid (145) 
A 0.5 M aqueous solution of sodium hydroxide (5 drops) was added to a solution of 
7-N-pyrrolidino-2,3-difluorosialic acid (148) (105 mg, 0.31 mmol) in water (2 mL) at 
4 ºC and the solution was left to warm to room temperature (1h). The solution was 
then neutralized (Dowex 50WX8, H+ form), filtered and the filtrate concentrated in 
vacuo to afford 7-N-pyrrolidino-2,3-difluorosialic acid (145) as a light brown solid 
(103 mg, quantitative). m.p. 30 ºC (hygroscopic). 1H NMR (400 MHz, CD3OD): 
δ 1.88 – 2.00 (m, 4H, N(C2H4)(C2H4)); 2.03 (s, 3H, NHC(O)CH3); 2.79 – 2.98 
(m, 6H, N(C2H4)(C2H4), H-7, H-7’); 4.17 – 4.19 (m, 1H, H-4); 4.26 – 4.30 (m, 1H, 
H-5); 4.70 – 4.73 (m, 1H, H-6); 4.82 – 5.00 (m, 1H, obscured by HDO peak, H-3). 
13C NMR (100 MHz, CD3OD): δ 22.56 (NHC(O)CH3); 24.06 (N(C2H4)(C2H4)); 
53.78 (d, J5,F3 = 5.4 Hz, C-5); 55.43 (N(C2H4)(C2H4)); 56.77 (C-7); 67.77 (C-6); 
68.39 (d, J4,F3 = 16.9 Hz, C-4); 86.97 (dd, J3,F2 = 26.1, J3,F3 = 198.2 Hz, C-3); 108.48 
(dd, J2,F3 = 25.4, J2,F2 = 245.4 Hz, C-2); 171.19 (d, J1,F2 = 26.9 Hz, C-1); 173.42 
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(NHC(O)CH3). 19F NMR (376 MHz, CD3OD): δ -135.74 (t, 1F, JF2,F3 = 21.4 Hz, 
F-2); 213.90 (ddt, 1F, JF3,4 = 4.5, JF3,3 = 42.7 Hz, F-3). [α ]20 = +57.1 (c 0.07, H2O). D 
HRMS (ESI -ve) m/z 321.1336 [M-H]- (C13H19N2F2O5 requires 321.1262). 
Methyl 2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-3-fluoro-5-N-trifluoroacetamido-D­
erythro-α-L-manno-non-2-ulopyranosonate (90) 
i) Methanesulfonic acid (3.1 mL, 47.8 mmol) was added to a solution of 3­
fluorosialic acid methyl ester (52) (3.1 g, 9.08 mmol) in methanol (31.0 mL) and the 
reaction mixture was stirred at reflux for 24h. After this time triethylamine was 
added until pH was neutral and the solution was used without further purification. 
ii) Triethylamine (3.1 mL, 22.2 mmol) was added, the solution was cooled to 4 °C 
and trifluoroacetic anhydride (2.53 mL, 18.2 mmol) was added and the reaction was 
stirred at this temperature for 1h. The solution was evaporated to dryness and the 
crude mixture used without further purification. 
iii) The crude mixture was dissolved in acetic anhydride (21.5 mL, 227 mmol), 
cooled to 4 °C and pyridine (75.0 mL) was slowly added. The reaction was stirred at 
room temperature for 24h. The solution was then concentrated in vacuo and residual 
pyridine removed by azeotropic evaporation with toluene to give a dark brown oil. 
The oil was subjected to a standard work up (EtOAc) and purified by flash 
chromatography (EtOAc:Pet Ether 9:1 → EtOAc) to give per-O-acetylated-5-N­
trifluoroacetamido-3-fluorosialic acid (90) as a white solid (1.08 g, 20% over 
3 steps). m. p. 75-81 °C. 1H NMR (400 MHz, CDCl3): δ 2.03, 2.05, 2.11, 2.16 
(4s, 15H, C(O)CH3); 3.84 (s, 3H, OCH3); 4.19 – 4.26 (m, 2H, H-5, H-9); 4.32 (dd, 
1H, J6,7 = 2.0, J5,6 = 10.6 Hz, H-6); 4.59 (br dd, 1H, J8,9’ = 2.4, J9,9’ = 12.5 Hz, H-9’); 
4.95 (br dd, 1H, J3,4 = 2.3, J3,F3 = 48.8 Hz, H-3); 5.08 – 5.11 (m, 1H, H-8); 5.32 (dd, 
1H, J7,8 = 5.1 Hz, H-7); 5.60 (ddd, 1H, J4,5 = 10.6, J4,F3 = 27.4 Hz, H-4); 6.90 (d, 1H, 
J5,NHTFA = 9.0 Hz, NH). 13C NMR (100 MHz, CDCl3): δ 20.34, 20.39, 20.62, 20.64, 
20.82 (C(O)CH3); 46.24 (C-5); 53.62 (OCH3); 61.89 (C-9); 67.56 (C-7); 67.77 
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(d, J4,F3 = 16.9 Hz, C-4); 70.94 (C-6); 71.31 (C-8); 86.71 (d, J3,F3 = 185.6 Hz, C-3); 
95.03 (d, J2,F3 = 28.4 Hz, C-2); 115.33 (q, JC,F = 288.3 Hz, NHC(O)CF3); 157.43 
(q, JC(O),F = 37.5 Hz, NHC(O)CF3); 164.72 (C-1); 167.00, 170.52, 170.56, 170.60, 
170.76 (C(O)CH3). 19F NMR (376 MHz, CDCl3): δ -76.27 (s, 3F, NHC(O)CF3); 
-209.06 (dd, 1F, JF3,4 = 27.4, JF3,3 = 48.8 Hz, F-3). HRMS (ESI +ve) m/z 628.1275 
[M+Na]+ (C22H27NF4O14Na requires 628.1265). 
Methyl 4,7,8,9-tetra-O-acetyl-3,5-dideoxy-3-fluoro-5-N-trifluoroacetamido-D­
erythro-α-L-manno-non-2-ulopyranosonate (91) 
A solution of hydrazine acetate (402 mg, 4.46 mmol) in methanol (10.0 mL) was 
added to a solution of per-O-acetylated-5-N-trifluoroacetamido-3-fluorosialic acid 
(90) (900 mg, 1.49 mmol) in dichloromethane (30.0 mL) at 4 ºC and the solution left 
to stand at this temperature (3h). The solution was then concentrated in vacuo, 
subjected to a standard work up (EtOAc) to afford the hemiketal (91) as a white solid 
(570 mg, 68%). m. p. 85-90 °C. 1H NMR (400 MHz, CDCl3): δ 2.03, 2.05, 2.11, 2.17 
(4s, 12H, C(O)CH3); 3.85 (OCH3); 4.11 – 4.15 (m, 1H, H-5); 4.47 – 4.51 (m, 2H, 
H-6, 9); 4.87 – 5.00 (m, 2H, H-3, H-9’); 5.25 – 5.38 (m, 3H, H-4, H-7, H-8); 5.92 (br 
s, 1H, OH); 7.74 (d, 1H, J5,NHTFA = 8.6 Hz, NH). 13C NMR (100 MHz, CDCl3): δ 
20.27, 20.55, 20.84, 20.88 (C(O)CH3); 45.35 (C-5); 53.46 (OCH3); 62.50 (C-9); 
68.41 (d, J4,F3 = 16.9 Hz, C-4); 68.84 (C-7); 71.38 (C-6); 72.67 (C-8); 86.41 
(d, J3,F3 = 187.1 Hz, C-3); 94.37 (d, J2,F3 = 25.3 Hz, C-2); 115.53 (q, JC,F = 287.6 Hz, 
NHC(O)CF3); 157.66 (q, JC(O),F = 37.6 Hz, NHC(O)CF3); 166.87 (C-1); 169.97, 
170.16, 171.93, 173.44 (C(O)CH3). 19F NMR (376 MHz, CDCl3): δ -76.16 (s, 3F, 
NHC(O)CF3); -205.34 (dd, 1F, JF3,4 = 27.5, JF3,3 = 48.9 Hz, F-3). HRMS (ESI +ve) 
m/z 586.1091 [M+Na]+ (C20H25NF4O13Na requires 586.1160). 
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Methyl 4,7,8,9-tetra-O-acetyl-2,3,5-trideoxy-2,3-difluoro-5-N-trifluoroacetamido-D­
erythro-β-L-manno-non-2-ulopyranosonate (92) 
(Diethylamino)sulphur trifluoride (0.2 mL, 1.49 mmol) was added drop-wise to a 
solution of hemiketal (91) (560 mg, 0.99 mmol) in dichloromethane (18.0 mL) at -30 
ºC and the solution held at this temperature (30 min). The solution was quenched by 
the addition of methanol (0.5 mL) and then subjected to a standard work up (DCM) 
and the residue purified by flash chromatography (EtOAc:Pet Ether 4:6 → 
EtOAc:Pet Ether 7:3) to give the per-O-acetylated-5-N-trifluoroacetamido-2,3­
difluorosialic acid (92) as an white solid (270 mg, 48%). m. p. 137 – 141 °C. 1H 
NMR (400 MHz, CDCl3): δ 2.03, 2.10, 2.11, 2,16 (4s, 12H, C(O)CH3); 3.90 (s, 3H, 
OCH3); 4.17 – 4.25 (m, 2H, H-5, H-9); 4.35 – 4.42 (m, 2H, H-6, H-9’); 5.11 (br dt, 
1H, J3,4 = 2.3, J3,F3 = 52.7 Hz, H-3); 5.26 (d, 1H, J7,8 = 7.4 Hz, H-7); 5.32 – 5.35 (m, 
1H, H-8); 5.52 (dd, 1H, J4,5 = 10.9, J4,F3 = 26.2 Hz, H-4); 6.95 (d, 1H, J5,NHTFA = 9.0 
Hz, NH). 13C NMR (100 MHz, CDCl3): δ 20.32, 20.53, 20.58, 20.82 (C(O)CH3); 
45.81 (d, J5,F3 = 3.8 Hz, C-5); 53.88 (OCH3); 61.70 (C-9); 66.87 (C-7); 68.22 (d, J4,F2 
= 6.1, J4,F3 = 17.6 Hz, C-4); 69.25 (C-8); 71.50 (d, J6,F2 = 4.6 Hz, C-6); 85.29 
(dd, J3,F2 = 19.2, J3,F3 = 195.6 Hz, C-3); 104.45 (dd, J2,F3 = 17.7, J2,F2 = 227.8 Hz, 
C-2); 115.32 (q, JC,F = 288.3 Hz, NHC(O)CF3); 157.45 (q, JC(O),F = 38.3 Hz, 
NHC(O)CF3); 164.23 (dd, J1,F3 = 4.6, J1,F2 = 29.9 Hz, C-1); 170.17, 170.43, 170.52, 
170.63 (C(O)CH3). 19F NMR (376 MHz, CDCl3): δ -76.29 (s, 3F, NHC(O)CF3); 
-123.85 (d, 1F, JF2,3 = 12.2 Hz, F-2); -216.97 (ddd, 1F, JF3,4 = 26.0, JF3,3 = 51.9 Hz, 
F-3). HRMS (ESI +ve) m/z 588.1115 [M+Na]+ (C20H24NF5O12Na requires 
588.1116). 
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Methyl 2,3,5-trideoxy-2,3-difluoro-5-N-trifluoroacetamido-D-erythro-β-L-manno­
non-2-ulopyranosonate (93) 
A 0.5 M solution of sodium methoxide in methanol (0.05 mL) was added to a 
solution of the per-O-acetylated-5-N-trifluoroacetamido-2,3-difluorosialic acid (92) 
(208 mg, 0.37 mmol) in methanol (5.0 mL) at 4 ºC and the solution was left to warm 
to room temperature overnight. The solution was then neutralized (Dowex 50WX8, 
H+ form), filtered and the filtrate concentrated in vacuo to afford the 
5-N-trifluoroacetamido-2,3-difluorosialic acid (93) as a light yellow solid (88.8 mg, 
54%). m.p. 30 ºC (hygroscopic) 1H NMR (400 MHz, CD3OD): δ 3.63 (dd, 1H, 
J8,9 = 5.9, J9,9’ = 12.1 Hz, H-9); 3.76 – 3.87 (m, 2H, H-8, H-9’); 3.88 (OCH3); 4.01 
(d, 1H, J5,6 = 10.5 Hz, H-6); 4.14 (br dd, 1H, J4,5 = 11.0, J4,F3 = 28.5 Hz, H-4); 
4.38 - 4.44 (m, 1H, H-5); 5.08 (br dt, 1H, J3,4 = 2.4, J3,F2 = 4.7, J3,F3 = 51.2 Hz, H-3). 
13C NMR (100 MHz, CD3OD): δ 48.07 (C-5); 52.50 (OCH3); 63.37 (C-9); 68.13 
(dd, J4,F2 = 5.3, J4,F3 = 18.4 Hz, C-4); 68.13 (C-7); 70.07 (C-8); 72.60 (d, J6,F2 = 4.6 
Hz, C-6); 87.91 (dd, J3,F2 = 17.7, J3,F3 = 187.9 Hz, C-3); 106.80 (dd, J2,F3 = 17.0, 
J2,F2 = 220.80 Hz, C-2); 117.43 (dd, JC,F = 287.5 Hz, NHC(O)CF3); 159.74 
(q, JC(O),F = 36.8 Hz, NHC(O)CF3); 165.32 (d, J1,F2 = 30.0 Hz, C-1). 19F NMR (376 
MHz, CD3OD): δ -77.15 (s, 3F, NHC(O)CF3); -123.97 (d, 1F, JF2,F3 = 12.2 Hz, F-2); 
-221.54 to -221.30 (m, 1F, F-3). HRMS (ESI +ve) m/z 398.0881 [M+H]+ 
(C14H19NF5O9 requires 398.0874); 420.0696 [M+Na]+ (C14H18NF5O9Na requires 
420.0694). 
2,3,5-Trideoxy-2,3-difluoro-5-N-trifluoroacetamido-D-erythro-β-L-manno-non-2­
ulopyranosonic acid (94) 
A 0.5 M aqueous sodium hydroxide solution (4 drops) was added to a solution of 
5-N-trifluoroacetamido-2,3-difluorosialic acid (93) (71.2 mg, 0.16 mmol) in water 
(1.0 mL) at 4 ºC and the solution left to warm to room temperature (1h). The solution 
184 
Chapter 11

was then neutralized (Dowex 50WX8, H+ form), filtered and the filtrate concentrated 
in vacuo to afford 5-N-trifluoroacetamido-2,3-difluorosialic acid (94) as a white solid 
(66.0 mg, quantitative). m.p. 30 ºC (hygroscopic). 1H NMR (400 MHz, CD3OD): 
δ 3.51 (t, 1H, J4,5 = 10.6 Hz, H-5); 3.70 – 3.76 (m, 2H, H-7, 9); 3.83 (dd, 1H, 
J8,9’ = 2.7, J9,9’ = 11.3 Hz, H-9’); 3.88 - 3.92 (m, 1H, H-8); 3.98 (d, 1H, J5,6 = 10.5 
Hz, H-6); 4.12 (br dd, J4,F3 = 27.4 Hz, H-4); 5.16 (d, 1H, J3,F3 = 52.4 Hz, H-3). 
13C NMR (100 MHz, CD3OD): δ 49.29 (C-5); 64.05 (C-9); 69.28 (C-7); 69.58 
(dd, J4,F2 = 6.1, J4,F3 = 18.4 Hz, C-4), 72.94 (C-8); 73.08 (d, J6,F2 = 5.4 Hz, C-6); 
90.19 (dd, J3,F2 = 18.4, J3,F3 = 187.1 Hz, C-3); 107.97 (dd, J2,F3 = 14.6, J2,F2 = 222.4 
Hz, C-2); 122.97 (q, JC,F = 212.4 Hz, NHC(O)CF3); 170.01 (d, J1,F2 = 25.3 Hz, C-1). 
19F NMR (376 MHz, CD3OD): δ -76.98 (s, 3F, NHC(O)CF3); -124.95 (d, 1F, 
JF2,F3 = 10.7 Hz, F-2); -221.26 (ddd, 1F, JF3,4 = 27.5, JF3,3 = 51.9 Hz, F-3). 
[ ]20 α D = +8.7 (c 0.05, H2O). HRMS (ESI -ve) m/z 286.0732 [M-TFA-H]­
(C9H14NF2O7 requires 286.0738). 
Methyl 5-N-acetamido-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-D-erythro-β-L-manno­
non-2-ulopyranosonate (101) 
Trifluoroacetic acid (10.0 mL, 129 mmol) was added to a solution of sialic acid (4) 
(10.0 g, 32.3 mmol) in methanol (500 mL) at 4 °C and the mixture was left to warm 
to room temperature overnight. The solution was then concentrated in vacuo to give 
a white solid (11.5 g). Acetic anhydride (55.6 mL, 588 mmol) was slowly added to a 
solution of the crude mixture (9.5 g, 29.4 mmol) in pyridine (258 mL) at 4 °C and the 
solution left to warm to room temperature (4 days). The solution was then 
concentrated in vacuo and residual pyridine removed by azeotropic evaporation with 
toluene to give a yellow oil. The oil was subjected to a standard work up (EtOAc) 
and purified by flash chromatography (EtOAc:Pet Ether 8:2 → EtOAc) to give the 
per-O-acetylated sialic acid (101) as a white solid (14.0 g, 81%). 1H NMR 
(270 MHz, CDCl3): δ 1.88 (s, 3H, NHC(O)CH3); 2.02, 2.04, 2.13, 2.13 (4s, 15H, 
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C(O)CH3); 2.07 – 2.08 (m, 1H, H-3); 2.53 (br dd, 1H, J3’,4 = 5.0, J3’,3 = 13.5 Hz, 
H-3’); 3.77 (s, 3H, OCH3); 4.05 – 4.15 (m, 3H, H-5, H-6, H-9); 4.47 (br dd, 1H, J8,9’ 
= 2.8, J9,9’ = 12.7 Hz, H-9’); 5.05 (ddd, 1H, J8,9 = 6.9 Hz, H-8); 5.18 – 5.26 (m, 1H, 
H-4); 5.36 (dd, 1H, J7,8 = 5.2 Hz, H-7). Spectroscopic data are analogous to those 
reported in the literature.226 
Methyl 5-N-acetamido-4,7,8,9-tetra-O-acetyl-2,3,5-trideoxy-D-glycero-D-galacto­
non-2-enopyranosonate (100) 
Trimethylsilyl trifluoromethanesulfonate (1.0 mL, 5.6 mmol) was added drop-wise to 
a solution of the per-O-acetylated sialic acid (101) (3.0 g, 5.6 mmol) in dry 
acetonitrile (100 mL) at 4 ºC, and the solution left to warm to room temperature 
overnight. The temperature was then lowered to 4 ºC and potassium carbonate (1.2 g, 
8.4 mmol) was added. The mixture was left at this temperature for 5 min, filtered, the 
filtrate evaporated in vacuo and the residue purified by flash chromatography 
(EtOAc:Hexane 9:1 → EtOAc) to afford the per-O-acetylated-Neu5Ac2ene (100) as 
a white solid (2.0 g, 75%). 1H NMR (400 MHz, CDCl3): δ 1.91 (s, 3H, 
NHC(O)CH3); 2.03, 2.04, 2.06, 2.10 (4s, 12H, C(O)CH3); 3.78 (s, 3H, OCH3); 4.17 
(dd, 1H, J8,9 = 7.0, J9,9’ = 12.5 Hz, H-9); 4.34 - 4.42 (m, 2H, H-5, H-6); 4.59 (dd, 1H, 
J8,9’ = 3.1 Hz, H-9’); 5.32 – 5.35 (m, 1H, H-8); 5.45 – 5.50 (m, 2H, H-4, H-7); 5.68 
(d, 1H, J5,NHAc = 8.6 Hz, NH); 5.97 (d, 1H, J3,4 = 3.1 Hz, H-3). 13C NMR (100 MHz, 
CDCl3): δ 20.71, 20.84 (C(O)CH3); 23.15 (NHC(O)CH3); 46.52 (C-5); 52.58 
(OCH3); 61.85 (C-9); 67.55 (C-4); 67.71 (C-7); 70.53 (C-8); 76.54 (C-6); 107.82 
(C-3); 144.99 (C-2); 161.57 (C-1); 170.02, 170.06, 170.13, 170.57 (C(O)CH3); 
170.72 (NHC(O)CH3). Spectroscopic data are analogous to those reported in the 
literature.227 
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Methyl 7,8,9-tri-O-acetyl-2,3-didehydro-2,3,5-trideoxy-4',5'-dihydro-2'­
methyloxazolo[5,4d]-D-glycero-D-talo-non-2-ulopyranosidonate (99) 
Trimethylsilyl trifluoromethanesulfonate (1.05 mL, 5.62 mmol) was added to a 
solution of per-O-acetylated-Neu5Ac2ene (100) (1.0 g, 1.87 mmol) in acetonitrile 
(20.0 mL) at 4 °C and the solution was heated to 50 °C overnight. The solution was 
then cooled to 4 °C and potassium carbonate (1.55 g, 11.3 mmol) was added and 
stirred for 5 min. The mixture was filtered over Celite® and the filtrate evaporated to 
dryness. The crude mixture was purified by flash chromatography (EtOAc:Pet Ether 
6:4 → EtOAc:Pet Ether 9:1) affording the oxazoline (99) as a light yellow solid 
(587 mg, 76%). 1H NMR (400 MHz, CDCl3): δ 2.01, 2.05, 2.06 (3s, 9H, C(O)CH3); 
2.15 (s, 3H, CCH3); 3.43 (dd, 1H, J6,7 = 2.7, J5,6 = 9.8 Hz, H-6); 3.81 (s, 3H, OCH3); 
3.95 (t, 1H, H-5); 4.23 (dd, 1H, J8,9 = 6.3, J9,9’ = 12.5 Hz, H-9); 4.60 (br dd, 1H, 
J8,9’ = 2.7 Hz, H-9’); 4.82 (dd, 1H, J3,4 = 4.0, J4,5 = 8.5 Hz, H-4); 5.44 (dt, 1H, 
J7,8 = 6.3 Hz, H-8); 5.63 (dd, 1H, H-7); 6.38 (d, 1H, H-3). 13C NMR (100 MHz, 
CDCl3): δ 14.18 (CCH3); 20.65, 20.81, 20.88 (C(O)CH3); 52.57 (OCH3); 62.02 
(C-9); 62.10 (C-5); 68.89 (C-7); 70.32 (C-8); 72.27 (C-4); 76.78 (C-6); 107.59 (C-3); 
147.19 (C-2); 161.90 (C-1); 167.20 (CCH3); 169.60, 169.83, 170.68 (C(O)CH3). 
HRMS (ESI +ve) m/z 414.1396 [M+H]+ (C18H24NO10 requires 414.1400). 
Spectroscopic data are analogous to those reported in the literature.156 
Methyl 5-N-acetamido-7,8,9-tri-O-acetyl-2,3-didehydro-2,3,4,5-tetradeoxy-4-N,N­
diethylamino-D-glycero-D-talo-non-2-ulopyranosidonate (119) 
Triethylphosphine (0.12 mL, 20 mol%) was added to palladium allyl chloride dimer 
(11.0 mg, 5 mol%) in deoxygenated dichloromethane (1.5 mL) and the mixture was 
stirred at room temperature for 30 min. The diethylamine (0.05 mL, 0.73 mmol) and 
the catalyst solution were then added to a solution of the oxazoline (99) (250 mg, 
0.61 mmol) in dichloromethane (1.5 mL) and the solution was stirred for a further 
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2h. The solution was then filtered over Celite® and the filtrate washed with EtOAc. 
The volume of the solution was reduced in vacuo and applied to a flash column 
(EtOAc → EtOAc:MeOH 8:2) to afford the per-O-acetylated-4-epi-N,N­
diethylamino Neu5Ac2ene (119) as a pale yellow solid (143 mg, 48%). 1H NMR 
(400 MHz, CD3OD): δ 1.04 (t, 6H, J = 7.4 Hz, N(CH2CH3)2); 1.94 (s, 3H, 
NHC(O)CH3); 2.03, 2.03, 2.06 (3s, 9H, C(O)CH3); 2.70 (q, 4H, N(CH2CH3)2); 3.51 – 
3.54 (m, 1H, H-4); 3.78 (s, 3H, OCH3); 4.16 – 4.20 (m, 3H, H-5, H-6, H-9); 4.60 
(br dd, 1H, J8,9’ = 2.9, J9,9’ = 12.4 Hz, H-9’); 5.34 (ddd, 1H, J8,9 = 6.5, J7,8 = 12.1 Hz, 
H-8); 5.46 (dd, 1H, J6,7 = 2.9 Hz, H-7); 6.11 (d, 1H, J3,4 = 5.2 Hz, H-3). 13C NMR 
(100 MHz, CD3OD): δ 13.68 (N(CH2CH3)2); 20.64, 20.70, 20.73 (C(O)CH3); 22.73 
(NHC(O)CH3); 46.96 (N(CH2CH3)2); 47.82 (C-5); 52.76 (OCH3); 54.65 (C-4); 63.20 
(C-9); 69.63 (C-7); 71.79 (C-8); 75.16 (C-6); 110.85 (C-3); 145.14 (C-2); 163.66 
(C-1); 171.58, 171.63, 172.42 (C(O)CH3); 173.06 (NHC(O)CH3). HRMS (ESI +ve) 
m/z 487.2285 [M+H]+ (C22H35N2O10 requires 487.2292); 509.2107 [M+Na]+ 
(C22H34N2O10Na requires 509.2111). Spectroscopic data are analogous to those 
reported in the literature.159 
Methyl 5-N-acetamido-2,3-didehydro-2,3,4,5-tetradeoxy-4-N,N-diethylamino-D­
glycero-D-talo-non-2-ulopyranosidonate (125) 
A 0.5 M solution of sodium methoxide in methanol (0.05 mL) was added to a 
solution of the per-O-acetylated-4-epi-N-diethylamino Neu5Ac2ene (119) (193 mg, 
0.4 mmol) in methanol (5.0 mL) at 4 ºC and the solution was stirred for 2h at room 
temperature. The solution was then neutralized (Dowex 50WX8, H+ form), filtered 
and the filtrate concentrated in vacuo. Flash chromatography (EtOAc → 
EtOAc:MeOH 9:1) afford the 4-epi-N,N-diethylamino Neu5Ac2ene (125) as a light 
yellow solid (111 mg, 78%). m.p. 30 ºC (hygroscopic). 1H NMR (400 MHz, 
CD3OD): δ 1.07 (t, 6H, J = 7.0 Hz, N(CH2CH3)2); 2.05 (s, 3H, NHC(O)CH3); 
2.66 - 2.77 (m, 4H, N(CH2CH3)2); 3.53 (dd, 1H, J6,7 = 1.2, J7,8 = 9.4 Hz, H-7); 3.60 
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(t, 1H, J4,5 = 5.4 Hz, H-4); 3.65 (dd, 1H, J8,9 = 5.5, J9,9’ = 11.8 Hz, H-9); 3.79 (s, 3H, 
OCH3); 3.82 (dd, 1H, J8,9’ = 2.7 Hz, H-9’); 3.88 – 3.92 (m, 1H, H-8); 4.07 (d, 1H, 
J5,6 = 10.5 Hz, H-6); 4.14 (dd, 1H, H-5); 6.10 (d, 1H, J3,4 = 5.5 Hz, H-3). 13C NMR 
(100 MHz, CD3OD): δ 12.40 (N(CH2CH3)2); 21.41 (NHC(O)CH3); 45.83 
(N(CH2CH3)2); 46.63 (C-5); 51.34 (OCH3); 53.34 (C-4); 63.56 (C-9); 69.06 (C-7); 
69.87 (C-8); 73.92 (C-6); 108.13 (C-3); 144.85 (C-2); 162.92 (C-1); 172.70 
(NHC(O)CH3). HRMS (ESI +ve) m/z 361.1993 [M+H]+ (C16H29N2O7 requires 
361.1975); 383.1814 [M+Na]+ (C16H28N2O7Na requires 383.1794). 
5-N-Acetamido-2,3-didehydro-2,3,4,5-tetradeoxy-4-N,N-diethylamino-D-glycero-D­
talo-non-2-ulopyranosonic acid (44) 
A 0.5 M aqueous solution of sodium hydroxide (2 drops) was added to a solution of 
4-epi-N,N-diethylamino Neu5Ac2ene (125) (96.0 mg, 0.27 mmol) in water (2 mL) at 
4 ºC and the solution left to warm to room temperature (2h). The solution was then 
neutralized (Dowex 50WX8, H+ form), filtered and the filtrate concentrated in vacuo 
to afford 4-epi-N,N-diethylamino Neu5Ac2ene (44) as a white solid (93 mg, 
quantitative). m.p. 141 – 143 ºC. 1H NMR (400 MHz, CD3OD): δ 1.34 (t, 6H, 
J = 7.4 Hz, N(CH2CH3)2); 2.07 (s, 3H, NHC(O)CH3); 3.33 – 3.44 (m, 4H, 
N(CH2CH3)2); 3.61 – 3.74 (m, 3H, H-7, H-8, H-9); 3.78 (dd, 1H, J8,9’ = 2.8, J9,9’ = 
11.0 Hz, H-9’); 4.44 (t, 1H, J6,7 = 3.9 Hz, H-6); 4.58 (q, 1H, J3,4 = 2.7, J4,5 = 4.6 Hz, 
H-4); 4.93 (t, 1H, H-5); 5.92 (br s, 1H, H-3). 13C NMR (100 MHz, CD3OD): δ 8.24 
(N(CH2CH3)2); 21.41 (NHC(O)CH3); 43.81 (C-5); 45.50 (N(CH2CH3)2); 55.18 
(C-4); 63.26 (C-9); 70.74 (C-7); 70.81 (C-8); 79.44 (C-6); 96.43 (C-3); 149.55 (C-2); 
164.75 (C-1); 173.03 (NHC(O)CH3). [α ]20 = -62.7 (c 0.05, H2O). HRMS (ESI -ve) D 
m/z 345.1711 [M-H]- (C15H25N2O7 requires 345.1662). 
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Methyl 5-N-acetamido-7,8,9-tri-O-acetyl-2,3-didehydro-2,3,4,5-tetradeoxy-4-N­
methylamino-D-glycero-D-talo-non-2-ulopyranosidonate (117) 
Triethylphosphine (0.12 mL, 20 mol%) was added to the palladium allyl chloride 
dimer (11.0 mg, 5 mol%) in deoxygenated dichloromethane (1.5 mL) and the 
mixture was stirred at room temperature (30 min). A solution of methylamine in 
tetrahydrofuran (0.37 mL, 2.0 M) and the catalyst solution were then added to a 
solution of oxazoline (99) (250 mg, 0.61 mmol) in dichloromethane (1.5 mL) and the 
solution was stirred for further 2h. The solution was then filtered over Celite® and the 
filtrate washed with EtOAc. The volume of the solution was reduced in vacuo and 
applied to a flash column (EtOAc:Et3N 1:0.05 → EtOAc:MeOH:Et3N 9:1:0.05) to 
afford per-O-acetylated-4-epi-N-methylamino Neu5Ac2ene (117) as a pale yellow 
solid (126 mg, 46%). m.p. 35 – 40 ºC. 1H NMR (400 MHz, CD3OD): δ 1.94 (s, 3H, 
NHC(O)CH3); 2.03, 2.04, 2.06 (3s, 9H, C(O)CH3); 2.45 (s, 3H, NHCH3); 3.22 (t, 1H, 
J4,5 = 4.9 Hz, H-4); 3.77 (s, 3H, OCH3); 4.18 (dd, 1H, J8,9 = 6.5, J9,9’ = 12.6 Hz, H-9); 
4.24 (dd, 1H, J5,6 = 9.7 Hz, H-5); 4.30 (dd, 1H, J6,7 = 2.9 Hz, H-6); 4.57 (dd, 1H, 
J8,9’ = 2.9 Hz, H-9’); 5.35 (ddd, 1H, J7,8 = 6.5 Hz, H-8); 5.47 (dd, 1H, H-7); 6.17 
(d, 1H, J3,4 = 5.2 Hz, H-3). 13C NMR (100 MHz, CD3OD): δ 20.65, 20.70, 20.75 
(C(O)CH3); 22.71 (NHC(O)CH3); 35.35 (NHCH3); 47.46 (C-5); 52.75 (OCH3); 
53.45 (C-4); 63.17 (C-9); 69.49 (C-7); 71.60 (C-8); 74.45 (C-6); 110.77 (C-3); 
144.67 (C-2); 163.87 (C-1); 171.58, 172.40 (C(O)CH3); 173.37 (NHC(O)CH3). 
HRMS (ESI +ve) m/z 445.1803 [M+H]+ (C19H29N2O10 requires 445.1822); 467.1619 
[M+Na]+ (C19H28N2O10Na requires 467.1642). Spectroscopic data are analogous to 
those reported in the literature.159 
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Methyl 5-N-acetamido-7,8,9-tri-O-acetyl-2,3-didehydro-2,3,4,5-tetradeoxy-4-(N­
methyl-N-4-methylbenzenesulfonamide)-D-glycero-D-talo-non-2-ulopyranosidonate 
(120) 
Triethylamine (0.06 mL, 0.43 mmol) and p-toluenesulfonyl chloride (81.7 mg, 0.43 
mmol) were added to a solution of per-O-acetylated-4-epi-N-methylamino 
Neu5Ac2ene (117) (127 mg, 0.29 mmol) in dichloromethane (2 mL) at room 
temperature and stirred overnight. The solution was then subject to a standard work 
up (DCM) and the residue purified by flash chromatography (EtOAc:Pet Ether 9:1 
→ EtOAc:MeOH:Et3N 7:3:0.5) to afford the tosyl protected compound (120) as a 
light yellow solid (64.2 mg, 38%). 1H NMR (400 MHz, CDCl3): δ 2.01 (s, 3H, 
NHC(O)CH3); 2.04, 2.06, 2.10 (3s, 9H, C(O)CH3); 2.44 (s, 3H, CH3NSO2PhCH3); 
2.76 (s, 3H, CH3NSO2PhCH3); 3.76 (s, 3H, OCH3); 4.12 (dd, 1H, J8,9 = 7.4, 
J9,9’ = 12.2 Hz, H-9); 4.17 (br dd, 1H, J6,7 = 2.2, J5,6 = 11.3 Hz, H-6); 4.47 – 4.53 
(m, 2H, H-4, H-5); 4.74 (dd, 1H, J8,9’ = 2.6 Hz, H-9’); 5.28 – 5.32 (m, 1H, H-8); 5.43 
(d, 1H, J3,4 = 5.2 Hz, H-3); 4.97 (dd, 1H, J7,8 = 4.3 Hz, H-7); 5.87 (d, 1H, 
J5,NHAc = 9.6 Hz, NH); 7.33 (d, 2H, J = 8.3 Hz, CH Ph); 7.65 (d, 2H, J = 8.3 Hz, CH 
Ph). 13C NMR (100 MHz, CDCl3): δ 20.63, 20.72, 20.85 (C(O)CH3); 21.51 
(CH3NSO2PhCH3); 23.24 (NHC(O)CH3); 34.67 (CH3NSO2PhCH3); 45.39 (C-4); 
51.10 (C-5); 52.56 (OCH3); 62.18 (C-9); 67.98 (C-7); 71.53 (C-8); 74.06 (C-6); 
104.81 (C-3); 127.18 (C Ph); 130.06 (C Ph); 134.80 (Cq Ph); 144.21 (Cq Ph); 146.49 
(C-2); 161.55 (C-1); 169.84, 170.32, 170.54 (C(O)CH3); 170.90 (NHC(O)CH3). 
HRMS (ESI +ve) m/z 599.1904 [M+H]+ (C26H35N2O12S requires 599.1911); 
621.1709 [M+Na]+ (C26H34N2O12SNa requires 621.1730). Spectroscopic data are 
analogous to those reported in the literature.159 
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Methyl 5-N-acetamido-2,3-didehydro-2,3,4,5-tetradeoxy-4-N-methylamino-D­
glycero-D-talo-2-nonulopyranosidonate (123) 
A 0.5 M solution of sodium methoxide in methanol (0.04 mL) was added to a 
solution of the per-O-acetylated-4-epi-N-methylamino Neu5Ac2ene (117) (74.5 mg, 
0.17 mmol) in methanol (2.2 mL) at 4 ºC and the solution allowed to warm to room 
temperature (2h). The solution was then neutralized (Dowex 50WX8, H+ form), 
filtered and the filtrate concentrated in vacuo. Flash chromatography (EtOAc → 
EtOAc:MeOH 8:2) afforded the 4-epi-N-methylamino Neu5Ac2ene (123) as a light 
yellow solid (45.0 mg, 83%). m.p. 30 ºC (hygroscopic). 1H NMR (400 MHz, 
CD3OD): δ 2.03 (s, 3H, NHC(O)CH3); 2.48 (s, 3H, NHCH3); 3.33 (t, 1H, J4,5 = 4.7 
Hz, H-4); 3.60 (d, 1H, J7,8 = 7.8 Hz, H-7); 3.65 (dd, 1H, J8,9 = 5.5, J9,9’ = 11.3 Hz, 
H-9); 3.78 (s, 3H, OCH3); 3.80 – 3.90 (m, 2H, H-8, H-9’); 4.17 (dd, 1H, J6,7 = 1.2, 
J5,6 = 9.0 Hz, H-6); 4.28 (dd, 1H, H-5); 6.19 (d, 1H, J3,4 = 5.1 Hz, H-3). 13C NMR 
(100 MHz, CD3OD): δ 21.28 (NHC(O)CH3); 33.51 (NHCH3); 46.55 (C-5); 51.34 
(OCH3); 51.71 (C-4); 63.49 (C-9); 69.37 (C-7); 70.19 (C-8); 74.17 (C-6); 108.90 
(C-3); 143.62 (C-2); 163.24 (C-1); 172.67 (NHC(O)CH3). HRMS (ESI +ve) m/z 
319.1497 [M+H]+ (C13H23N2O7 requires 319.1505); 341.1319 [M+Na]+ 
(C13H22N2O7Na requires 341.1325). 
5-N-Acetamido-2,3-didehydro-2,3,4,5-tetradeoxy-4-N-methylamino-D-glycero-D­
talo-2-nonulopyranosonic acid (42) 
A 0.5 M aqueous solution of sodium hydroxide (1 drop) was added to a solution of 
4-epi-N-methylamino Neu5Ac2ene (123) (14.6 mg, 0.05 mmol) in water (0.5 mL) at 
4 ºC and the solution left to warm to room temperature (2h). The solution was then 
neutralized (Dowex 50WX8, H+ form), filtered and the filtrate concentrated in vacuo 
to afford 4-epi-N-methylamino Neu5Ac2ene (42) as a white solid (20 mg, 
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quantitative). m.p. 30 ºC (hygroscopic). 1H NMR (500 MHz, D2O): δ 2.00 (s, 3H, 
NHC(O)CH3); 2.34 (s, 3H, NHCH3); 3.38 – 3.40 (m, 1H, H-4); 3.58 – 3.89 (m, 4H, 
H-7, H-8, H-9, H-9’); 4.23 (dd, 1H, J6,7 = 2.0, J5,6 = 8.5 Hz, H-6); 4.31 (dd, 1H, J4,5 = 
4.5 Hz, H-5); 5.81 (d, 1H, J3,4 = 4.5 Hz, H-3). 13C NMR (125 MHz, D2O): δ 21.68 
(NHC(O)CH3); 32.58 (NHCH3); 46.23 (C-5); 50.96 (C-4); 62.85 (C-9); 68.94 (C-7); 
70.04 (C-8); 73.04 (C-6); 104.06 (C-3); 146.02 (C-2); 165.04 (C-1); 173.07 
(NHC(O)CH3). [α ]20 = +22.2 (c 0.03, H2O). HRMS (ESI -ve) m/z 303.1199 [M-H]­D 
(C12H19N2O7 requires 303.1192). 
Methyl 5-N-acetamido-7,8,9-tri-O-acetyl-2,3-didehydro-2,3,4,5-tetradeoxy-4-N­
ethylamino-D-glycero-D-talo-non-2-ulopyranosidonate (118) 
Triethylphosphine (0.24 mL, 20 mol%) was added to the palladium allyl chloride 
dimer (22.0 mg, 5 mol%) in deoxygenated dichloromethane (3 mL) and the mixture 
was stirred at room temperature (30 min). A solution of ethylamine in 
tetrahydrofuran (1.45 mL, 2.0 M) and the catalyst solution were then added to a 
solution of oxazoline (99) (500 mg, 1.21 mmol) in dichloromethane (3 mL) and the 
solution was stirred for further 2h. The solution was then filtered over Celite® and 
this was washed with EtOAc. The volume of the solution was reduced in vacuo and 
applied to a flash column (EtOAc → EtOAc:MeOH:Et3N 9:1:0.5) to afford per-O­
acetylated-4-epi-N-ethylamino Neu5Ac2ene (118) as an off white solid (356 mg, 
64%). 1H NMR (400 MHz, CD3OD): δ 1.12 (t, 3H, J = 7.3 Hz, NHCH2CH3); 1.94 
(s, 3H, NHC(O)CH3); 2.03, 2.04, 2.06 (3s, 9H, C(O)CH3); 2.66–2.82 (m, 2H, 
NHCH2CH3); 3.30–3.34 (m, 1H, H-4); 3.77 (s, 3H, OCH3); 4.18 (br dd, 1H, 
J8,9 = 6.6, J9,9’ = 12.2 Hz, H-9); 4.22 (dd, 1H, J4,5 = 4.8, J5,6 = 9.8 Hz, H-5); 4.29 
(dd, 1H, J6,7 = 3.1 Hz, H-6); 4.59 (br dd, 1H, J8,9’ = 3.1, H-9’); 5.35 (ddd, 1H, 
J7,8 = 6.3 Hz, H-8); 5.47 (dd, 1H, H-7); 6.16 (d, 1H, J3,4 = 5.2 Hz, H-3). 13C NMR 
(100 MHz, CD3OD): δ 15.33 (NHCH2CH3); 20.65, 20.73, 20.76, (C(O)CH3); 22.73 
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(NHC(O)CH3); 44.00 (NHCH2CH3); 47.42 (C-5); 51.59 (C-4); 52.76 (OCH3); 63.20 
(C-9); 69.52 (C-7); 71.70 (C-8); 74.57 (C-6); 111.08 (C-3); 144.64 (C-2); 163.87 
(C-1); 171.58, 171.61, 172.39 (C(O)CH3); 173.29 (NHC(O)CH3). HRMS (ESI +ve) 
m/z 459.1960 [M+H]+ (C20H31N2O10 requires 459.1979); 481.1790 [M+Na]+ 
(C20H30N2O10Na requires 481.1798). Spectroscopic data are analogous to those 
reported in the literature.159 
Methyl 5-N-acetamido-7,8,9-tri-O-acetyl-2,3-didehydro-2,3,4,5-tetradeoxy-4-(N­
ethyl-N-4-methylbenzenesulfonamide)-D-glycero-D-talo-non-2-ulopyranosidonate 
(121) 
Triethylamine (0.08 mL, 0.64 mmol) and p-toluenesulfonyl chloride (122 mg, 0.64 
mmol) were added to a solution of per-O-acetylated-4-epi-N-ethylamino 
Neu5Ac2ene (118) (195mg, 0.42 mmol) in dichloromethane (2 mL) at room 
temperature and stirred overnight. The solution was then subject to a standard work 
up (DCM) and the residue purified by flash chromatography (EtOAc:Pet Ether 9:1 
→ EtOAc:MeOH:Et3N 7:3:0.5) to give the tosyl protected compound (121) as an off 
white solid (76.1 mg, 29%). 1H NMR (400 MHz, CDCl3): δ 1.18 (t, 3H, J = 7.1 Hz, 
CH3CH2NSO2PhCH3); 2.02 (s, 3H, NHC(O)CH3); 2.05, 2.06, 2.09 (3s, 9H, 
C(O)CH3); 2.43 (s, 3H, CH3CH2NSO2PhCH3); 3.21 – 3.28 (m, 2H, 
CH3CH2NSO2PhCH3); 3.76 (s, 3H, OCH3); 4.15 (br dd, 1H, J8,9 = 7.1, J9,9’ = 12.3 
Hz, H-9); 4.28 (br dd, 1H, J6,7 = 2.4, J5,6 = 10.4 Hz, H-6); 4.34 (t, 1H, J3,4 = 5.2 Hz, 
H-4); 4.50 – 4.57 (m, 1H, H-5); 4.64 (dd, 1H, J8,9’ = 2.8 Hz, H-9’); 5.31 – 5.35 
(m, 1H, H-8); 5.45 – 5.47 (m, 1H, H-7); 5.51 (d, 1H, H-3); 5.88 (d, 1H, J5,NHAc = 9.9 
Hz, NH); 7.30 (d, 2H, J = 8.0 Hz, CH Ph); 7.66 (d, 2H, J = 8.0 Hz, CH Ph). 13C 
NMR (100 MHz, CDCl3): δ 15.94 (CH3CH2NSO2PhCH3); 20.64, 20.75, 20.82 
(C(O)CH3); 21.51 (CH3CH2NSO2PhCH3); 23.30 (NHC(O)CH3); 43.48 
(CH3CH2NSO2PhCH3); 45.31 (C-5); 52.53 (C-4); 52.54 (OCH3); 62.04 (C-9); 67.83 
(C-7); 70.96 (C-8); 73.73 (C-6); 106.45 (C-3); 127.26 (C Ph), 129.92 (C Ph); 136.73 
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(Cq Ph), 144.10 (Cq Ph); 145.88 (C-2); 161.66 (C-1); 169.87, 170.14, 170.59 
(C(O)CH3); 170.84 (NHC(O)CH3). HRMS (ESI +ve) m/z 613.2074 [M+H]+ 
(C27H37N2O12S requires 613.2067); 635.1897 [M+Na]+ (C27H36N2O12SNa requires 
635.1887). 
Methyl 5-N-acetamido-2,3-didehydro-2,3,4,5-tetradeoxy-4-N-ethylamino-D-glycero-
D-talo-2-nonulopyranosidonate (124) 
A 0.5 M solution of sodium methoxide in methanol (0.08 mL) was added to a 
solution of the per-O-acetylated-4-epi-N-ethylamino Neu5Ac2ene (118) (267 mg, 
0.58 mmol) in methanol (8.0 mL) at 4 ºC and the solution stirred for 2h at room 
temperature. The solution was then neutralized (Dowex 50WX8, H+ form), filtered 
and the filtrate concentrated in vacuo. The residue was subjected to flash 
chromatography (EtOAc:MeOH 9:1) to afford the 4-epi-N-ethylamino Neu5Ac2ene 
(124) as a white solid (116 mg, 60%). m.p. 30 ºC (hygroscopic). 1H NMR (400 MHz, 
CD3OD): δ 1.13 (t, 3H, J = 7.0 Hz, NHCH2CH3); 2.04 (s, 3H, NHC(O)CH3); 
2.69 - 2.75 (m, 1H, NHCH2CH3); 2.81 – 2.87 (m, 1H, NHCH2CH3); 3.43 (t, 1H, 
J4,5 = 5.1 Hz, H-4); 3.58 (d, 1H, J7,8 = 9.0 Hz, H-7); 3.65 (dd, 1H, J8,9 = 5.5 Hz, 
J9,9’ = 11.3 Hz, H-9); 3.78 (s, 3H, OCH3); 3.81 – 3.89 (m, 2H, H-8, 9’); 4.15 (d, 1H, 
J5,6 = 9.4 Hz, H-6); 4.24 (dd, J4,5 = 4.9, J5,6 = 9.5 Hz, 1H, H-5); 6.18 (d, 1H, J3,4 = 4.7 
Hz, H-3). 13C NMR (100 MHz, CD3OD): δ 14.11 (NHCH2CH3); 21.47 
(NHC(O)CH3); 42.21 (NHCH2CH3); 46.53 (C-5); 49.90 (C-4); 51.49 (OCH3); 63.55 
(C-9); 69.35 (C-7); 70.18 (C-8); 74.17 (C-6); 109.38 (C-3); 143.56 (C-2); 163.28 (C­
1); 172.67 (NHC(O)CH3). HRMS (ESI +ve) m/z 333.1666 [M+H]+ (C14H25N2O7 
requires 333.1662); 355.1490 [M+Na]+ (C14H24N2O7Na requires 355.1481). 
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5-N-Acetamido-2,3-didehydro-2,3,4,5-tetradeoxy-4-N-ethylamino-D-glycero-D-talo­
non-2-ulopyranosonic acid (43) 
A 0.5 M aqueous solution of sodium hydroxide (5 drops) was added to a solution of 
the 4-epi-N-ethylamino Neu5Ac2ene (124) (100 mg, 0.3 mmol) in water (3.0 mL) at 
4 ºC and the solution left to warm to room temperature (2h). The solution was then 
neutralized (Dowex 50WX8, H+ form), filtered and the filtrate concentrated in vacuo 
to afford the 4-epi-N-ethylamino Neu5Ac2ene (43) as a yellow solid (110 mg, 
quantitative). m.p. 30 ºC (hygroscopic). 1H NMR (400 MHz, CD3OD): δ 1.33 (t, 3H, 
J = 7.4 Hz, NHCH2CH3); 2.06 (s, 3H, NHC(O)CH3); 3.20 (t, 2H, NHCH2CH3); 3.61 
– 3.69 (m, 2H, H-7, H-9); 3.77 – 3.82 (m, 2H, H-8, H-9’); 4.20 (t, 1H, J3,4 = 3.9 Hz, 
H-4); 4.49 (br dd, 1H, J6,7 = 2.8, J5,6 = 7.5 Hz, H-6); 4.64 – 4.67 (m, 1H, H-5); 5.70 
(d, 1H, J3,4 = 3.9 Hz, H-3). 13C NMR (100 MHz, CD3OD): δ 10.11 (NHCH2CH3); 
21.49 (NHC(O)CH3); 40.92 (NHCH2CH3); 44.48 (C-5); 51.28 (C-4); 63.32 (C-9); 
69.84 (C-7); 70.53 (C-8); 75.29 (C-6); 95.30 (C-3); 151.53 (C-2); 166.96 (C-1); 
173.03 (NHC(O)CH3). [α ]20 = -47.9 (c 0.15, H2O). HRMS (ESI -ve) m/z 317.1347 D 
[M-H]- (C13H21N2O7 requires 317.1349). 
Methyl 5-N-acetamido-7,8,9-tri-O-acetyl-4-azido-2,3-didehydro-2,3,4,5-tetradeoxy-
D-glycero-D-talo-non-2-ulopyranosidonate (128) 
Tris(dibenzyldeneacetone) dipalladium (332 mg, 0.36 mmol) and triphenylphosphine 
(190 mg, 0.73 mmol) were added to a solution of oxazoline (99) (1.5 g, 3.63 mmol) 
in tetrahydrofuran (15.0 mL) at room temperature and heated to 50 ºC. After 30 min 
azidotrimethylsilane (1.91 mL, 14.5 mmol) was added and the solution was stirred at 
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this temperature overnight. The solution was then filtered over Celite® and the filtrate 
concentrated in vacuo. The crude mixture was purified by flash chromatography 
(EtOAc:Pet Ether 7:3 → EtOAc:Pet Ether 9:1) to afford the per-O-acetylated-4-epi­
azido Neu5Ac2ene (128) as a white solid (496 mg, 30%). 1H NMR (400 MHz, 
CDCl3): δ 1.97 (s, 3H, NHC(O)CH3); 2.05, 2.07, 2.09 (3s, 9H, C(O)CH3); 3.82 
(s, 3H, OCH3); 4.13 – 4.19 (m, 3H, H-4, H-6, H-9); 4.50 (dt, 1H, J4,5 = 4.3, J5,6 = 
10.5 Hz, H-5); 4.69 (br dd, 1H, J8,9’ = 2.3, J9,9’ = 12.1 Hz, H-9’); 5.30 – 5.33 (m, 1H, 
H-8); 5.45 (dd, 1H, J7,8 = 2.3, J6,7 = 5.1 Hz, H-7); 5.66 (br d, 1H, NH); 6.15 (d, 1H, 
J3,4 = 5.9 Hz, H-3). 13C NMR (100 MHz, CDCl3): δ 20.66, 20.75, 20.88 (C(O)CH3); 
23.20 (NHC(O)CH3); 44.80 (C-5); 52.67 (OCH3); 54.80 (C-4); 62.08 (C-9); 67.56 
(C-7); 71.25 (C-8); 73.56 (C-6); 104.47 (C-3); 146.32 (C-2); 161.47 (C-1); 169.84 
(NHC(O)CH3); 169.98, 170.19, 170.56 (C(O)CH3). HRMS (ESI +ve) m/z 457.1564 
[M+H]+ (C18H25N4O10 requires 457.1571); 479.1379 [M+Na]+ (C18H24N4O10Na 
requires 479.1390). Spectroscopic data are analogous to those reported in the 
literature.156 
Methyl 5-N-acetamido-7,8,9-tri-O-acetyl-4-N-amino-2,3-didehydro-2,3,4,5­
tetradeoxy-D-glycero-D-talo-2-nonulopyranosidonate (127) 
1,3-Propanedithiol (0.22 mL, 2.15 mmol) and triethylamine (0.3 mL, 2.15 mmol) 
were added to a solution of per-O-acetylated-4-epi-azido Neu5Ac2ene (128) (197 
mg, 0.43 mmol) in methanol (4 mL) at 4 ºC and stirred for 5 min after which the 
solution was allowed to warm to room temperature (2h). Acetic acid was added until 
pH 3 and then the solution was concentrated in vacuo. Flash chromatography 
(EtOAc:Pet Ether 9:1) afforded the per-O-acetylated-4-epi-amino Neu5Ac2ene (127) 
as a white solid (118 mg, 63%). m.p. 30 ºC (hygroscopic). 1H NMR (400 MHz, 
CDCl3): δ 1.95 (s, 3H, NHC(O)CH3); 2.05, 2.06, 2.10 (3s, 9H, C(O)CH3); 3.43 - 3.49 
(m, 1H, H-4); 3.78 (s, 3H, OCH3); 4.02 (br dd, 1H, J6,7 = 2.7, J5,6 = 10.5 Hz, H-6); 
4.17 (dd, 1H, J8,9 = 7.4, J9,9’ = 12.1 Hz, H-9); 4.28 (td, 1H, J4,5 = 4.7, J5,6 = 10.2 Hz, 
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H-5); 4.74 (dd, 1H, J8,9’ = 2.8, H-9’); 5.30 – 5.34 (m, 1H, H-8); 5.43 (dd, 1H, J7,8 = 
4.3 Hz, H-7); 6.06 (d, J5,NHAc = 10.2 Hz, 1H, NH); 6.11 (d, J3,4 = 5.4 Hz, H-3). 13C 
NMR (100 MHz, CDCl3): δ 20.79, 20.82, 20.95 (C(O)CH3); 23.44 (NHC(O)CH3); 
43.75 (C-4); 45.91 (C-5); 52.40 (OCH3); 62.32 (C-9); 68.21 (C-7); 71.77 (C-8); 
73.48 (C-6); 111.82 (C-3); 143.81 (C-2); 162.35 (C-1); 169.90 (NHC(O)CH3); 
170.20, 170.40, 170.60 (C(O)CH3). HRMS (ESI +ve) m/z 431.1715 [M+H]+ 
(C18H27N2O10 requires 431.1666); 453.1543 [M+Na]+ (C18H26N2O10Na requires 
453.1485). 
Methyl 5-N-acetamido-4-N-amino-2,3-didehydro-2,3,4,5-tetradeoxy-D-glycero-D­
talo-non-2-ulopyranosidonate (132) 
A 0.5 M solution of sodium methoxide solution in methanol (0.04 mL) was added to 
a solution of the per-O-acetylated-4-epi-amino Neu5Ac2ene (127) (158 mg, 
0.37 mmol) in methanol (4 mL) at 4 ºC and the solution stirred at room temperature 
(2h). The solution was then neutralized (Dowex 50WX8, H+ form), filtered and the 
filtrate concentrated in vacuo. Flash chromatography (EtOAc → EtOAc:MeOH 8:2) 
afford the 4-epi-amino-Neu5Ac2ene (132) as a white solid (62.3 mg, 54%). m. p. 
65 - 70 °C. 1H NMR (400 MHz, CD3OD): δ 2.04 (s, 3H, NHC(O)CH3); 3.55 – 3.60 
(m, 2H, H-4, H-7); 3.66 (br dd, 1H, J8,9 = 5.5, J9,9’ = 11.3 Hz, H-9); 3.77 (s, 3H, 
OCH3); 3.83 (br dd, 1H, J8,9’ = 2.8 Hz, H-9’); 3.88 – 3.92 (m, 1H, H-8); 4.15 – 4.22 
(m, 2H, H-5, H-6); 6.10 (d, J3,4 = 5.1 Hz, H-3). 13C NMR (100 MHz, CD3OD): δ 
21.27 (NHC(O)CH3); 43.78 (C-4); 47.65 (C-5); 51.31 (OCH3); 63.49 (C-9); 68.97 
(C-7); 70.12 (C-8); 72.38 (C-6); 111.14 (C-3); 143.63 (C-2); 163.27 (C-1); 172.70 
(NHC(O)CH3). HRMS (ESI +ve) m/z 305.1375 [M+H]+ (C12H21N2O7 requires 
305.1349); 327.1196 [M+Na]+ (C12H20N2O7Na requires 327.1168). 
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5-N-Acetamido-4-N-amino-2,3-didehydro-2,3,4,5-tetradeoxy-D-glycero-D-talo-non­
2-ulopyranosonic acid (126) 
A 0.5 M aqueous solution of sodium hydroxide (1 drop) was added to a solution of 
the 4-epi-amino Neu5Ac2ene (132) (24.0 mg, 0.08 mmol) in water (0.6 mL) at 4 ºC 
and the solution left to warm to room temperature (1h). The solution was then 
neutralized (Dowex 50WX8, H+ form), filtered and the filtrate concentrated in vacuo 
to afford the 4-epi-amino-Neu5Ac2ene (126) as a white solid (23 mg, quantitative). 
1H NMR (500 MHz, D2O): δ 2.02 (s, 3H, NHC(O)CH3); 3.60 – 3.90 (m, 4H, H-7, 8, 
9, 9’); 4.17 (br s, 1H, H-4); 4.43 – 4.50 (m, 2H, H-5, H-6); 5.69 (d, J3,4 = 4.0 Hz, H­
3). 13C NMR (125 MHz, D2O): δ 21.98 (NHC(O)CH3); 44.84 (C-4); 44.97 (C-5); 
62.91 (C-9); 68.83 (C-7); 69.92 (C-8); 72.05 (C-6); 98.48 (C-3); 151.00 (C-2); 
168.57 (C-1); 174.71 (NHC(O)CH3). HRMS (ESI -ve) m/z 289.1001 [M-H]­
(C11H17N2O7 requires 289.1036). 
Methyl 5-N-acetamido-4-azido-2,3-didehydro-2,3,4,5-tetradeoxy-D-glycero-D-talo­
non-2-ulopyranosidonate (130) 
A 0.5 M solution of sodium methoxide solution in methanol (0.08 mL) was added to 
a solution of the per-O-acetylated-4-epi-azido Neu5Ac2ene (128) (279.3 mg, 
0.61 mmol) in methanol (8.0 mL) at 4 ºC and the solution stirred for 2h at room 
temperature. The solution was then neutralized (Dowex 50WX8, H+ form), filtered 
and the filtrate concentrated in vacuo to afford 4-epi-azido-Neu5Ac2ene (130) as a 
light brown solid (183 mg, 92%). m. p. 145 – 147 °C. 1H NMR (400 MHz, CD3OD): 
δ 2.02 (s, 3H, NHC(O)CH3); 3.62 (d, 1H, J6,7 = 10.2 Hz, H-7); 3.67 (dd, 1H, 
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J8,9 = 5.4 J9,9’ = 11.3 Hz, H-9); 3.80 (s, 3H, OCH3); 3.80 – 3.84 (m, 1H, H-9’); 
3.88 - 3.99 (m, 1H, H-8); 4.28 (d, 1H, J5,6 = 11.0 Hz, H-6); 4.35 (t, 1H, J3,4 = 5.9 Hz, 
H-4); 4.41 (dd, 1H, J4,5 = 3.9 Hz, H-5); 6.12 (d, 1H, H-3). 13C NMR (100 MHz, 
CD3OD): δ 21.01 (NHC(O)CH3); 46.61 (C-5); 51.60 (OCH3); 54.39 (C-4); 63.40 
(C-9); 68.23 (C-7); 69.85 (C-8); 72.74 (C-6); 104.42 (C-3); 145.92 (C-2); 162.57 
(C-1); 172.35 (NHC(O)CH3). HRMS (ESI +ve) m/z 331.1283 [M+H]+ (C12H18N4O7 
requires 331.1254); 353.1087 [M+Na]+ (C12H18N4O7Na requires 353.1073). 
5-N-Acetamido-4-azido-2,3-didehydro-2,3,4,5-tetradeoxy-D-glycero-D-talo-non-2­
ulopyranosonic acid (131) 
A 0.5 M aqueous solution of sodium hydroxide (2 drops) was added to a solution of 
4-epi-azido Neu5Ac2ene (130) (27.0 mg, 0.08 mmol) in water (0.5 mL) at 4 ºC and 
the solution left to warm to room temperature (1h). The solution was then neutralized 
(Dowex 50WX8, H+ form), filtered and the filtrate concentrated in vacuo to afford 
4-epi-azido Neu5Ac2ene (131) as a light yellow solid (27.8 mg, quantitative). 
1H NMR (400 MHz, D2O): δ 1.88 (s, 3H, NHC(O)CH3); 3.44 – 3.50 (m, 2H, H-7, 
H-9); 3.69 (br dd, 1H, J8,9’ = 2.7, J9,9’ = 12.1 Hz, H-9’); 3.74 – 3.79 (m, 1H, H-8); 
4.08 (dd, 1H, J6,7 = 0.8, J5,6 = 10.6 Hz, H-6); 4.19 – 4.25 (m, 2H, H-4, H-5); 5.99 (d, 
1H, J3,4 = 5.9 Hz, H-3). 13C NMR (100 MHz, D2O): δ 21.63 (NHC(O)CH3); 46.35 
(C-5); 54.23 (C-4); 62.87 (C-9); 67.84 (C-7); 69.76 (C-8); 72.03 (C-6); 104.92 (C-3); 
146.15 (C-2); 165.73 (C-1); 174.05 (NHC(O)CH3). [α ]20 = -229.3 (c 0.08, H2O). D 
HRMS (ESI -ve) m/z 315.0938 [M-H]- (C11H15N4O7 requires 315.0941). 
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11.3 Biology 
11.3.1 Inhibition of influenza neuraminidase 
The kinetics studies were performed by following the changes in UV/vis absorbance 
at a wavelength of 400 nm, in a PerkinElmer Lambda 25 equipped with a circulating 
Jubalo F10 water bath, maintaining the cells at a temperature of 37 ºC. Cells of 1 cm 
path length were employed for all experiments. The buffer employed was 56 mM 
Tris.HCl, pH 7.2, containing 4 mM CaCl2. The time dependent inactivation of 
influenza neuraminidase by the 7-N,N-diethylamino derivative (39) was monitored 
by incubation of the enzyme under the above conditions in the presence of several 
concentrations (0.1, 0.25 and 2.5 mM) of the inhibitor. Residual enzyme activity was 
determined at specific time points by the addition of an aliquot (20 µL) of the 
inactivation mixture to an assay solution (150 µL) containing 4-nitrophenol-sialic 
acid (100 µM). 
11.3.2 Inhibition of Trypanosoma cruzi trans-sialidase 
11.3.2.1 IC50 determination 
The enzyme activity was determined using purified TcTS and the activity measured 
as a factor of the transfer of sialic acid from 1 mM sialyl-α-(2→3)-lactose to 12 µM 
[D-glucose-1-14C]lactose (55 mCi/mmol), in 30 µL containing 0.5 ng of TcTS, 20 
mM Hepes-Na (pH 7.5), 0.2% BSA and 30 mM NaCl. After 30 min at 25 ºC the 
reaction was stopped by dilution with 1mL of water, QAE-Sephadex was added, and 
the resin washed twice with water. Negatively charged compounds were eluted with 
0.8 mL of 1M NaCl and quantified in a WinSpectral 1414 liquid scintillation 
counter.223 The inhibition of the TcTS will cause a lower transfer of sialic acid to the 
14C radio labelled lactose. The amount of 14C radio labelled lactose was measured 
with a scintillation counter. 
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11.3.2.2 Inhibition of the infection of cells by trypomastigotes 
Vero cells were inserted in a 24-well plate (104 cells/well) fitted with a sterile 
12-mm-diameter glass cover slip in 500 µL 10% FBS-MEM and used after 24h of 
growth. Before infection, the medium was removed and the cells were washed twice 
with PBS. Different concentrations of inhibitor were added followed by 0.2% 
BSA-MEM. Prior to incubation, trypomastigotes (100 parasites/cell) were added and 
the plate was examined under a microscope to ensure that both cells and parasites 
were viable, and that the introduction of the inhibitor did not produce secondary 
effects, such as death of the cells and/or parasites. Once the inspection was complete, 
the plate was incubated for 20h, at a constant temperature of 37 ºC under 5% CO2. 
The plate was re-examined before changing the medium to ensure that both cells and 
parasites were alive after the incubation period and that the inhibitor was not 
cytotoxic. After removing the parasites, the wells were washed with PBS and 
maintained with 3% FBS-MEM. After the changing of the medium, the plate was 
examined again with the microscope to certify that the cells were not removed during 
the procedure. The plate was incubated for a final 72h period. After 72h incubation, 
the medium was removed and the wells washed with PBS to remove any free 
particles (e.g. dead cells, some parasites that survived the previous wash) several 
times. After the washings, the glass plates were conditioned for visualisation by the 
addition of dyes, firstly may-Grünwald (250 µL). It was left to stand for 5 min, after 
which water (250 µL) was added and left to stand for a further 1 min. After removal 
of the liquid another dye, Giemsa (1/4 dilution with water, 600 µL) was added and 
left to stand for 5 min. The role of the dyes is to stain and fix the cells and 
amastigotes (present in the cytoplasm), and ultimately to close the cell membrane, 
making it impermeable. After this time the glass support was carefully removed, 
dipped in water to remove the excess of dye and dried. The plate supports were 
mounted with DPX mountant onto a glass support plate. The number of infected cells 
was counted (by eye) and the results expressed as the average of the percentage of 
infected cells with respect to healthy ones. 
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